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Genetic and epigenetic data provide the opportunity to robustly appraise the causal effect of an 
exposure on an outcome of interest, improve understanding of risk and prognostic pathways, and 
predict the status of a risk factor, prognostic factor, or outcome. In the case of oropharyngeal cancer 
(OPC), genetic and epigenetic data have rarely been applied in these contexts.  
Using large population-based OPC cohorts alongside bioinformatic, genetic and epigenetic 
resources, I have applied a series of methodologies which aim to improve understanding of the causal 
risk factor pathways associated with this disease, beyond the limited degree of inference afforded by 
conventional observational studies. To this end, throughout this thesis I have employed: enriched 
literature object mining, genome-wide association studies (GWAS), epigenome-wide association 
studies (EWAS), two-sample Mendelian randomization (MR), MR-phenome-wide association studies 
(MR-PheWAS), two-step MR and epigenetic prediction scores. 
The OPC cohorts forming the core data resources in this thesis are the Head and Neck 5000 
study (HN5000) and the head and neck cancer OncoArray study: HN5000 contains genetic, epigenetic 
and mortality data for 448 individuals with oropharyngeal cancer, whilst OncoArray contains genetic 
data on 2,641 cases and 6,585 controls. 
Methods applied in this thesis have provided evidence for enrichment in literature of 4 risk 
factors for OPC, the association of 16 phenotypes with OPC incidence, novel whole-blood-based CpG 
sites associated with HPV, alcohol, smoking and oropharyngeal cancer survival, evidence for a causal 
effect of smoking-related methylation at the SPEG gene with OPC survival, and finally, evidence for 
the value of blood-based methylation signatures in predicting mortality in those with OPC. These 
findings highlight the merits of using genetic and epigenetic data to improve on conventional 
observational analyses, with the caveat that replication and triangulation of these findings from a 
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This chapter introduces the cancer type and background relevant to this thesis. Firstly, 
oropharyngeal cancer is introduced by briefly describing its biology, epidemiology and clinical impact. 
Secondly, the current genetic and epigenetic understanding of oropharyngeal cancer (OPC) is outlined. 
Finally, the chapter is summarised. In addition to introducing the thesis, this section provides a 
justification of the work presented throughout it. 
 
1.1.1. A brief introduction to oropharyngeal cancer biology 
OPC is one of the aetiologically similar cancers of the mouth, pharynx, larynx, paranasal 
sinuses, nasal cavity and salivary glands collectively known as head and neck cancer (HNC). OPC is 
located in the pharynx – the hollow tube inside the neck that starts behind the nose and ends at the 
top of the oesophagus. The oropharynx is the central area of the pharynx (Figure 1.1), bordered by 
the nasopharynx (the top portion of the pharynx) and the hypopharynx (the bottom portion of the 
pharynx). It includes the soft palate, side and back walls of the throat and the back third of the tongue. 
The function of the pharynx is to ensure that air travels through the trachea, and that food and water 
travel to the oesophagus. The oropharynx accepts air from the nasopharynx, which passes through to 
the hypopharynx and laryngeal pharynx. The oropharynx also accepts food and water from the mouth, 
passing it to the oesophagus via peristaltic muscular contraction.  
 
 
Figure 1.1 - Head and neck cancer anatomical sites 
The majority of the oropharynx is lined by non-keratinizing stratified squamous epithelium 




(Figure 1.2) [2]. As it isn’t keratinizing (i.e. it doesn’t possess dead, keratin-transformed surface cells), 
the surface squamous cells in this type of epithelium lack rigidity, allowing damaged cells to be 
sloughed and replaced rapidly. Rapid sloughing of oropharyngeal epithelium is an important 
characteristic of the tissue as it provides a first-line defence from physical (e.g. mechanical shearing 
caused by the pharyngeal phase of swallowing [3]), chemical (e.g. gastric acid exposure via 




The predominance of squamous cells over other cell types in the oropharynx result in 
approximately 95% of oropharyngeal tumours being oropharyngeal squamous cell carcinomas 
(OPSCCs) [6] . Less common neoplasms originating in the oropharynx include minor salivary gland 
tumours [7] and squamous carcinoma with lymphoid stroma (lymphoepithelioma) [8]. Additionally, 
malignant lymphomas can occur in Waldeyer’s ring of the oropharynx [9]; a ringed arrangement of 
lymphoid tissue in the pharynx, surrounding the nasopharynx and oropharynx, with tonsillar tissue 
located above and below the soft palate and back of the mouth cavity. 
 
1.1.2. Epidemiology 
Incidence and prevalence of oropharyngeal cancer in the UK 
Epidemiology typically quantifies a disease by considering its incidence (the number of new 
cases of a disease within a given time period) and prevalence (the proportion of individuals with a 
disease at a given time) within a defined population. When combined, HNCs are the seventh most 
common cancer type [10], accounting for an estimated 550,000 incident cases globally, per year, 
corresponding to ~3.9% of all cancer cases [11]. Of these incident cases, an estimated 100,500 are of 





the oropharynx (~0.8% of all cancer cases; ~18% of all HNCs), with an age-standardised incidence rate 
(ASR: a weighted average of age-specific incidence rates, where the weights are the proportions of 
individuals in each age group) of 1.4 per 100,000 for both sexes combined (2.3 for men; 0.5 for women) 
[11].  
 
The number of region-specific OPC diagnoses contributing to the 100,500 global diagnoses 
ranges substantially, from ~0.9% in Oceania to ~35% in south-central Asia. Northern and western 
Europe contribute ~13.2% of all OPC diagnoses; third highest, behind south-central Asia (35%; above) 
and northern America (15%) (Figure 1.3 – inner chart). OPC diagnoses as a proportion of all HNC sub-
types also show marked geographic variability, ranging from ~8.2% of all HNCs in northern Africa and 
western Asia, to ~34.2% of all HNCs in northern America. The proportion of OPC in HNC in northern 
and western Europe was second highest at ~29.5% (Figure 1.3 - outer chart).  Understandably, the 
regional heterogeneity of OPC incidence affects the heterogeneity of ASRs for this disease. Worldwide, 
the ASR for OPC is 1.4 per 100,000 (calculated using the world standard), but ranges from 0.5 in 
eastern/south-east Asia to as high as 2.9 in northern America. Rate disparities such as these indicate 
that a proportion of these cancers are preventable; if not entirely due to genetic differences between 
populations, ASR rate disparities are suggestive, in part, of a geographic and cultural heterogeneity in 
exposure to causal risk factors. Large regional differences in OPC prevalence provide a rationale for 
targeted investigation of risk factors for OPC, particularly where prevalence of this sub-type is 






Figure 1.3 - Geographic variation in prevalence of OPC as a HNC sub-type 
  
In 2011 in the UK, the ASR of HNC for both sexes was 15.9 per 100,000; a 30.3% increase from 
12.2 per 100,000 in 2002 [12]. However, during this time, incidence of the OPSCC sub-type increased 
by 100.6%. Sex-specific incidence rates in the UK from 1995-2011 have been reported in 
epidemiological literature, showing that the ASR for OPSCC almost tripled in men (from 2.0 to 5.8), 
and more than doubled in women (0.8 to 1.7) during this period [12]. Additionally, the Oxford Cancer 
Intelligence Unit Profile of Head and Neck Cancers in England: Incidence, Mortality and Survival 
reports that the incidence of OPC more than doubled from 1990 to 2006, and nearly doubled again 
from 2006 to 2011 [13]. A notable increase in OPC incidence is also similar across Ireland, Scotland 
and Wales, respectively (Figure 1.4). It appears, therefore, that OPC is increasing at a rapid rate, 






Figure 1.4 - Incident cases of OPC from 1993-2017 across England, Ireland, Scotland and Wales 
 
Common OPC risk factors 
Globally [11], and in the UK [14], the most prevalent risk factors in observational 
epidemiological literature for OPC are tobacco smoking [15, 16], alcohol consumption [17-19] and 
human papillomavirus (HPV) infection (notably the HPV16 subtype) [20-24]. Of these risk factors, 
tobacco smoking and alcohol consumption show synergistic effects on OPC [25]. Both smoking and 
HPV16 infection, and alcohol and HPV16 infection, however, do not currently appear to affect risk of 
OPC synergistically [26], despite both increasing risk of HPV [27, 28]. In 2015 in the UK, smoking, 
alcohol and HPV were estimated to attribute 88.4% of the population risk for pharyngeal cancer 
(tobacco 37.4%; alcohol 37.8%; infections 70.2%) [29]. A brief overview of each can be seen below. 
 
Alcohol consumption 
Consumption of alcohol varies significantly across the world. In 2016, the worldwide average 




differences in drink preference]; age 15+) (Figure 1.5) [30]. Moldova showed the highest alcohol 
consumption of 15.2L; the lowest alcohol consumption was 0L in Bangladesh, Kuwait, Libya, 
Mauritania and Somalia. In the European Union, which was the second highest alcohol consumption 
of any continent/grouping (Central Europe and the Baltics was highest at 12.2L), consumption 
averaged 11.3L [30]. The UK average in 2016 was 11.5L, establishing it as one of the largest consumers 
of alcohol in the world – 1.8x the global average – a prime target for primary prevention of OPC if 
established as a true causal risk factor. 
 
Figure 1.5 - Alcohol consumption across the world in 2016. Data are plotted from the World Bank - World Development 
Indicators 
 
Observational evidence for the effect of general alcohol consumption on OPC 
Epidemiological studies investigating alcohol consumption in relation to risk of OPC appear to 
show consistent evidence of elevated risk with increasing alcohol consumption [31]. In an analysis of 
data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study, the 
relative risk of oral-pharyngeal (combined oral cavity, nasopharyngeal, oropharyngeal and 
hypopharyngeal) cancer for over 60 grams (4 drinks) per day was calculated to be 9.2 (95% confidence 
interval [CI]: 2.8 to 30.9) [31, 32]. Other prospective cohort studies reported lower, albeit still notable 
risks of alcohol consumption on risk of oral-pharyngeal cancer. The American Cancer Society (ACS) 
prospective study report a risk ratio (RR) of 3.2 (95% CI: 1.7 to 6.1) for more than 4 drinks/day [33], 




consumption of alcohol 4–7 times per week [34]. Prospective cohort studies are considered to have a 
high level of evidence in the hierarchy of evidence for epidemiological study design (Figure 1.6), due 
to their longitudinal nature and regular contemporaneous collection of results. Longitudinal 
observation in prospective studies allows a direction of effect to be established between an exposure 
and outcome (in this case, alcohol → OPC), whilst regular, contemporaneous collection of results 
minimises recall bias; a systematic error that occurs when study participants do not remember past 
experiences accurately or omit details (as generally found in case-control or cross-sectional studies). 
However, prospective cohort study design still presents with drawbacks. At baseline, it is not possible 
to measure and control for every factor which may affect OPC via alcohol consumption; thus it cannot 
be ruled out that the association of alcohol with OPC seen in the prospective studies above may be 
due to confounding. As such, association, not causation, can be asserted for the effect of alcohol on 
OPC in these studies. This is in contrast to the gold standard of epidemiological study design – the 
randomised controlled trial (RCT) - which uses random allocation of individuals to an intervention or 
control group at baseline to account for confounding. It should be noted, however, that an RCT 
investigating alcohol consumption on risk of OPC would be both unethical and infeasible, due to the 
relative rarity, latency and harmful nature of OPC (and indeed, other alcohol-related diseases) as an 
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Finally, there is observational evidence for the effect of alcohol on OPC in England. A case-
control study of risk factors for oral cancer in newly diagnosed patients aged 45 years and younger 
found that males who drank >21 units of alcohol per week were over 8 times more likely to develop 
oral cancer or OPC (RR: 8.1; 95% CI: 1.6 to 40.1) [35]. However, the level of evidence from this study 
is lower than the prospective studies mentioned above. In addition to being unable to fully measure 
and control for confounding, case-control studies are not prospective, thus cannot establish a true 
direction of effect; it is uncertain whether alcohol affects risk of OPC, or those with OPC tend to drink 
more alcohol as a result. Case-control studies do have an advantage over prospective studies, 
however. Statistical power is increased by being able to match participants who already have OPC 
with healthy controls. This can afford a smaller sample size to achieve adequate power and, more 
generally, a viable method of investigating rarer outcomes with long latency periods (such as OPC). 
Statistical power is a pitfall of prospective cohort studies, as sample sizes need to be particularly large 
to have sufficient power to account for the rarity and latency of OPC (and other similar outcomes). 
 
Observational evidence for the effect of type of alcohol consumed on OPC 
Between 1890-2014, the population share of alcohol type consumed (beer, wine and spirits) 
in the UK changed significantly [36]. A sharp increase in the population share of wine drinking, from 
4% in 1964 to 41% in 2014, affected a decrease in the population share of beer drinking from 81% in 
1964 to 37% in 2014. Spirit drinking in the UK was 30% of the population share in 1890, but remained 
largely steady, at around 20% of the UK’s total pure alcohol consumption from 1929-2014 (Figure 1.7). 
The notable increase in wine consumption is thought to be due to a combination of Big 6 brewers 
recognising the influence of women as consumers of alcohol, and also due to the ability of UK 
consumers to travel abroad for their holidays (particularly France, Italy and Spain), establishing wine 






Figure 1.7 - Share of total alcohol consumption from wine, beer and spirits in the UK from 1890-2014, as a percentage of pure 
alcohol 
 
Epidemiological evidence pertaining to type of alcohol consumed and risk of OPC show 
differences between risk of wine, beer and spirit drinking in relation to pharyngeal cancer 
(nasopharynx, oropharynx and hypopharynx cancers combined), yet no notable difference when 
solely investigating OPC. In a meta-analysis examining type of alcohol on HNC risk in Europeans (9,107 
cases, 14,219 controls; N = 15 case-control studies), Purdue et al. found that, for moderate alcohol 
consumption (≤15 standardised drinks per week), wine and spirit consumption provided no conclusive 
evidence of association with pharyngeal cancer (wine OR: 1.4; 95% CI: 0.9 to 2.2 | spirit OR: 2.0; 95% 
CI: 0.9 to 4.6), as opposed to beer consumption, which showed a positive association (OR: 2.3; 95% CI: 
1.7 to 3.1) [38]. By only analysing case-control studies, findings from this meta-analysis cannot be 
entirely free of unmeasured confounding factors, and the direction of effect cannot be ascertained. 
The authors discuss their wine consumption findings, providing evidence to suggest that confounding 
factors may have affected these results. In studies conducted in the United States and Northern 
Europe, wine has previously been associated with higher intake of a healthy diet, higher education 
and lower smoking levels compared to other alcohol types [39-41]. In seems, therefore, that wine 
consumption may be correlated with socio-economic position (SEP), which is itself an independent 
risk factor for OPC (see “Socio-economic position” below). However, it should be noted that findings 
from this study do not stratify by pharyngeal cancer sub-type, thus results may be biased by a different 
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Turati et al. investigated type of alcohol consumed against risk of OPC uniquely, in Europeans. 
In a 2013 meta-analysis (N studies = 11), compared with non- or occasional drinking (combined), 
pooled RRs for type of alcohol consumed were found to be 2.12 (95% CI: 1.37 to 3.29) for wine-only, 
2.43 (95% CI: 1.92 to 3.07) for beer-only and 2.30 (95% CI: 1.78 to 2.98) for spirit-only consumption 
[42]. No heterogeneity was found between types of beverages (P = 0.856), though interestingly, within 
the wine-only studies (N = 10), there was evidence of substantial heterogeneity (I2: 76.9%; P: 0.000). 
Four studies of 11 showed null findings for the effect of this beverage type on OPC risk, indicating 
presence of a source of confounding. As with Purdue et al., Turati et al. cannot assert causality with 
their findings; confounding and reverse causation are key limitations of observational epidemiology 
and further causal inference methodologies are required to ascertain the true causal effect of type of 
alcohol consumed on risk of OPC.  
 
Observational evidence for the effect of alcohol cessation on OPC 
 There is epidemiological evidence for an inverse association between cessation of alcohol 
consumption and risk of OPC. In a 2010 paper published by the International Head and Neck Cancer 
(INHANCE) consortium, length of alcohol cessation was investigated against risk of HNC in Europeans 
(N case-control studies = 13) [43]. Among subjects who drank one or more drinks per day, the risk of 
HNC seemed to decrease as years of drinking cessation increased. ORs for HNC risk were 0.99 (95% CI: 
0.69 to 1.43) for >1–4 years cessation, 0.90 (95% CI: 0.62 to 1.30) for 5–9 years cessation, 0.94 (95% 
CI: 0.75 to 1.18) for 10–19 years and 0.60 (95% CI: 0.40 to 0.89) for ≥20 years cessation. However, 
when investigating OPC and hypopharyngeal cancer as a grouping, there was no evidence that alcohol 
cessation affected risk of these cancers (OR ≥20 years cessation: 0.74; 95% CI: 0.50 to 1.09). Given an 
initial evidence base for an inverse association between alcohol cessation and HNC, robust causal 
inference methods and investigation into an OPC-specific effect is needed to ascertain the true casual 
effect of this risk factor on OPC incidence. 
Observational evidence for an independent effect of alcohol consumption on OPC 
Alcohol consumption and smoking are strongly correlated in the general population [44] and 
thought to confer a synergistic (greater than multiplicative interaction) effect on HNC risk [25]. Given 
the strength of interaction effect conferred by these risk factors on OPC, it is important to distinguish 
the individual effect of alcohol consumption on OPC in addition to quantifying the joint effect of 




Observational evidence for an independent effect of alcohol consumption on OPC below). By 
ascertaining these metrics, a more suitable, cost-effective intervention strategy can be generated for 
reduction of OPC; the sub-group which would benefit most (smokers vs drinkers) from intervention 
can be established. The effect of alcohol on oropharyngeal and hypopharyngeal cancer (combined) in 
American and European non-smokers (i.e. independently of smoking) has been assessed by the 
INHANCE Consortium. In a 2009 paper, including 3,899 cases and 15,751 controls, the authors found 
that 3 or more alcoholic drinks per day (vs no drinks per day) showed an elevated risk of these cancers 
in non-smokers (OR: 2.94; 95% CI: 1.73 to 5.02), though found no evidence for 1-2 drinks per day on 
pharyngeal cancer risk amongst non-smokers (OR: 1.26; 95% CI: 0.92 to 1.73) [25]. For oropharyngeal 
and hypopharyngeal cancer combined, the population-attributable fraction of alcohol (in 2009), 
independent of smoking, was 5.6 % (95% CI: 1.9% to 7.3%) [25]. 
 
Summary of alcohol as a risk factor for OPC 
In summary, alcohol appears to be an independent risk factor for Europeans and Americans 
for HNC, oral cancer and pharyngeal cancer, with 3-4 drinks per day conferring a 3-fold increased risk 
of these cancers. However, there appears to be a paucity of OPC-specific publications with respect to 
this risk factor; most of the epidemiological evidence provided above was derived from articles which 
group OPC with either oral cavity of hypopharyngeal cancer, potentially biasing effect estimates. Using 
genetic and epigenetic data with robust causal inference methods such as Mendelian randomization 
(MR; see Chapter 2.2.4 – Mendelian randomization), an effect estimate specific to OPC for alcohol 
consumption could be derived to address this shortfall and augment current understanding of the risk 
of alcohol on OPC. Furthermore, using MR, the hypothesis that wine consumption specifically may be 




Much like alcohol consumption, prevalence of tobacco consumption varies significantly across 
the world. The average worldwide prevalence of smoking in 2016 was 20.5% (Figure 1.8) [30]. Kiribati 
(a sovereign state in Micronesia) showed the largest smoking prevalence of 48.3% in 2016, with 
Montenegro and Greece second and third at 46.1% and 43.8%, respectively. Honduras showed the 
smallest smoking prevalence at 2.1%, followed by Ghana and Ethiopia at 4.0% and 4.4%, respectively. 




Control Scale (TCS; a quantitative scoring system based on expert opinions that evaluates policies on 
tobacco prices, smoke-free places, spending on information campaigns, bans on advertising, health 
warning labels and treatment for smoking cessation), possibly reflects a lack of meaningful change in 
policy implementation by the region (Figure 1.9). For Europe, TCS scores ranged between 40 and 60 
(out of 100), showing substantial room for improvement in each of North, South, East and West 
Europe. In 2016, smoking prevalence was 23.1% in the UK. Unlike alcohol consumption, smoking 
prevalence in the UK is below the European average, reflecting being at the forefront of tobacco 
control policies and scientific research on tobacco control (#1 in the EU) with a TCS score of 81 in 2016 
(https://www.europeancancerleagues.org/ecl-map/) [45, 46]. Such a push towards tobacco control 
has resulted in a steady decline in prevalence of smoking from 2000-2016 (Figure 1.10). Given a 
decrease in smoking in the UK over the past 16 years, in contrast to an increase in OPC incidence, it 
would appear that the causal landscape of OPC has shifted to include other risk factors (e.g. HPV 











Figure 1.9 - Trends in implementation of tobacco control policies by European region (2007–2013). Plots obtained using the 
Tobacco Control Scale scoring system from Joossens & Raw. Markers indicate mean scores for the countries included in the 
study, except for Macedonia in East Europe (not available). Y-axes show theoretical ranges. “Other policies” is the 




Figure 1.10 - Change in smoking prevalence in the UK from 2000-2016. Global average (World), highest prevalence (Kiribati) 








Observational evidence for the effect of general tobacco consumption on OPC  
Tobacco has been found to be associated with OPC in European populations by multiple 
epidemiological studies. The 2004 IARC monograph establishing the carcinogenic effect of tobacco 
smoke and involuntary smoking on cancer considered tobacco smoking to have sufficient 
epidemiological evidence to be causally related to risk of OPC [47]. More recent epidemiological 
evidence supports this assertion. Anantharaman et al. conducted a case-control analysis of smoking 
against OPC using data from the HNC case-control study within EPIC and the Alcohol-Related Cancers 
and Genetic Susceptibility in Europe (ARCAGE) study. With a sample size of 1,093 (274 cases and 819 
controls), Anantharaman et al. observed greater than a 5-fold increase in risk of OPC (OR: 5.34; 95% 
CI: 3.89 to 7.33) when comparing current vs never smokers [48]. The increased risk of smoking on OPC 
appears to persist when examining the effect of ever vs never smoking (that is, with former smokers 
also included in the analysis). Wyss et al. report a tripling in risk of OPC in ever vs never smokers (OR: 
3.01; 95% CI: 2.71 to 3.35 for their case-control study using INHANCE data, containing  3,828 cases 
and 11,277 controls [49]. The INHANCE consortium also report the effect of increasing cigarettes per 
day, revealing a consistently elevated risk estimate for every additional 10 cigarettes smoked (vs not 
smoking), observing a dose-response relationship (1-10 cigarettes/day OR: 2.55; 11-20 cigarettes/day 
OR: 2.15; 21-30 cigarettes/day OR: 3.86; 31 to 40 cigarettes/day OR: 4.82; >40 cigarettes/day OR: 3.10; 
P[trend] < 0.001) [19]. It should be noted for these studies that a case-control design is susceptible to 
the same biases as discussed for the alcohol case-control studies. Furthermore, there is a paucity of 
studies exclusively investigating the risk of smoking on OPC as a distinct sub-type. Despite existing 
epidemiological evidence, more studies with larger sample sizes (investigating OPC exclusively) and a 
longitudinal framework are required to provide greater causal inference, in an observational setting, 
between smoking and OPC. 
 
Observational evidence for the effect of type of tobacco product on OPC 
Wyss et al. studied the risk of cancer associated with several tobacco products in relation to 
HNC sub-types [49]. For combustible products, this revealed increased risks of OPC for cigars (OR: 
2.31; 95% CI: 1.54 to 3.45; 543 cases and 6,979 controls) and pipes (OR: 1.65; 95% CI: 1.04 to 2.60; 
553 cases and 7,145 controls) vs never cigarette smokers, in addition to (as seen above) an increased 
risk seen for ever cigarette smokers vs never smokers (OR: 3.01; 95% CI: 2.71 to 3.35; 3,828 cases and 
11,277 controls). Interestingly, in a later publication by the same author, smokeless tobacco was 




between smokeless tobacco users and never smokers (OR: 0.98; 95% CI: 0.57 to 1.68; 524 cases and 
3,333 controls) , or smokeless tobacco users and ever smokers (OR: 0.94; 95% CI: 0.72 to 1.22; 1,847 
cases and 5,041 controls) [50]. However, these risk estimates were derived in a population (US) where 
the average smokeless tobacco prevalence is ~4 times higher than the UK (US men: 6.5%, US women: 
0.4% [51]; UK men: 1.6%, UK women: 0.5% [52]). Currently, no evidence exists for use of smokeless 
tobacco and increased risk of OPC in Europe [53]. A 2015 systematic review and meta-analysis 
examining the global burden of smokeless tobacco on disease found no evidence to suggest smokeless 
tobacco affected risk of pharyngeal cancer in Europeans (OR: 1.45; 95% CI: 0.84 to 3.01), albeit with 
data restricted to Scandinavian countries [54]. As such, it may not be viable to extrapolate either 
finding to the UK and further research is needed to ascertain the effect of smokeless tobacco in the 
UK population. 
 
Observational evidence for the effect of smoking cessation on OPC 
 There is epidemiological evidence for an inverse association between cessation of smoking 
and risk of OPC. The same 2010 paper published by the INHANCE consortium mentioned above for 
alcohol cessation investigated the length of smoking cessation against risk of OPC in Europeans (N 
case-control studies = 13) [43]. Compared to current smokers who smoke ≥10 cigarettes a day, 
increased time since cessation of smoking was associated with decreased risk of OPC (grouped with 
hypopharyngeal cancer). Risk estimates were calculated as follows: OR >1-4 years cessation: 0.70 (95% 
CI: 0.53 to 0.94), OR 5-9 years cessation: 0.47 (95% CI 0.36 to 0.61), OR 10-19 years cessation: 0.34 
(95% CI: 0.25 to 0.45), OR ≥20 years cessation: 0.23 (95% CI: 0.16 to 0.35); estimates showed a dose-
response relationship (P for trend <0.01). Comparatively, never smokers were calculated as having an 
OR of 0.17 (95% CI: 0.11 to 0.27) vs current smokers, indicating that risk of OPC approaches that of 
never smokers at around 20 years smoking cessation. 
 
Summary of smoking as a risk factor for OPC 
In summary, smoking is reported in epidemiological literature as a significant risk factor for 
OPC. In European populations, smoking prevalence is still above average (28.2% vs the worldwide 
average of 20.5%), with no evidence of meaningful interventions being employed across the continent 
as a whole. Interestingly, smoking prevalence in the UK has steadily declined as a result of employing 
effective tobacco control measures, evidenced by the 2016 UK TCS score of 81/100; the highest in 




23.1%. Observational epidemiology consistently reports smoking as a significant risk factor for OPC, 
with current smokers at a ~3-fold risk of OPC compared to never smokers. Cessation of smoking has 
been seen to be associated with a marked decrease in risk of OPC, approaching the equivalent risk of 
never smokers past 20 years cessation. Current epidemiological research tends to combine OPC with 
other HNC sub-types, potentially biasing effect estimates for smoking on risk of OPC. Furthermore, 
evidence for association between smoking and OPC is derived from observational epidemiological 
literature, which has shown to be prone to confounding, reverse causation and other innate biases 
from using observational data. Methods such as MR could potentially overcome these shortcomings 
and provide an unconfounded, OPC-specific risk estimate (see Chapter 2). Furthermore, given the 
substantial estimated risk of smoking on OPC incidence, establishing potential causal intermediates 




HPV infection is recognised in epidemiological literature as one of the primary causes of OPC 
and is transmitted from person to person via oral, vaginal or anal sex [55]. Biologically, HPV is a DNA 
oncovirus, meaning its genome can integrate directly into the host genome (as opposed to RNA 
oncovirus genomes, which must be reverse-transcribed to DNA before integration) to affect 
tumorigenesis [56]. HPV is also epitheliotropic; it possesses an affinity for epithelium, making the 
oropharynx a common, local site of infection for this virus [57]. There are over 120 different HPV 
subtypes: “low-risk” types such as HPV6 and HPV11 are responsible for benign proliferation of 
epithelial tissue. Two “high-risk”, oncogenic types, HPV16 and HPV18, are both well-established 
initiators of around 30% of worldwide OPSCC [58-60]. HPV16 in particular is thought to account for 
more than 90% of all HPV-positive OPC. The “high-risk” HPV sub-types are known to affect oncogenesis 
via two oncoproteins, HPV E6 and HPV E7, which inhibit p53 and pRB tumour suppressor pathways. 
Disruption of these two common cancer pathways greatly increases risk of mutation and oncogenesis 
[22, 61].  
 
One of the most common methods for determining if an individual has a (high-risk) HPV 
infection is serological examination; that is, assessing presence of HPV antibodies (namely E6 and E7) 
in blood serum. Case–control studies of HPV serology in OPC are feasible in serum due to the relative 
ease and low patient burden of obtaining blood samples compared to fresh tumour biopsies. 
Detecting HPV in tissue samples (e.g. buccal rinses) is problematic due to a low yield of detectable 




not a perfect measure of HPV infection. As HPV infections are sexually transmitted diseases which are 
typically localised, it is difficult to distinguish between any combination of oral, cervical, anal and 
penile infections (all of which are possible HPV infection sites) based on serology alone. Furthermore, 
there are individual differences in the time between infection and development of an HPV E6- or E7-
specific antibody (seroconversion) detectable in blood [63], with some individuals failing to 
seroconvert altogether [64]. Therefore, in studies examining HPV infection using seropositivity, HPV-
seronegative subjects may still be infected with the virus, thus may bias results of observational 
analyses. 
 
The attributable fraction of HPV to OPC varies dramatically depending on world region. A 2012 
systematic review estimating this metric found fractions ranging from 13% in sub-Saharan Africa to 
60% in Korea [60]. In 2008, the global population-attributable fraction of HPV for OPC was 25.6%, and 
4.8% across all cancers [65]. In 2012, the global attributable fraction of HPV for OPC was estimated to 
be 30.8%. In the same year, HPV in North-West Europe showed a population attributable fraction of 
42% [66]. The incidence of HNCs attributable to HPV can be seen in Figure 1.11. Generally, Western, 
more economically-developed countries have greater incidence of HPV-driven HNCs than their 
Eastern and less economically-developed contemporaries. 
 
 
Figure 1.11 - Age-standardised incident rates for HPV-driven HNC worldwide in 2012. Figure adapted from Martel et al. [60] 
 
Between 2002 and 2011, HPV prevalence amongst OPC in the UK was estimated to be 51.8% 




this period, incidence of OPC (specifically, OPSCC) almost doubled (UK ASR for 2002: 2.1 [95% CI: 1.9 
to 2.2]; UK ASR for 2011: 4.1 [95% CI: 4.0 to 4.3]). Although the total number of OPSCCs diagnosed 
within the United Kingdom from 2002 to 2011 nearly doubled, the proportion of HPV-positive cases 
remained at approximately 50%. Schache et al. argue that the rapidly increasing incidence of OPSCC 
in the United Kingdom cannot be solely attributable to the influence of HPV [12]. The stable, equal 
proportion of HPV-positive and HPV-negative cases provide a motivation to determine whether other 
risk factors are playing a role in OPC aetiology (particularly in the case of HPV-negative OPC). 
 
Following evidence of the carcinogenic effect of HPV on cervical cancer, a national HPV 
immunisation program was introduced to women aged 16-18 the UK in September 2008 by the UK 
Department of Health [67]. Compared to 2010, prevalence of either HPV16 or HPV18 in 16 to 18-year-
old women dramatically decreased by 2016 (postvaccination prevalence 2010: 8.2% [95% CI: 6.6% to 
9.9%], postvaccination prevalence 2016: 1.6% [95% CI: 0.6% to 2.6%], Ptrend < 0.001). These findings 
allude to the future emergence of a novel OPC population who are neither HPV-positive nor heavy or 
sustained smokers or drinkers. Currently, this population is restricted to women, as UK males are not 
part of the nation HPV immunisation program. 
 
Observational evidence for HPV as an OPC risk factor  
In 2007, IARC concluded that there was sufficient evidence to report a carcinogenic role of 
HPV16 in tumours of the oropharynx, estimating that ∼31% of OPSCC cases were attributable to HPV 
[68]. HPV has since been recognised as one of the predominant aetiological factors for OPC, with a 
growing body of research suggesting that HPV-positive OPC is a distinct entity from the “traditional” 
OPC caused by smoking and alcohol consumption [23, 69].  
Few studies quantify the risk of HPV16 infection on incidence of OPC. One study by 
Anantharaman et al. observed huge odds ratios for the risk of OPC for HPV16 E6-positive individuals 
vs negative controls (OR: 147.31; 95% CI: 83.07 to 361.24). Additionally, this study investigated 
whether HPV16 infection and smoking exhibited a synergistic effect on OPC risk. HPV16 E6-positivity 
and smoking appeared to interact on an additive scale (synergy index [SI; a confidence interval 
estimation of interaction derived by Hosmer and Lemeshow [70]] for interaction 1.32; 95% CI: 0.51 to 
3.45), finding similar results when HPV16 L1-positivity was examined (SI for interaction: 0.75; 95% CI: 





As mentioned above, HPV16 E6 seropositivity is thought to be a marker of persistent HPV 
infection and HPV-driven OPC [71]. Seropositivity of another HPV protein, HPV16 L1, in the absence 
of HPV16 E6 seropositivity, is considered a marker of past infection [72-74]. In the same study as 
above, Anantharaman et al. found that even those with L1 seropositivity (i.e. a historic, perceivably 
cleared infection) were still at almost a 9-fold risk of OPC (OR: 8.96; 95% CI: 5.27 to 15.23) vs those 
that were L1 seronegative. D’Souza et al. estimated presence vs absence of the HPV16 L1 protein to 
confer an OR of 32.2 (95% CI: 14.6 to 71.3) for risk of OPC [23]. Furthermore, Mork et al. estimated 
the presence of HPV 16 L1 antibodies in pre-diagnostic serum samples to affect a 14.4-fold increased 
risk of OPC. The pre-diagnostic samples preceded OPC by over 10 years, providing evidence for a 
temporal association between HPV infection and OPC.  
 
HPV-driven OPC as a unique biological entity 
There is a growing body of evidence to suggest that HPV-driven OPC is a distinct biological and 
clinical entity compared to HPV-negative OPC (commonly associated with smoking and alcohol 
consumption). Firstly, HPV appears to affect younger populations [75]. In a retrospective analysis of 
stage III and IV OPC patients enrolled in a randomized controlled trial comparing radiotherapeutic 
methods, Ang et al. found the median age of a HPV-positive OPC patient to be 53.5 years (N = 206), 
compared to the median age of a HPV-negative OPC patient of 57 years (N = 117) [76]. Additionally, 
HPV-positive patients typically show less exposure to tobacco and alcohol. In a cohort study of 356 
newly-diagnosed OPC patients by Dahlstrom et al., HPV-positive OPC patients showed markedly lower 
numbers of current smokers at diagnosis compared to those who were HPV-negative (19% vs. 51%; P 
< 0.001) and presented fewer individuals with a history of >10 pack years of smoking (37% vs. 76%; P 
< 0.001). A case-control study by Gillison et al. also found that, compared with subjects who neither 
smoked tobacco nor drank alcohol, those with heavy use of tobacco (≥20 pack-years) and alcohol had 
an increased risk of HPV-16-negative HNSCC (OR: 4.8; 95% CI: 1.8 to 12) but not of HPV-16-positive 
HNSCC (OR: 0.67; 95% CI: 0.29 to 1.9). Interestingly, HPV-driven OPC appears to confer a survival 
advantage over “traditional” OPC. Ang et al. found, in the same randomized controlled trial mentioned 
above, that HPV-positive patients had improved 3-year survival vs HPV-negative patients (82.4%, vs. 
57.1%; P<0.001 by the log-rank test). Furthermore, after adjustment for age, race, tumor and nodal 
stage, tobacco exposure, and treatment assignment, HPV-positive OPC patients had under half the 





Summary of HPV as a risk factor for OPC 
HPV is established in observational literature as one of the predominant risk factors for OPC. 
Given the huge ORs conferred by current and even historic HPV infection on OPC, in addition to the 
clear demographic and aetiological differences between those with HPV-driven OPC and those with 
“traditional” OPC, there appears to be strong observational evidence for a marked effect of HPV16 
infection on risk of developing an aetiologically-distinct cancer. The paucity of risk estimates for 
current HPV16 infection (proxied by HPV16 E6 seropositivity), in conjunction with the abnormally large 
estimates seen in current observational literature, necessitate investigation into the establishing the 
true causal effect of this risk factor on OPC. 
 
Socioeconomic position 
In observational epidemiology, socioeconomic position (SEP) appears to be associated with a 
global increased risk of OPC independently of major established OPC risk factors (smoking, alcohol 
consumption and HPV infection).  A systematic review assessing the impact of low SEP on the global 
risk of oral cancer (oral cavity cancer and OPC combined) (41 studies; 15,344 cases and 33,852 
controls) found low SEP to be significantly associated with increased oral cancer risk in high- and 
lower-income countries across the world [77]. This association remained when adjusting for potential 
confounders, including: method of SEP measure, age, sex, global region, development index (as 
classified by the World Bank), time period and lifestyle factors (including smoking and alcohol 
consumption). Compared with individuals who were in high SEP strata, the pooled ORs for the risk of 
developing oral cancer were 1.85 (95% CI: 1.60 to 2.15; N studies: 37) for individuals with low 
educational attainment, 1.84 (95% CI: 1.47 to 2.31; N studies: 14) for those with low occupational 
social class and 2.41 (95% CI: 1.59 to 3.65; N studies: 5) for people with low income. As a systematic 
review, the above represents a high level of observational evidence for the association of SEP with 
OPC. However, findings from this research relate to a combination of OPC and oral cavity cancer, thus 
the exact effects of SEP measures on the risk of OPC as a unique HNC sub-type may differ from those 
reported. 
 
At a regional level, a study investigating the socioeconomic factors associated with risk of 
upper aerodigestive tract cancer (cancer of the lip, tongue, major salivary glands, gums and adjacent 
oral cavity tissues, floor of the mouth, tonsils, oropharynx, nasopharynx, hypopharynx and other oral 
regions, nasal cavity, accessory sinuses, middle ear, and larynx) in Europe found educational 
attainment to be significantly associated with risk of oral cancer incidence [78]. Educational 




further/technical and university. (Further and technical education is education beyond secondary level 
and includes further and technical colleges.) This was further grouped into three broad educational 
levels: primary (no education/primary); secondary and tertiary (further/technical/university). 
Compared to those with a tertiary education, primary education was associated with an 81% increase 
in risk of incident oral cancer (OR: 1.81; 95% CI: 1.46 to 2.23). Additionally, when compared to tertiary 
education in Europe, adults only possessing a primary education in the British Isles were associated 
with risk of upper aerodigestive tract cancer (oral cavity, pharynx [excluding nasopharynx], larynx and 
oesophagus) in men with an OR of 19.88 (95% CI: 2.55 to 154.94) and in women with an OR of 3.07 
(95% CI: 0.61 to 15.42). Whilst this study adds to the evidence for SEP affecting risk of OPC (this time 
in Europe, via a large multi-centre study), as above, it does not examine SEP against OPC as a unique 
HNC sub-type.  
 
In the UK, the association between socioeconomic factors and incidence of upper 
aerodigestive tract cancers has been assessed in the Scottish Longitudinal Study; a large-scale linkage 
study including: census data from 1991 onwards, vital events data (births, deaths, marriages), NHS 
Central Register data (gives information on migration into or out of Scotland), and education data 
(including Schools Census and SQA data) [79]. When examining the interrelationship between 
deprivation and educational attainment on risk of upper aerodigestive tract cancers, comparing 
individuals from affluent areas with a diploma/higher education to individuals from a deprived area 
with no education, men had a >2-fold increase in risk of upper aerodigestive tract cancer (OR: 2.10; 
95% CI: 1.55 to 2.84) and women had a 64% increase in risk (OR: 1.64; 95% CI: 1.09 to 2.49). At a global 
European, and country-specific (Scotland) level, it appears that the risk of SEP on OPC has only been 
established as part of a broader combination of HNC sub-types. Accordingly, whilst these cancers may 
share some common risk factors, the risk of SEP on OPC specifically may differ from these estimates; 
they are not the same entities. 
 
The evidence above provides a basis for investigation of macro-environment associated with 
low SEP against risk of OPC. Low educational attainment, restrictions in healthcare, poor hygiene, poor 
nutrition, type of profession and poor environment may all affect risk of OPC through complex societal 
interactions in synergy with risk behaviours (e.g. smoking, alcohol consumption, sexual behaviour) 






 BMI appears to show moderate evidence of an inverse association with OPC in 
epidemiological literature, with lower BMI greatly increasing OPC risk. A 2003 case-control study of 
304 cases and 304 controls by Nieto et al., lifetime BMI was investigated against risk of oral cancer 
and OPC (combined) in a European population (Spain) [80]. The authors found that both low weight 
(≤65kg) and low BMI (≤22kg/m2) at diagnosis showed substantial increases in OPC risk (weight OR: 
3.57; 95% CI: 2.32 to 5.51, BMI OR: 3.64; 95% CI: 2.27 to 5.82). Interestingly, these findings were also 
established 2 years prior to diagnosis, displaying equally large risk estimates (weight OR: 2.96; 95% CI: 
1.93 to 4.53, BMI OR: 3.31; 95% CI: 2.04 to 5.39). Despite the presence of pre-diagnostic information, 
phenotype derivation was based on patient self-report questionnaires responses for patient height 
and weight. Accordingly, recall bias and measurement error may be a source of significant bias, 
decreasing the level of evidence these findings represent. Furthermore, these findings represent the 
effect of self-report BMI on a combination of oral cancer and OPC. As such, there is ambiguity with 
regard to the effect of weight and BMI on OPC specifically. 
 
 A 2015 paper by Maasland et al., using the Netherlands cohort study to investigate BMI on 
risks of sub-types of HNC, found that a BMI of <18.5 kg/m2 at diagnosis (vs those with a BMI between 
18.5 kg/m2 and 25 kg/m2) conferred a risk ratio for hypopharyngeal and OPC (combined) of 4.96 
(95%CI: 1.34 to 18.33) [81]. BMI of greater than 25 kg/m2 did not affect risk of these cancers. However, 
despite use of a population cohort study, BMI was again measured using self-report questionnaire, 
conferring the same risk of bias as Nieto et al. Furthermore, the authors combined OPC and 
hypopharyngeal cancer, preventing the quantification of an OPC-specific BMI risk estimate. Lastly, the 
number of cases in this study with a BMI <18.5 kg/m2 was 3, with 44 cases as the 18 kg/m2 to 25 kg/m2 
reference. The small number of cases and controls in this study greatly increases the likelihood of a 
type 1 error affecting the results, thus decreasing the confidence with which any findings can be 
established as true.  
 
 Finally, a study of BMI and risk of HNC in a pooled analysis of 17 case-control studies from the 
INHANCE consortium reports OPC risk estimates of 2.64 (95% CI: 2.05 to 3.39) for a BMI of ≤18.5 
kg/m2 (vs a BMI of >18.5 kg/m2 to 25 kg/m2; 215 cases, 358 controls) [82]. Interestingly, higher BMI 
categories show an inverse association with risk of OPC, including those with a BMI exceeding the 
obese index of 30 (BMI >25 kg/m2 to 30 kg/m2 OR: 0.49; 95% CI: 0.40 to 0.60; 845 cases and 5,714 
controls,  BMI >30 kg/m2 OR: 0.42; 95% CI: 0.32 to 0.56; 302 cases and 2,211 controls). The same 




3.84; 74 cases and 187 controls, BMI >25kg/m2  to 30 kg/m2 OR: 0.55; 95% CI: 0.44 to 0.70; 374 cases 
and 1,855 controls, BMI >30kg/m2 OR: 0.46; 95% CI: 0.28 to 0.75; 139 cases and 867 controls). This 
study presents evidence for the effect of BMI on OPC as a distinct HNC sub-type and possesses a large 
sample size, increasing the reliability of evidence provided. However, it still relies on self-report 
questionnaire data to derive BMI, thus introduces recall and measurement biases to the risk estimate 
given. Finally, a key issue for all of the above observational studies is that reverse causality cannot be 
excluded. Whilst it is plausible that low BMI increases risk of OPC, it is equally plausible that OPC 
carcinogenesis and progression causes a reduction in BMI.  
 
 In summary, low BMI appears to be consistently associated with risk of OPC (or a combination 
of OPC and another HNC sub-type). However, the combination of OPC with other sub-types and small 
sample sizes in an observational design may lead to effect estimates which are biased by multiple 
factors, including recall bias and measurement error from self-report questionnaire use (affecting the 
precision of BMI measurement), reverse causation and a lack of precision (alluded to above). 
Accordingly, a directional, robust causal estimate for BMI on OPC risk has yet to be determined.  
  
1.1.3. Clinical impact of OPC 
Diagnosis of OPC 
OPC often presents with nonspecific symptoms, resulting in a high number of late-stage diagnoses 
and highlighting the need for primary prevention of this disease. A common presentation of an OPC 
patient is a painless neck lump, with few other symptoms. Other possible symptoms may include a 
sore throat or tongue, otalgia (ear pain), pain and/or difficulty swallowing and/or a change in voice 
quality. The United Kingdom Multidisciplinary Guidelines for OPC [83] recommend the following four 
practices for assessment of the disease. Box 1.1 describes the various techniques mentioned by these 
practices. 
 
1. Cross-sectional imaging is required in all cases to complete assessment and staging 
2. Magnetic resonance imaging (MRI) is recommended for primary site and computed 
tomography (CT) scan for neck and chest 
3. Positron emission tomography (PET) combined with CT scanning (PET-CT) is recommended for 
the assessment of response after chemoradiotherapy, and has a role in assessing recurrence 





Box 1.1 - Description of techniques used in the UK Disciplinary Guidelines for management of OPC 
Cross-sectional imaging methods employed in the diagnosis of OPC include MRI, CT, ultrasound and 
PET (typically combined with CT scanning). MRI employs strong magnetic fields and radio waves to create an 
image of human anatomy. Furthermore, MRI can be conducted with the inclusion of a contrast dye injection 
(gadolinium contrast media) to make tissue and blood vessels show up in greater detail. Consequently, MRI with 
contrast is considered optimal for staging the primary (origin) oropharyngeal tumour; the tumour and soft tissue 
spread from it can be visualised, allowing the full extent of the primary to be viewed.  
CT scans combine a series of X-ray images to create cross-sectional images (sometimes 3-dimensional) 
of bones, blood vessels and tissue within the body. As such, CT scans are particularly useful in assessing the 
extent of nodal metastases and bony invasion; a vital component of determining cancer stage (see Staging, 
below). Distant metastases should be assessed by CT scanning of the chest and upper abdomen, to exclude 
metastatic disease to the lungs and liver.  
Positron emission tomography (PET) involves injection of a radioactive sugar (a radiotracer) into the 
body, which is detected by a scanner in order to visualise metabolic processes. Cancers typically require more 
energy than healthy tissue, thus the cancer may be visualised by a detected concentration of radiotracer in the 
body. Fluoro-deoxy-glucose (FDG) is a radiotracer commonly used in oncological PET scans. Supported by the 
results of the UK PET-Neck randomised controlled trial (RCT) study, PET using FDG, combined with CT scanning 
(F-FDG PET–CT) is recommended for the assessment of an individual’s response to treatment approximately 
three months post-chemoradiotherapy, particularly in patients with advanced nodal disease. F-FDG PET–CT 
scanning also has a role in the assessment of recurrent tumours and can detect recurrence at primary sites, neck 
nodes and/or distant metastases due to it allowing visualisation of contrasting (healthy vs cancer) metabolic 
rates.  
Finally, ultrasound is a form of imaging which uses high-frequency sound waves to create an image of 
internal anatomy. Ultrasound can be used to guide a needle to conduct a histological biopsy (fine needle biopsy), 
or without a needle biopsy as a direct visualisation of an OPC tumour. According to the UK Multidisciplinary 
Guidelines for OPC, ultrasound should be carried out for all patients presenting with a neck lump and is an 
accurate method of staging nodal disease in experienced hands.  
 
Staging of OPC 
Pre-treatment staging for primary oropharyngeal tumours is based on the tumour–node–
metastasis (TNM) classification (8th edition) [84], shown in Box 1.2. Each letter describes a different 
aspect of tumour biology: “T” describes the size of the tumor and any spread of cancer into nearby 
tissue, “N” describes spread of cancer to nearby lymph nodes and “M” describes metastasis. This 
system was created and is updated by the American Joint Committee on Cancer (AJCC) and the 





Box 1.2 – Details of TNM staging criteria for OPC  
TNM staging for oropharyngeal squamous cell carcinoma 
TX: Primary tumour cannot be assessed 
T0: No evidence of primary tumour 
Tis: Carcinoma in situ 
T1: Tumour 2 cm or less in greatest dimension 
T2: Tumour larger than 2 cm but 4 cm or less in greatest dimension 
T3: Tumour larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis 
T4a: Tumour invades the larynx, deep/extrinsic muscle of tongue, medial pterygoid, hard palate or mandible 
T4b: Tumour invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases 
carotid artery 
 
Quality of life for OPC patients 
Quality of life (QoL) in HNC is commonly assessed via self-report questionnaire [85-87]. 
Despite only being the 8th most common cancer worldwide, HNC development and treatment are 
known to cause a substantial deterioration in a patient’s QoL [88]. Current OPC treatment modalities 
include external beam radiation therapy (EBRT: high-energy x-ray beams are targeted at the tumour 
from outside the body to destroy cancer cells), chemoradiation therapy (CRT: combined 
chemotherapy and radiation therapy to improve disease response to treatment [89]), altered-
fractionation radiation therapy (AFRT: the use of varied, frequent, short doses of radiotherapy [90]), 
intensity-modulated radiation therapy (IMRT: a type of radiotherapy that closely conforms to the 
shape of a tumour to minimise radiation of healthy neighbouring tissue [91] - sometimes this modality 
is combined with chemotherapy), surgery or brachytherapy (BT: treatment which places sealed 
radioactive sources inside the patient to destroy tumour cells [92]). The above treatments impact QoL 
of OPC patients differentially, affecting swallowing, pain, speech, salivation, social and emotional 
factors [93]. Consequently, social and personal intimacy, nutrition, biological function and self-esteem 
(and depression) can be substantially affected, providing a strong rationale for development of 
prevention strategies for OPC.  
 
1.1.4. OPC prognostication 
Current prognostication for OPC in clinical practice is based on a combination of HPV status 
and TNM staging [94]. However, despite the prognostic value added by taking HPV status into 




stage [95]. The prognostic importance of molecular biomarkers and clinical features separate from 
TNM staging and HPV status have become increasingly apparent in epidemiological literature [96]. As 
such, there remains a need for accurate risk stratification that combines existing prognostic factors 
with novel molecular biomarkers and other personalized features. With more accurate 
prognostication in patients with OPC, patient treatment and management can be optimised and 
prioritised. Below, prognostic indicators of OPC will be explored. 
 
Prognostic factors for OPC 
 Perhaps the most reported prognostic factor other than TNM stage for OPC in epidemiological 
literature is HPV. The substantial survival advantage seen by those with OPC who are HPV-positive 
compared with HPV−negative has led to the 8th edition TNM classification for these cancers to include 
p16INK4A immunostaining as a proxy for HPV-positivity, resulting in a lower TNM stage for these 
tumours compared to previous editions [84]. Furthermore, clinical trials are beginning to investigate 
the effect of de-escalation of treatment for HPV-positive OPC. One proposal for de-escalation of 
treatment of this sub-group is that, to reduce toxicity, radiotherapy in conjunction with cisplatin may 
be able to be replaced with radiotherapy in conjunction with cetuximab. However, two recently 
published trials, De-ESCALaTE HPV (Determination of Epidermal growth factor receptor-inhibitor 
[cetuximab] versus Standard Chemotherapy [cisplatin] early And Late Toxicity Events in Human 
Papillomavirus-positive oropharyngeal squamous cell carcinoma) [97] and RTOG-1016 (Radiation 
Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer) [98], have 
found that attempting to de-escalate treatment with cetuximab and radiotherapy vs cisplatin and 
radiotherapy unexpectedly causes a decrease in overall survival. Whilst these findings clearly highlight 
the need for caution in de-escalation trial design and operation, they also demonstrate the high level 
of evidence established for the improved prognostic value of HPV-positivity in OPC. 
 
In 2015, Keck et al. discovered that HPV-positive HNC could be stratified depending on gene 
expression patterns [99]. Using gene expression-based consensus clustering, the authors found that 
HPV-positive HNC (including an OPC-only analysis) could be classified into 2 groups based on 
expression of CD8A/B; a marker of enrichment of cytotoxic T-cell infiltration. Zhang et al. were also 
able to stratify HPV-positive HNCs by gene expression, characterised by either by elevated immune 
response and mesenchymal differentiation (named HPV-IMU), or by elevated keratinocyte 
differentiation and oxidation-reduction process (named HPV-KRT) [100]. Expression analyses showed 
that HPV-KRT tumours showed a higher frequency of integrated HPV in genic regions and had higher 




to the non-spliced E6 variant (which is reported to downregulate a large number of genes involved in 
keratinocyte differentiation, and upregulate genes normally expressed in mesenchymal lineages 
[102]). Interestingly, HPV-IMU tumours were enriched for chromosome 16q losses compared to HPV-
KRT tumours; shown to correlate with improved survival in OPC [103]. Moreover, HPV-IMU tumours 
displayed improved immune response compared to HPV-KRT, which has been shown to confer a 
survival advantage amongst those with HPV-positive cancer [104]. Given the divergence between the 
HPV-IMU and HPV-KRT subgroups, different treatment strategies may improve prognosis. Zhang et al. 
hypothesise that the HPV-IMU subgroup may benefit more from immunotherapies and treatment 
targeting epithelial-to-mesenchymal transition, whilst HPV-KRT may benefit from strategies to induce 
tissue-based inflammation. In light of unexpected de-escalation trial findings and a lack of 
personalised medicine for OPC, the above unique expression profiles offer important translational 
findings. 
 
Other prognostic factors to have been shown to derive effective prognostic models in HPV-
positive OPC, highlighting their prognostic importance. Ward et al. developed a prognostic model for 
HPV-positive tumours, consisting of a combination of tumour-infiltrating lymphocyte levels, heavy 
smoking, and T-stage [105].  Findings were validated by area under a receiver-operator-characteristic 
(ROC) curve (AUC: a measure between 0 and 1 of the sensitivity and specificity of a predictive model, 
where 1 is perfect prediction) and found to show good predictive value in an independent ‘testing’ 
cohort (AUC: 0·82). In agreement with current literature, Ward et al.’s findings suggest that immune 
response (in this instance shown by tumour-infiltrating lymphocyte levels) plays an important role in 
the improved survival seen in most HPV-positive patients and is relevant for the clinical evaluation of 
HPV-positive OPC. Notably, this model also features heavy smoking as a prognostic factor, highlighting 
the importance of this behaviour on OPC outcomes, independently of HPV infection. 
 
In a prospective study to identify markers of response to therapy to prevent organ loss in 
advanced OPC, Kumar et al. report low EGFR expression and high p16 expression (highly correlated 
with HPV infection in HNC [106]) to be markers of good response to organ-sparing therapy (induction 
chemotherapy and chemoradiotherapy), overall survival and disease-specific survival [107]. 
Conversely, high EGFR expression, combined low p53 and high antiapoptotic protein Bcl-xL expression 
(associated with chemotherapy and radiation resistance [108], in addition to cisplatin resistance 
[109]), female sex and smoking were associated with a poor outcome. The authors found EGFR 
expression to be associated with current smoking (P: 0.04), female sex (P: 0.05), and lower HPV titre 




determination of HPV status and stratification by combined p53/Bcl-xL expression are key 
considerations when determining the prognostic outcome, intensity of treatment and modality of 
treatment for OPC patients. 
 
In summary, HPV status and smoking appear to be consistently, strongly associated with OPC 
prognosis. Interestingly, alcohol consumption did not appear as a major prognostic indicator in any of 
the models described above. Within HPV-positive tumours, there appears to be sub-categories of OPC 
which show gene expression profiles associated with improved immune response (HPV-IMU) or 
keratinocyte differentiation (HPV-KRT). These tumours have different prognostic outcomes and 
response to therapy; thus, care should be taken to discern the sub-categories of HPV-positive OPC 
when determining treatment strategies, particularly when considering de-escalation of treatment. 
Finally, expression of EGFR, p53 and Bcl-xL appear to also show both an interplay with HPV status and 
smoking, in addition to independent effects on survival and treatment resistance.  
 
1.2. Genetics of oropharyngeal cancer 
1.2.1. Introduction to genetics of OPC 
The genetic contribution to OPC carcinogenesis describes an accumulation of genetic 
variations (via genetic mutation, amplification or translocation) in proto-oncogenes and tumor-
suppressor genes, which cause genetic instability and cumulatively lead to OPC. An oncogene is 
created by mutation (typically a gain-of-function mutation) of a proto-oncogene, which alters the 
original function of the proto-oncogene to affect transformation of normal cells into cancer cells. 
Proto-oncogenes typically encode proteins such as growth factors and their receptors, signal-
transduction proteins, transcription factors and cell cycle control proteins. Gain-of-function of these 
proteins in oncogenes results in rapid, abnormal cell growth seen in cancer. Conversely to proto-
oncogenes, tumor-suppressor genes generally produce proteins which arrest and monitor cell 
proliferation; loss-of-function mutations in these genes promotes oncogenesis. Tumor-suppressor 
genes inhibit cell cycle progression at specific stages, inhibit general cell proliferation, stop cell cycle 
progression if DNA is damaged/abnormal, promote apoptosis and produce enzymes which aid in DNA 
repair. Loss-of-function of tumor-suppressor genes, coupled with oncogene activation, result in a 
severely dysregulated cell cycle, allowing rapid proliferation of cells containing abnormal DNA. 
Identifying factors which affect the genetic stability of a healthy oropharynx cell to promote 




common genetic causes of tumorigenesis are chromosomal instability and copy number variation. 
These will be discussed below in the context of OPC. 
 
1.2.2. Chromosomal instability 
Chromosomal instability is a genetic variation, recognized as a hallmark of cancer [110], which 
affects chromosome structure and number in cells. Chromosomal instability is typically classified as 
either numerical or structural instability in solid tumors - structural instability involves gain or loss of 
part of a chromosome, whereas numerical instability involves gain or loss of entire chromosomes 
(known as aneuploidy) [111]. Although poorly understood, chromosomal instability is thought to 
result from defects in mitotic processes  (Figure 1.12) [112]. 
 
 
Figure 1.12 - The process of chromosomal instability via defects in mitotic processes. Incorrect replication is thought to cause 
structural instability and errors in segregation are thought to affect numerical instability. 
 
One method of quantifying chromosomal instability is via fluorescence in-situ hybridization 
(FISH). FISH is a cytogenetic technique which implements fluorescent DNA probes to localize positions 
within a chromosome, through use of highly complementary sequences and a fluorescent microscope. 
A 2010 study by Sato et al. used FISH to investigate fine-needle aspiration (FNA – a procedure where 
a thin, hollow needle is used to retrieve cells) biopsy samples for chromosomal instability in oral 




(CIN grade) in 77 OSCCs, choosing to examine chromosomes 7, 9 and 11. CIN grade was defined 
according to the proportion of cells within the tumor that had copies of chromosomal genetic 
information which differed to (greater or less than) the modal average [114]. A three-tier scale was 
used: CIN1 was defined as < 20% of the cells in the tumor differing from the modal average, CIN2 as 
≧ 20% and < 40% of the cells, and CIN3 as ≧ 40% of the cells differing from the modal average. Using 
this method, Sato et al. established that CIN grade could “be useful in predicting of recurrence and 
poor prognosis in patients with oral SCCs”. CIN3 was seen in 11.7% (9/77) OSCC tumors and showed a 
significant association with reduced disease-free 5-year survival (P: 0.008). Furthermore, CIN grade 
was associated with a poor outcome in disease-free 5-year survival (HR: 3.48; 95% CI: 1.10 to 11.1; P: 
0.035) and overall 5-year survival (HR: 3.71; 95% CI: 1.06 to 13.0; P: 0.041) in Cox proportional-hazards 
analyses adjusting for age, sex, cellular differentiation and disease stage. 
 
In the context of OPC, chromosomal instability has been investigated in relation to smoking 
and HPV16 infection. A 2019 study by Villepelet et al. investigated the effects of tobacco abuse on 
major chromosomal instability in HPV16-positive OPSCC using an array-based comparative genomic 
hybridization approach [115]. Examining 50 OPSCC patients, Villepelet et al. discovered that HPV‑
positive tumors had fewer genomic aberrations (P=0.008) and fewer breakpoints (P=0.048) than HPV
‑negative tumors. The authors confirmed an association between HPV‑positive OPSCC and 
chromosomal losses at 11q. They also reported an association between HPV‑negative OPSCC, losses 
at 3p and 9p and gains at 7q and 11q13. In the patients with OPSCC who were HPV‑positive, the total 
number of chromosomal aberrations per tumor was significantly higher in the group of patients who 
were smokers (P=0.003). In support of these findings, recent in-vitro studies investigating the effect 
of HPV16 on chromosomal instability have found the two to be inversely associated, finding that high-
risk HPV sub-types with a high viral immortalization capacity (HPV16/18/31/33/35) can immortalize a 
cancer cell much faster than other HPV types. Instead, it is thought that high-risk HPV with a lower 
viral immortalization capacity (HPV45/51/59/66/70) requires DNA to undergo many more aberrations 
to achieve the same immortalized state.  
1.2.3. Copy number variation 
As a tumor cell acquires genetic mutations, the number of copies of chromosomal regions or 
sections of genes can change (most commonly via deletion and duplication), known as copy number 
variation. Affected genes can include oncogenes, tumor suppressor genes and other genes associated 
with genomic instability. Few studies investigate these copy number variations specifically in the 




were shared across oral cavity, hypopharyngeal cancer and OPC [116]. Gains of genomic regions from 
the long arm of chromosome 3 (3q), containing PIK3CA and AGTR1 genes, were more frequent in 
cancer cases with lymph node involvement vs those without affected lymph nodes. In addition, cancer 
cases not treated with surgery were associated with gains of band 21 on the long arm of chromosome 
7 (7q21) and gains of the entire long arm of chromosome 20 (20q) vs those cancer cases that were not 
[116]. Interestingly, Suda et al. found that copy number amplification of PIK3CA was associated with 
HNC relapse (which occurs in lymph nodes in most cases [117]) in those who did not have lymph node 
involvement [118]. This finding may partly explain the increase in copy number of PIK3CA seen by 
Zagradišnik et al.; PIK3CA copy number increase may be associated with relapse in individuals without 
lymph node involvement, causing the observed associated with lymph node involvement. In contrast 
to Zagradišnik et al. and Suda et al., Resteghini et al. found that an increase in copy number of PIK3CA 
genes was associated with favourable clinical outcome in HPV-negative OPC [119]. Despite being a 
known oncogene, the specific prognostic role of PIK3CA copy number in OPC is currently unclear. 
 
1.2.4. Conclusion 
OPC shows a higher incidence rate in developing countries due to increased tobacco and 
alcohol consumption. These risk behaviors are known to increase the rate of genetic mutation and 
could bring about carcinogenesis by disrupting the genomic stability of a healthy cell. The gene regions 
discovered by investigation of chromosomal instability and copy number variation could provide 
deeper insight into OPC etiology and may be useful as therapeutic targets for the disease. Greater 
insight is needed into the somatic mutational landscape of OPC as a unique HNC sub-type. 
 
1.3. Epigenetics of oropharyngeal cancer 
1.3.1. Introduction to epigenetics 
The epigenetic contribution to cancer describes heritable changes in gene expression which 
occur independently of the primary DNA sequence to affect carcinogenesis [120]. Whereas genetic 
drivers of cancer directly affect the underlying sequence of bases in a DNA sequence, epigenetic 
changes regulate gene expression by affecting the access of cellular machinery to the DNA sequence. 
Two predominant types of epigenetic change are investigated with respect to cancer: DNA 
methylation and histone modification. DNA methylation involves the addition of a methyl (CH3) group 






Figure 1.13 - The process of DNA methylation, as the addition of a methyl group to the fifth carbon of a cytosine base 
 
This reversible process is catalysed by enzymes known as DNA methyltransferases (DNMTs), 
predominantly occurring (>98% in somatic cells) between cytosine and guanine bases, naturally 
separated by a single phosphate molecule in the DNA sequence. As such, specific sites of methylation 
in the genome are referred to as “CpG” dinucleotides. CpG sites typically play a central role in the 
silencing of gene expression, though in less common situations, methylation can also increase gene 
expression. 
 
It is largely accepted that a variety of environment and lifestyle factors (diet, behaviour, stress, 
physical activity, working habits, alcohol and tobacco consumption, etc.) can have a negative impact 
on health, and contribute to the development of a large array of diseases (including that of cancer). 
Synergistically with other epigenetic mechanisms, DNA methylation allows cells (and by extension, 
organisms) to adapt to these factors at a speed that mutational mechanisms cannot. Thus far, DNA 
methylation has been associated with numerous cellular processes, including transcriptional 
repression, X chromosome inactivation, cell differentiation, genomic imprinting, alteration of 
chromatin structure and transposon inactivation. If dysregulated, the adaptation DNA methylation 
confers can be disrupted, potentially mediating the development of diseases such as cancer. DNA 
methylation has been the most measured epigenetic mark because of its obviously fundamental 
biological interest, its mitotic stability, the availability of methods for its quantification (globally or in 
targeted regions), its stability during DNA extraction and purification procedures, and its durability in 
archival biological materials. 
 
The second type of epigenetic modification commonly investigated is histone modification. 
Histones are proteins which affect the compaction of DNA, which provide structural support and affect 
how available DNA is for transcriptional activation. A histone “core” consists of 8 histone proteins (2 




histone cores (each of 8 histone proteins) is known as a nucleosome and is considered a basic unit of 
chromatin. Histone proteins have an outward-facing “tail” of amino acid residues, which are positively 
charged. The positive charge of histone protein amino acid tails interacts with the negatively charged 
phosphate groups in DNA to form tightly compacted chromatin. To relax the compaction of DNA, a 
process known as histone acetylation modifies the charge of histone protein amino acid tails. 
Facilitated by enzymes known as histone acetyltransferases, acetyl groups are transferred from 
available acetyl coenzyme-A molecules to NH3+ groups of lysine amino acids of histone protein tails, 
neutralising the overall positive charge. This reduces the degree to which histone cores are bound to 
DNA, relaxing a nucleosome, thus making it more available for transcriptional machinery to access. 
The process can be reversed, known as histone deacetylation, via facilitation by enzymes known as 
histone deacetylases. 
 
1.3.2. Example of blood-based methylation changes in OPC 
Tumour suppressor activity has been shown to be associated with changes in DNA 
methylation in OPC. The galanin gene codes for a neuropeptide which regulates anterior pituitary 
hormone secretion and acts as neurotransmitter [121]. GALR1 and GALR2, two receptors for GAL, are 
members of the G protein-coupled receptor (GPCR) superfamily. Galanin and these receptors regulate 
cell growth by inhibiting extracellular signal-regulated kinase (ERK) 1/2, upregulating cyclin-dependent 
kinase inhibitors p27 and p57, and decreasing expression of cyclin D1 [122]. These cellular processes 
work to arrest the cell cycle. Hypermethylation of these genes causes them to lose their tumour 
suppressor activity. Misawa et al. found that, in a study of HNC methylation patterns, 13 out of 20 OPC 
cases (65%) had hypermethylation of at least one of the above genes [123]. 
 
1.3.3. Example of saliva-based methylation changes in OPC 
Saliva is an emerging diagnostic medium for OPC which may prove a lucrative resource for 
examination of shed tumour DNA, in addition to being a non-invasive collection technique. 
Furthermore, saliva may prove to be a tissue proxy for the tonsillar crypt DNA, which are difficult to 
extract DNA samples from. Genes observed to be hypermethylated in saliva samples in OPC in wider 







Table 1.1 - List of genes found hypermethylated in saliva samples and their function 
Gene Gene product Function 
CCNA1 Cyclin A1 Cell cycle regulation 
DAPK1 Death-associated protein 
kinase 1 
Apoptosis and autophagy 
ERCC1 Excision repair cross-
complementation group 1 
Repair of DNA damage induced by 
ultraviolet light or cisplatin 
TIMP3 Metalloproteinase inhibitor 3 Inhibitor of the matrix metalloproteinases 
 
1.4. Summary, research gaps and aims of this thesis 
OPC is an increasingly prevalent disease in the UK, affecting greater proportions of younger 
individuals. Epidemiological literature surrounding risk factors for OPC incidence provide 
observational estimates, with most studies combining OPC with other HNC sub-types. It should also 
be noted that a vast amount of epidemiological literature has been published investigating the same 
three risk factors. Observational epidemiological literature is prone to bias from confounding and 
reverse causation; coupled with few studies investigating OPC exclusively, it is difficult to ascertain the 
true causal effect of reported risk factors on OPC. Genetic epidemiology can circumvent the common 
pitfalls of observational epidemiology by proxying these phenotypes with genetic variants, in an 
approach known as Mendelian randomization (MR; see Chapter 2). Furthermore, few epigenetic 
studies of OPC exist (indeed, a paucity in relation to OPC prognosis/mortality) – those that do display 
low sample sizes with a lack of replication of findings. Larger sample sizes, repeated findings and causal 
inference methods are necessary to elucidate and appraise legitimate causal pathways, potentially 
improving our knowledge of risk factor and prognostic pathways in OPC. The aims of this thesis are 
therefore as follows: 
 
1) Retrieve existing risk factors from observational epidemiological literature, via literature 
mining, to form an evidence base for downstream analyses and identify novel areas of 
investigation 
2) In a hypothesis-free approach, appraise risk factors against OPC incidence in a robust causal 
inference framework (Mendelian randomization) using genetic data. Risk factors currently 




3) Use epigenetic data from whole-blood to investigate whether DNA methylation is associated 
with OPC risk factors, and if so, whether DNA methylation can be used to interrogate biological 
pathways associated with these risk factors. Furthermore, ascertain whether DNA 
methylation is associated with OPC mortality, and if so, whether shared methylation patterns 
with risk factors can be used to appraise causal pathways between the two 
4) Exploit the utility of whole-blood methylation as a biosocial archive to derive epigenetic 
predictors of risk factors and mortality, to ascertain whether epigenetic predictors of the 











This chapter will introduce the basic methodological principles which underpin the thesis, 
from which more applied approaches are derived and applied in later results chapters. Core methods 
are described, then classified according to how they supplement the thesis workflow, in Figure 2.1. 
Additionally, the datasets utilised throughout this thesis are introduced and described, detailing which 
methods they are applicable to.  
 
We are currently in an era where a vast amount of genetic and epigenetic data are publicly 
available, as well as a multitude of bioinformatic techniques to curate them. These data can be used 
(in both a hypothesis-generating, and subsequent hypothesis-driven manner) to improve elucidation 
and understanding of the causal pathways of OPC incidence and progression. Using a combination of 
hypothesis-generating methodology, including genome-wide and epigenome-wide association studies 
(GWAS and EWAS, respectively), enriched literature object mining and MR analyses (hypothesis-free 
[124], two-sample [125], and two-step MR [126]), robust causal pathways associated with OPC 
incidence and progression may be established and appraised. This chapter highlights how the 
employed methods and data resources combine to form a theoretical workflow which aims to 
augment understanding of OPC incidence and mortality. 
 




2.2. Methodological workflow 
2.2.1. Literature mining 
Published scientific literature contains a wealth of information from multiple specialist fields. 
Given that, at its core, science is a cumulative endeavour, possessing a solid foundation of existing 
knowledge to build upon and compare findings to is fundamentally important to the progression of 
any scientific research. Review of scientific literature allows the researcher to: identify what 
information already exists, identify patterns or trends in data, combine existing findings to answer a 
specific research question, generate novel hypotheses and identify areas where a paucity of research 
exists. Templier and Paré outline 6 steps necessary to write a typical review article [127]: 
1. Formulating the research question(s) and objective(s) 
2. Searching the extant literature 
3. Screening for inclusion 
4. Assessing the quality of primary studies 
5. Extracting data 
6. Analysing data 
Despite the generic steps taken to write a review article, methodologies differ widely depending 
on the research question, aims and scope of the review. Nine review types comprise the vast majority 
of published literature reviews [128], overviewed in Table 2.1. These are then briefly described in 





Table 2.1- Nine of the most common scientific review types, the goals they seek to achieve and the methods they employ to achieve them 














Narrative review Broad Usually selective Conceptual and empirical No No Narrative summary 
Descriptive review Broad Representative Empirical Yes No Content analysis/frequency 
analysis 
Scoping review Broad Comprehensive Conceptual and empirical Yes Not essential Content or thematic analysis 
Data aggregation 
or integration 




Narrow Comprehensive Empirical (quantitative) Yes Yes Narrative synthesis 
Umbrella review Narrow Comprehensive Systematic reviews Yes Yes Narrative synthesis 
Explanation 
building 
Theoretical review Broad Comprehensive Conceptual and empirical Yes No Content analysis or 
interpretive methods 
Realist review Narrow Iterative and 
purposive 




Critical review Broad Selective or 
representative 






Table 2.2 - Examples and rationales for each of the most common types of epidemiological review 
Review type Why is it conducted? Example 
Narrative review To identify what has been written on a 
subject 
Skogen and Øverland conducted a narrative 
review to identify information pertaining to 
the fetal origins of adult disease [129] 
Descriptive 
review 
To examine data for patterns/trends, 
against pre-existing research questions, 
hypotheses or focuses 
Harborne et al. conducted a descriptive 
review of the evidence for the efficacy of 
metformin in polycystic ovary syndrome, to 
improve clinicians' knowledge of the 
available published clinical evidence [130] 
Scoping review To indicate the volume and nature of 
literature related to a particular subject 
Takahashi et al. conducted a scoping review 
of the volume and quality of literature 
describing risks and supports to 
competence for occupational therapists, 






To aggregate and appraise quantitative 
data in the form of standard effect 
measures (e.g. odds ratios, prevalence 
etc.) from two or more functionally 
similar studies, taking into account the 
relative sample size of each study 
Zhou et al. conducted a meta-analysis of 
spider mite sensitivity, to estimate the 
global prevalence of allergies to spider 




To search, identify, select, appraise, and 
abstract data from literature using 
narrative and more subjective (rather 
than statistical, above) methods to bring 
together the findings of included studies 
Beasant et al. conducted a qualitative 
systematic review to determine treatment 
preference and recruitment in paediatric 
randomised controlled trials [133] 
Umbrella review To integrate information from multiple 
systematic reviews (qualitative or 
quantitative) into one accessible and 
usable document to address a narrow 
research question 
Veronese et al. conducted an umbrella 
review to collate systematic review 
information on whether chocolate 




To develop a conceptual framework or 
model with a set of research propositions 
or hypotheses 
Grover et al. published a review protocol. 
They will evaluate the methodological and 
clinical aspects of Mendelian randomization 
studies using neurodegenerative disorders 




Review type Why is it conducted? Example 
depth understanding of what can be done 
in future for the derivation of true causal 
risk factors [135] 
Realist review To inform, enhance, extend or 
supplement conventional systematic 
reviews by explaining conflicting 
evidence about complex interventions 
applied in diverse contexts, typically to 
inform policy decision making 
Mogre et al. conducted a realist review of 
educational interventions (what sort of 
educational interventions work, how, for 
whom, and in what circumstances) to 
improve the delivery of nutrition care by 
doctors and future doctors [136] 
Critical review To critically analyse the existing literature 
related to a broad topic to reveal 
weaknesses, contradictions, 
controversies, or inconsistencies 
Chang et al. conducted a critical review of 
the various epidemiological studies 
investigating Agent Orange or 2,3,7,8-
tetrachlorodibenzo-p-dioxin and lymphoid 
malignancies [137] 
 
In the context of appraising risk factors and intermediates for OPC, various stages in the 6-
point list for conducting literature reviews are a source of potential subjectivity and a large time 
burden. Firstly, deriving a search strategy to systematically appraise all epidemiological risk factors 
and intermediates for OPC (above simply screening all OPC literature) would introduce subjective bias 
based on what a researcher deemed necessary to include as a potential risk factor. Secondly, the sheer 
volume of literature available for review introduces a substantial time burden when searching and 
screening manually. Search strategies are often refined by inefficient methodologies such as arbitrary 
criteria, filtering by journal impact factor, social media influence and word of mouth [138]. In addition 
to the introduction of bias to a literature review, “filtering” in this way also greatly reduces the number 
of hypotheses that can be examined. Automated, systematic text-mining may be a review approach 
that can augment discovery and appraisal of mechanisms of disease alongside current literature 
review approaches. 
 
Semantic MEDLINE Literature Annotation Objects 
Rather than extracting information from raw literature text, pre-calculated literature annotation 
objects can be implemented. The Semantic MEDLINE Database (SemMedDB) is a computationally-
derived repository of semantic predications which utilises the Unified Medical Language System 
(UMLS). When scientific literature are parsed by SemMedDB, a “subject-PREDICATE-object” 




concepts from the UMLS Metathesaurus (a large, multi-purpose, and multi-lingual thesaurus that 
contains millions of biomedical and health related concepts, their synonymous names, and their 
relationships) [141, 142], whereas the predicate is a relation term from the UMLS Semantic Network 
(a set of broad subject categories and relationships between them) linking them together. For 
example, the sentence "We used hemofiltration to treat a patient with digoxin overdose that was 
complicated by refractory hyperkalaemia" will produce the following four triples: 
 
• Hemofiltration-TREATS-Patients  
• Digoxin overdose-PROCESS\_OF-Patients  
• Hyperkalaemia-COMPLICATES-Digoxin overdose 
• Hemofiltration-TREATS(INFER)-Digoxin overdose  
 
Mining Enriched Literature Objects to Derive Intermediates (MELODI) 
MELODI is a hypothesis-free application that can be used to derive mechanistic pathways 
using SemMedDB annotation [138]. It utilises a graph database to find enriched relationships between 
two “search sets” of articles, with the entire MEDLINE database as a preloaded repository. Data 
analysis of this nature is well-suited to graph databases, as the presence of graphs (relationships) 
between individual articles, or “nodes”, allow for efficient retrieval of related data using a single 
operation. First, for a given search set (a set of articles that represent a concept, such as “smoking”, 
or “head and neck cancer”), the enriched elements are identified. Identification of enriched elements 
is based on the number of times a SemMedDB triple has been annotated within the articles in the 
search set, compared to the frequency of this triple in every article in the MEDLINE database. The 
enrichment is restricted to concepts which are present less than 150,000 times in SemMedDB; to 
remove generic terms that would otherwise introduce unnecessary noise. Additionally, a Fisher's exact 
test is performed for each element and corrected for multiple testing using Bonferroni correction 
[143]. The Fishers exact test determines if there are non-random associations between two categorical 
variables, using the following formulae: 
 





 (2)    𝑃𝑐𝑢𝑡𝑜𝑓𝑓 =  
(𝑅1! 𝑅2! ⋯ 𝑅𝑚!)(𝐶1! 𝐶2! ⋯ 𝐶𝑛!)
𝑁! ∏ 𝑎𝑖 𝑗!𝑖,𝑗
 
Let there exist two variables, 𝑋 and 𝑌, with 𝑚 and 𝑛 observed states, respectively. Form an  𝑚 x 𝑛 matrix in which the entries 




respectively, and the total sum of the matrix using (1). Next, calculate the conditional probability of getting the actual matrix 
given the derived row and column sums, given by (2). Finally, find all possible matrices of nonnegative integers consistent 
with the row and column sums 𝑅𝑖 and 𝐶𝑗. For each one, calculate the associated conditional probability using (2), where the 
sum of these probabilities must be 1. 
 
A Bonferroni correction for multiple testing can be calculated as follows: 
α′ = α / k 
Assuming k independent significance tests at the α level, the probability of no significant differences in all tests is simply the 
product of the individual probabilities: (1 - α)k. For example, with α = 0.05 and k = 10 we get p = 0.9510 = 0.60. For 10 tests, 
there is a 40% chance that one is significant, despite each individual test only being at a 5% level (α = 0.05). In order to 
guarantee that the overall significance test is still at the intended α level after multiple tests, we have to adapt the significance 
level α′ of the individual test by dividing the original alpha, α, by the number of tests, k. 
 
Once enriched elements are identified for two search sets, overlap elements are identified. 
The use of SemMedDB triples allows for a high-resolution analysis which provides a direction from 
one search set to another, allowing for multi-step relationships, traversing from one search set to 
another via overlapping concepts.  
 
Systematic retrieval of epidemiological risk factors 
Implementing the enrichment stage of MELODI’s comparison process (as above), it is possible 
to retrieve subject-PREDICATE-object triples that are enriched in a specific search set, prior to 
comparing them against another search set. This allows the user to parse risk factors that arise in 
literature, related to a search term of interest (e.g. OPC) more times than expected by chance. By 
filtering SemMedDB predicates to those that may describe a potentially modifiable risk factor 
(AFFECTS, ASSOCIATED_WITH, CAUSES, and PREDISPOSES), a scan of epidemiological observational 
risk factors for a specific search term can be performed, with enriched ‘risk factors’ for that concept 
determined. Additionally, two search sets can be compared against each other using MELODI; 
overlapping predicates between them indicate potential intermediates (which may also be 
independent risk factors) for greater resolution of potential causal pathways. Both approaches are of 
particular use in genetic epidemiology as, if a genetic proxy (see “Genome-wide Association Studies 
below) exists for a novel modifiable risk factor or intermediate, they can be validated using robust 





2.2.2. Genome-wide association studies 
A brief introduction to genome-wide association studies 
A genome-wide association study (GWAS) involves comparing the genetic data of many 
individuals to discern potential genetic variations between them based on a phenotype of interest. 
GWAS most commonly investigate single-nucleotide polymorphisms (SNPs) as the genetic variation of 
interest. SNPs are differences at single positions in an individual’s DNA sequence which occur roughly 
every 1000 nucleotides, resulting in around 4-5 million SNPs in the human genome of over 3 billion 
nucleotides. A 1999 paper by Halushka et al. estimated that 50% of SNPs occur in noncoding DNA, 
whereas 25% affect missense mutations in coding DNA, and a further 25% affect “silent” mutations in 
coding DNA [144]. SNPs causing “silent” mutations are named so because they don’t change the amino 
acid they encode and are thought not to impact an individual’s health. SNPs which do cause a change 
in an amino acid, however, may impact an individual’s health. In a given population, SNP differences 
can be observed between people which influence (but are not limited to) transcriptional and 
translational efficacy of cell machinery, protein structure and protein function. As such, SNPs can 
contribute towards the biological function of an individual, phenotypic expression of tens of 
thousands of traits, metabolism of drugs, and the susceptibility of an individual to disease states. For 
example, SNPs have been associated with nicotine addiction [145], self-reported risk-taking [146], 
heterochromia [147], susceptibility to infection [148] and OPC [149]. With their high frequency in the 
genome and scope for impact on the health and biology of an individual, SNPs are an important source 
of genetic variation to investigate. 
 
Since the first study applying GWAS methodology was published in 2007, the frequency of 
published GWAS has increased exponentially. A well-established repository of published GWAS data, 
the NHGRI-EBI GWAS Catalog, has grown ~40-fold since its launch in 2008 with 139 GWAS studies, to 
5687 studies in 2018 [150]. Furthermore, the complexity of methodology, sample size of published 
GWAS and number of traits per published GWAS has increased over time, generating robust SNP-trait 
associations for a huge number of phenotypes (Figure 2.4) (GWAS Catalog SNP-trait associations in 
2018: 71,673). Accordingly, GWAS data represent a resource of vast scope and scale for investigation 








Figure 2.2 - The increasing complexity of GWAS over time. Adapted from MacArthur et al. 2017 [151]: Increasing complexity 
of GWAS studies over time (A) number of SNP-by-environment interaction studies, (B) number of SNP-by-SNP interaction 
publications, (C) number of traits per publication, (D) number of ancestry categories each GWAS publication analyzed and (E) 
number of GWAS analyses per publication. Values were normalized to provide equal weighting to each category. 
 
GWAS Design 
Brief introduction to linear, logistic and survival GWAS formulae 
Depending on the phenotype being assessed in a GWAS, different statistical models are 
employed to accurately determine and interpret the magnitude of effect an associated genetic variant 
confers [152]. For GWAS of continuous phenotypes (e.g. height or alcohol in units per week) a linear 
regression model is commonly used. Linear regression models assume that a continuous phenotype 
is normally-distributed within a population and typically calculated as: 
 
𝑦 =  𝛽0 + 𝛽𝐺𝐺𝑖 + 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒1−𝑗 +  𝜀 
Where Gi is the genotype of the i-th person, βG is the quantitative increase in phenotype per additional reference 
allele, 𝛽0 is the intercept term, covariates 1-j are included in the model (i.e. age, sex, ethnicity etc.) and ε denotes 
model residuals 
 
The beta value from this model interpreted as the quantitative change in phenotype (e.g. for smoking, 
the change in units per week) per additional reference SNP. 
 
For GWAS of binary phenotypes (e.g. ever vs never smoking, or HPV16E6 seropositivity vs 
HPV16E6 seronegativity) a logistic regression model is typically employed. Logistic regressions 
generally assume that a phenotype of interest is Bernoullli-distributed; that is, it has two possible 
outcomes where the probabilities of either occurring sum to 1, but neither can have a probability of 1 




or 1, the state of the outcome is typically denoted as being either 0 or 1 (i.e. for ever vs never smoking, 
“1” would denote an ever smoker and “0” would denote a never smoker). This is depicted in statistical 
notation as the random variable 𝑌𝑖  (i.e. flipping a coin) having a probability of π (i.e. for flipping a fair 
coin, π = 0.5) of occurring for each i-th individual: 
 
𝑌𝑖  ~ 𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝜋𝑖) 
 
If this is the case, a “logit link” function is used to link the probability of a phenotypic state occurring 
in a Bernoulli distribution to a linear function of the predictors (in the case of a GWAS, how much a 
trait increases per additional copy of a SNP) [154]: 
 
𝑙𝑜𝑔𝑖𝑡(𝜋𝑖) = log (
𝜋𝑖
1 −  𝜋𝑖
) =  𝑥𝑖
′𝛽 
Where xi is a vector of covariates and β is a vector of regression coefficients. 
 
With this function linking 𝜋𝑖 to a linear function, a logistic regression is calculated using: 
 
𝑥𝑖
′𝛽 =  𝛽0 + 𝛽𝐺𝐺𝑖 + 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒1−𝑗 +  𝜀 
Where Gi is the genotype of the i-th person, βG is the log(odds ratio) per additional reference allele, 𝛽0 is the 
intercept term, covariates 1-j are included in the model (i.e. age, sex, ethnicity etc.) and ε denotes model residuals 
 
The beta value from this model is interpreted as the change in the log(odds ratio) of an individual 
being a “case” (e.g. smoker) vs a “control” (e.g. non-smoker), per copy of a given reference SNP.  
 
Finally, for time-to-event phenotypes (e.g. 5-year mortality), a Cox proportional-hazards 
GWAS model is regularly used. One of the key assumptions for Cox proportional-hazards models, 
known as the proportional-hazards assumption, is that over time the model covariates have a 
constant, multiplicative effect on the hazard function. The hazard function models the probability of 
an event (e.g. death in the case of 5-year mortality) occurring at a given point in time. Therefore, the 
proportional hazards assumption ensures that covariates don’t interact with time to cause a 
disproportionate change in occurrence of an event of interest over time. A Cox proportional-hazards 
model is calculated as follows: 
ℎ𝑖(𝑡) =  ℎ0(𝑡)exp (𝑥𝑖
′𝛽) 
Where hi(𝑡) is the hazard function for i-th individual, h0(𝑡)is the baseline hazard when time = 0, xi is a vector of 





Beta values from Cox proportional-hazards GWAS models are interpreted as the change in log(hazard 
ratio) per additional reference SNP on the probability of an event occurring.  
 
Confounding and GWAS precision 
When conducting GWAS, it is important to be able to determine whether a genetic variant has 
an independent, direct association with a phenotype of interest, rather than a spurious association 
caused by confounding factors. Perhaps the largest confounding factor in GWAS is population 
structure [155], which generates systematic differences between individuals based on their ancestry. 
In a 1994 paper by Lander and Schork, a useful exemplar is given to illustrate this issue in the case of 
genetic association studies [156]: 
“In a mixed population, any trait present at a higher frequency in an ethnic group will show 
positive association with any allele that also happens to be more common in that group. To 
give a light-hearted example, suppose that a would-be geneticist set out to study the "trait" 
of ability to eat with chopsticks in the San Francisco population by performing an 
association study with the HLA complex. The allele HLA-Al would turn out to be positively 
associated with ability to use chopsticks not because immunological determinants play any 
role in manual dexterity, but simply because the allele HLA-Al is more common among 
Asians than Caucasians.” 
 
Standard GWAS regression models assume that the source population is not related, and 
therefore that each variable is identically and independently distributed [157]. However, in modern 
GWAS datasets of up to hundreds of thousands of individuals, a certain degree of ancestral 
relatedness is inevitable [158]. Whilst the chopstick association above may be a light-hearted example, 
confounding of health-related phenotypes by population structure presents a serious issue for 
researchers when attempting to understand and improve disease aetiology. Several methods have 
been developed to address confounding by population stratification, including (more recently) the use 
of mixed models [159] and principal components analysis (PCA) [160]. Mixed model approaches 
include fixed-effects phenotypes (phenotypes constant over time across individuals) such as SNPs, age 
and sex in their statistical model, but also model heritable variation as a random effect in the form of 
a kinship matrix of pairwise genotypic similarity between study individuals. By including a kinship 
matrix of this design, phenotypic differences which are a result of population stratification can be 
accounted for in a GWAS regression model [161]. PCA, in the context of a GWAS, aims to determine 




data. If genetic data is converted to a high-dimensional construct (a hypersphere) containing X 
dimensions (where X is the number of SNPs), the first principle component is an estimation of the 
direction through the hypersphere that explains the greatest amount of variance in the genetic data. 
The second principle component is the direction through the hypersphere that will create the second-
greatest spread of data, with the constraint that it is uncorrelated (orthogonal) to the previous 
principle component [162]. All consequent principal components will iteratively explain the largest 
variance in the genetic data, given that they are orthogonal to the other principal components. This 
process creates an axis of “directions” (the principal components) with fewer dimensions than the 
original data but with the same variance, which the genetic data is projected onto. For PCA in GWAS, 
the underlying assumption is that most genetic variation is due to population structure. Therefore, 
identifying and adjusting for the top principal components from a PCA analysis should correspondingly 
ensure adjustment for population structure. 
 
Another source of bias in GWAS studies can result from either a lack of adjustment, or 
problematic adjustment for covariates in a GWAS regression model. If not accounted for correctly, a 
scenario can occur where an association between a SNP and a particular phenotype (e.g. smoking) can 
cause an apparent association between the same SNP and another closely-associated phenotype (e.g. 
alcohol -  smokers are more likely to drink alcohol, causing SNPs associated with smoking to appear in 
a GWAS of alcohol consumption, if not accounted for) [163]. This “contamination” can bias GWAS 
results by affecting SNP beta values (falsely inflating or attenuating them) or simply creating spurious 
SNP-phenotype associations. Known confounding can be adjusted for by including the confounder as 
a covariate in the GWAS regression model. Unknown confounding can largely be accounted for by 
adjusting GWAS regression models for principal components as detailed above. However, care should 
be taken in choice of covariates when adjusting for known confounding. If a covariate in a GWAS model 
is heritable (i.e. a proportion of the variation in the trait is attributable to genetic factors, rather than 
demographic factors), then a SNP can potentially be associated with both the phenotype of interest 
and the covariate [164]. In this scenario, given the number of pleiotropic genes associated with many 
complex traits, the effect of a SNP on a phenotype of interest is likely not independent, and instead 
biased towards the covariate [165]. Without sound knowledge of the covariate’s pathophysiology, it 
is difficult to ascertain what the independent effect of a SNP on a phenotype of interest is likely to be. 
Therefore, care should be taken to understand how a SNP-trait association was derived (e.g. how a 
GWAS has been conducted) and how to interpret the effect estimate of the SNP on a trait (e.g. what 






 GWAS involve investigating the effect of millions of SNPs against a phenotype of interest. 
Therefore, due to the number of tests, the probability of spurious false-positive associations (type 1 
error) being discovered is increased. To account for the multitude of statistical tests, a p-value 
correction is applied to GWAS results. In an attempt to quantify a significance threshold for GWAS, 
Dudbridge and Gusnato estimated the threshold for GWAS in Caucasian populations to be P < 5x10-8 
[166]. Accordingly, this p-value threshold has become a standard for most GWAS investigating 
common genetic variants.  
 
Other than the aforementioned threshold, two of the most common corrections for 
determining an adequate p-value threshold for GWAS include Bonferroni correction and false 
discovery rate (FDR)  [167]. The Bonferroni correction attempts to minimise the likelihood of a single 
false-positive finding by adjusting the p-value threshold for a single test of 0.05 by the overall number 
of tests (0.05/N, where N is the overall number of tests – see 2.2.1 - Mining Enriched Literature Objects 
to Derive Intermediates (MELODI) ) [168]. In the case of a GWAS, this number of tests is equal to the 
number of SNPs (per person) in the genetic data. However, many SNPs are correlated due to linkage 
disequilibrium (LD: see “Linkage Disequilibrium” below) and are therefore not entirely independent. 
Consequently, the Bonferroni correction is likely too conservative a correction for GWAS, elevating 
the likelihood of false-negative findings (type 2 error) for the sake of minimising type 1 error. FDR 
correction adjusts the p-value for a single test by assuming that a fixed proportion of findings are false-
positives [169]. FDR is calculated as follows: 
 
FDR =  𝔼(V/R | R >  0) P(R >  0) 
Where V = number of Type I errors and R = number of rejected hypotheses 
 
Like a Bonferroni correction, FDR assumes that SNPs are independent, thus making the 
estimation of the fixed proportion of findings expected to be false-positive difficult. However, despite 
their limitations, these methods, alongside the Dudbridge and Gusnato P < 5x10-8 threshold, are 
currently the most commonly accepted corrections for use in GWAS. 
 
Linkage disequilibrium 
Linkage disequilibrium (LD) is the non-random distribution of alleles within a population. 
Linkage equilibrium would occur if all genetic variants were distributed randomly, as a result of 




DNA sequence still exist in human populations, allowing certain SNPs to be inherited with others. In 
GWAS, LD is measured using the r-squared statistic (r2). The r2 statistic is a quantification of correlation, 
with a high r2 value between two SNPs describing a relationship where one SNP contains most of the 
information of the other. A benefit of this phenomenon is that ~80% of common, genome-wide SNPs 
in European populations can be captured using a subset of around 500,000-1,000,000 “tag” SNPs, 
usually incorporated onto a microarray (see 2.3.2 – Introduction to the OncoArray platform). 
However, due to the number of correlated SNPs and high complexity of the genome, when using 
GWAS results for downstream analysis (such as MR; see 2.2.4) it is difficult to ascertain the degree of 
bias which arises from non-independent instruments. To address this issue, a statistical approach 
known as LD clumping can be used to minimise the presence of correlated variants. LD pruning uses 
p-values of GWAS results to order the SNPs by their association with a phenotype of interest. The 
most-associated SNP is selected, and SNPs at a specified r2 value (typically around 0.1 – 0.01) in a 
“window” around it (commonly 10,000 kilo-bases [kb]) are removed. The process is repeated 
iteratively, selecting the subsequent most-associated SNP that has not yet been removed, to result in 




 In order to comprehensively investigate the genome for novel variants associated with a trait 
of interest in a GWAS, larger sample sizes, next-generation DNA sequencing techniques or SNP arrays 
with denser coverage are required. As this isn’t always financially or practically feasible (for example, 
due to lack of next-generation sequencing equipment or a ceiling on the coverage currently provided 
by SNP arrays), a technique known as genotype imputation can be used as an alternative to predict 
untyped genetic information, using a reference panel. To provide a reliable reference panel, 
international consortia with national whole-genome sequencing projects have been established [170]. 
Shared blocks of genetic variants which are inherited together, per chromosome, known as 
haplotypes, exist between individuals with a recent common ancestor. It is from haplotypes that 
genetic imputation is possible. To perform genetic imputation, the data to undergo genotype 
imputation are compared against multiple reference haplotype sequences which contain many more 
genetic markers. Stretches of shared haplotype between the original samples and the reference panel 
are then identified and genetic variants are assigned to missing genotypes in the original samples 
where possible. Multiple computational tools exist to facilitate genetic imputation, which have been 
grouped by Li et al. as either computationally intensive tools, such as IMPUTE [171], MACH [172] and 




missing allele, or more computationally efficient tools such as PLINK [175], TUNA [176], WHAP [177] 
and BEAGLE [178], which impute genotypes based on a window of nearby markers [179]. Both 
classifications of programs are able to provide an estimate of the quality of imputation known as an 
INFO score. INFO score ranges from 0 to 1, where 1 constitutes no uncertainty in the imputed 
genotype, and 0 constitutes a situation akin to guessing the genotype based on population allele 
frequencies. An INFO score of 0.8 is commonly accepted as a sufficiently accurate estimate of 
genotype. INFO scores are calculated per locus, 𝑙, using the following formula: 
 









Where 𝑣𝑖𝑙 is the variance of person 𝑖’s genotype distribution at locus 𝑙, and 𝑤𝑙 denotes the variance of the genotype 
distribution under Hardy-Weinberg equilibrium. 
 
Scott et al. were the first authors to publish an investigation into the performance of genotype 
imputation in GWAS [180]. The authors genotyped around 300,000 SNPs in a type 2 diabetes case-
control study with 1,161 cases and 1,174 controls, before imputing over 2 million SNPs to allow them 
to compare results with two other type 2 diabetes GWAS that had used different genotyping 
platforms. Scott et al. compared imputed genotypes to actual genotypes for 510 SNPs not present on 
their GWAS panel, finding an imputed to “actual” genotype concordance rate of 98.5%. Given the 
huge coverage increase and high concordance between imputed and measured SNPs, genetic 
imputation is an extremely valuable technique for GWAS and genetic epidemiology more generally. 
 
2.2.3. Epigenome-wide association studies 
A brief introduction to epigenome-wide association studies 
As mentioned previously (see 1.3.1. Introduction to epigenetics of OPC), the epigenome is 
known to regulate gene expression whilst being independent of the underlying genetic architecture. 
The epigenome is also modifiable, in that the degree of epigenetic regulation of gene expression is 
affected by internal (biological – e.g. lung function [181]) and external (lifestyle – e.g. smoking [182]) 
factors such as immune response, alcohol consumption or cigarette smoking. By being both modifiable 
and a regulator of gene expression, the epigenome can lie on and potentially mediate the causal 





The modifiable changes to the epigenome are partly elastic; if an internal or external factor 
causes a change in epigenetic regulation of gene expression, and that factor no longer occurs, some 
epigenetic modifications will begin to return to their inherited “normal” level [183]. Others, however, 
will persist as a marker of historical exposure, particularly where an individual has had chronic 
exposure to a factor. Ultimately, in addition to being a potential factor-disease mediator, the 
epigenome can be thought of as a “biosocial archive”, capturing the exposure history of many 
biological and behavioural factors important to epidemiological research [184]. 
 
Similar to a GWAS with respect to SNPs, an epigenome-wide association study (EWAS) is an 
epidemiological method which compares epigenetic marks (typically DNA methylation) between large 
populations of individuals to find epigenetic variation associated with a particular phenotype. 
Epigenetic information (typically extracted from blood samples) is compared against a phenotype 
using regression analyses pertinent to linear, binary or time-to-event phenotypes (see “Brief 
introduction to linear, logistic and survival GWAS formulae”). Epigenetic marks associated with a 
phenotype of interest can provide valuable insight into potential biological pathways which modify 
them, affect downstream biological pathways, or highlight specific gene regions for further 
investigation.  
 
In addition to finding individual epigenetic marks associated with a phenotype of interest, 
another common EWAS examines the association between differentially-methylated regions (DMRs) 
and a phenotype. DMRs are stretches of correlated epigenetic marks which commonly occur around 
gene regions and may show increased biological plausibility compared to single CpG sites [185]. DMR 
regression analyses are conducted much in the same way as single-site EWAS, albeit adjust for 
autocorrelation between neighbouring CpG sites to give a regional (across multiple CpG sites) rather 
than individual CpG p-value of association [186]. 
 
Whole blood, saliva and tumour tissue DNA extraction 
 DNA can be extracted from a variety of biological tissues for downstream generation of 
methylation data for use in EWAS and other epigenetic analyses. Among the most common sources 
of DNA methylation are saliva, whole blood and formalin-fixed, paraffin-embedded (FFPE) tumour 
tissue blocks. In this thesis, whole blood is used as the tissue of choice due to its minimally-invasive,  
high-yield and reliable response to exposures without contamination. The comparative characteristics 




Table 2.3 - Comparative characteristics from commonly-extracted DNA sources for use with DNA methylation arrays 
Characteristic 
Methylation source 
Saliva Whole blood Tumour tissue block 
Collection method 
Non‐invasive collection by 
buccal swab or mouth 
rinse 
Blood draw; minimally 
invasive 
Biopsy, typically formalin-
fixed; invasive, may not be 
possible in live patients 
Ease of collection 
Self-collection possible/no 





collection of specimens 
DNA stability 
Stable storage at room 
temperature for up to 5 
years [187] 
Stable storage for years 
on a Whatman FTA 
Card; stable for 24 hours 
at ambient temperature 
or 4C in an EDTA tube; 
over a year at -80C or -
20C with preservative 
[188] 
No notable difference 
between blocks stored 
over 11–12 years, 5–7 
years, or 1–2 years in 
comparison to current 
year blocks [189] 
Yield 
Mean 24μg  
Range 0.2–52μg [190] 
Mean 210μg  
Range 58–577μg [190] 
Mean 57μg 
Range 4.3-141.6μg 
(Average of Nanodrop results) 
[191] 
Heterogeneity 
Large (also varies with 
choice of cell reference) 
[192] 
Large (prior to 
deconvolution) [193] 
Large (dependent on 
origin of sample) [194] 
Acute/chronic 
exposure indicator 
Both Both Both 
Used in biomarker 
discovery in 
literature? 




Negligible [196] Negligible [197] 
Cell reference for 
decomposition 
Yes  Yes Yes 
Applicability to OPC 
May prove lucrative in 
understanding HPV-
associated methylation 
patterns due to proximity 
Reliable, robust archive 
of biosocial exposure 
with substantial 
literature evidence. 
Opportunity to assess 
OPC-specific changes 
rather than more global 






Saliva Whole blood Tumour tissue block 
to tonsillar crypts. May 
also prove useful for acute 
tobacco and alcohol-
related epigenetic 
changes. Comparative lack 
of reference studies to 
other DNAm sources and 
unable to determine site-
specific changes 
Useful for determining 
exposure history, with 
many previous blood-
based EWAS of smoking 
and alcohol 





between cases and 
controls, in addition to 
low vs high grade 
tumours. Potential high 
prognostic value. 
  
Genetic associations with DNA methylation 
With the advent of genome-wide association studies (GWAS) it has become increasingly clear 
that much of the genetic variation linked to disease acts not through altering protein coding genes but 
via gene regulatory pathways. Genetic variants identified in these studies explain only a small 
proportion of disease variability with effects that confer only small increase in risk. The ‘missing’ or 
unexplained heritability observed in many GWAS has been suggested to be partially due to the effects 
of the epigenome, which form a second “layer” of heritability through gene control. This leaves open 
the possibility for an epigenetic component to almost all human complex diseases that are at least 
partially heritable. Recent studies have demonstrated that a sizable proportion of GWAS SNPs exert 
their influence on disease through their effect on DNA methylation [198]. Furthermore, it has been 
demonstrated that DNA methylation is associated with extensive genetic variation, such that a high 
proportion of methylation variable CpG sites are associated with one or more SNPs. Over 50% of CpG 
sites are estimated to have a genetic component, such that variance in methylation at any given site 
includes both genetic and environmental contributions. Methylation quantitative trait loci (mQTLs) 
are sequence variants that associate with DNA methylation and are categorised based on their 
proximity to CpGs as either in-cis (usually defined as <1Mb or nearby on the chromosome) or in-trans 
(>1Mb or on different chromosomes) [199, 200]. Cis-mQTLs are generally of large effect whereas 
trans-mQTLs are more polygenic and have only small effects on methylation variation at any given 
CpG site. The genetic architecture of DNA methylation is only beginning to emerge but forms an 





DNA methylation as a predictor of phenotype 
 Transient and permanent changes in DNA methylation can be used to construct DNA 
methylation “scores” to predict phenotypes. If an EWAS discovers CpG sites associated with a trait of 
interest, the beta values from the EWAS at those sites can be used as weights to derive a weighted 
score of the trait in an independent population. Both smoking and alcohol have shown high 
concordance between methylation score and directly-measured phenotype [201, 202]. The derivation 
of a simple weighted score can obtained by multiplying the methylation value at a given CpG by the 
effect size from an EWAS, and then summing the values:  
 
b1cpg1 + b2cpg2 + … + bncpgn 
Where “cpg” is the normalized methylation value from a BeadChip or other methylation measurement platform and “b” is 
the effect size from an EWAS of a trait of interest  
 
2.2.4. Mendelian randomization 
Genetic variants as instrumental variables  
Gregor Mendel, known as “the father of modern genetics”, was a monk born in Austria in 
1822. Mendel discovered the basic principles of heredity through experiments conducted in his 
monastery’s garden. His experiments showed that the inheritance of certain traits in pea plants 
followed specific patterns, upon which the foundation of the laws of modern genetic inheritance were 
developed; the first two of which are pertinent to Genetic Epidemiology: 
 
1. The Law of Segregation of genes states that every trait within an individual contains two 
alleles, and that these alleles separate during meiosis such that each gamete contains only 
one of these alleles. As such, an offspring will receive a pair of alleles for a trait by inheriting 
homologous chromosomes; one allele for each trait from each parent.  
2. The Law of Independent Assortment states that alleles for separate traits are passed 
independently of one another from parents to offspring. This means that the biological 
selection of an allele for one trait occurs completely independently of an allele for another. 
 
As mentioned previously (see Genome-Wide Association Studies), genetic variants can proxy 
for a certain phenotype by being strongly associated with it. Building on the Laws of Segregation and 
Independent Assortment, Genetic Epidemiology can implement genetic variants as instrumental 




inheritance within a target population, these proxies are analogous to arms of a randomised control 





Taken from Yarmolinsky et al. 2018 [204]: In an RCT, individuals are randomly allocated to an intervention or control group 
(In SELECT, 200 μg/d selenium [114 μg/L increase in blood selenium] or placebo). If the trial is adequately sized, random 
assignment should ensure that intervention and control groups are comparable in all respects (eg, approximately equal 
distribution of potential confounding factors) except for the intervention being tested. In an intention-to-treat analysis, any 
observed differences in outcomes between intervention and control groups can then be attributed to the trial arm to which 
they were allocated. In a Mendelian randomization (MR) analysis, alleles that influence levels of a trait of interest are 
randomly allocated at conception. (In MR, the additive effects of selenium-raising alleles on 11 single nucleotide 
polymorphisms were scaled to mirror a 114 μg/L increase in blood selenium.) Groups defined by genotype should be 
comparable in all respects (eg, distribution of both genetic and environmental confounding factors) except for their exposure 
to a trait of interest. Any observed differences in outcomes between groups defined by genotype can then be attributed to 
differences in lifelong exposure to the trait of interest under study. Mendelian randomization is an application of the technique 
of instrumental variable (IV) analysis. In order for a genetic variant (or a multi-allelic instrument) to be used as an IV, three 
key assumptions must be met: 1) the instrument must be reliably associated with the exposure of interest, 2) the instrument 
should be independent of other factors affecting the outcome (confounders), and 3) the instrument should only affect the 
outcome through the exposure of interest (known as the exclusion restriction criterion). CI = confidence interval; HR = hazard 
ratio; SELECT = Selenium and Vitamin E Cancer Prevention Trial. 
 
Furthermore, an individual’s genotype is determined at conception; therefore, genetic 
variants are not modified by the later development of a disease or health outcome, removing the 
complication of reverse causation. Finally, the increasing accuracy of genotyping arrays produces very 
little measurement error when examining the effect of a genetic variant on a phenotype. When used 
in instrumental variable analyses such as Mendelian randomization (MR), a genetic variant proxying 
for a phenotype is free of the limitations that would otherwise weaken causal inference in 
observational studies [205]. 
Figure 2.3  – Schematic comparison of a randomized controlled trial (RCT; Selenium and Vitamin E Cancer Prevention Trial 





Methodological assumptions of Mendelian randomization  
MR relies on a number of key assumptions to reliably derive the causal effect of a genetic 
variant on an outcome of interest, shown in Figure 2.6. Provided these assumptions are met, genetic 
variants can be used as instrumental variables to provide a true causal effect estimate between an 
exposure (e.g. smoking) and an outcome (e.g. OPC). 
 
 
Figure 2.4 - Directed acyclic graph (DAG) of the theory and key assumptions of Mendelian randomization. A genetic variant 
(or variants, G) can be used as instrumental variables for an exposure of interest (E) to assess the causal association between 
E and the outcome of interest (O) given that the following three assumptions hold: (IV1) G must be robustly associated with 
E; (IV2) G must not be associated with any measured or unmeasured confounding variable (C); and (IV3) there must be no 
independent association between G and O, given E and C. 
 
Applications of Mendelian randomization 
Two-sample Mendelian Randomization  
Two-sample MR involves using two different (non-overlapping) study samples to estimate the 
instrument-risk factor and instrument-outcome associations to estimate a causal effect of the risk 
factor on the outcome [125, 206, 207]. This can be useful when the risk factor or outcome, or both, 
are expensive to measure. It also provides an opportunity to substantially increase the statistical 
power, by incorporating data from multiple sources, including large consortia. Furthermore, MR is 
able to utilise summary-level instrument-exposure and instrument-outcome association results 
(typically, per-allele regression coefficients and standard errors from GWAS) to obtain causal effect 




improves the potential for data sharing, consequently improving the scope of MR analyses which can 
be conducted. 
 
Phenome-wide Mendelian Randomization 
An extension of the two-sample MR approach is phenome-wide MR analysis [124, 208]. Given 
the availability of vast amounts of genetic data (pertaining to numerous exposures and outcomes) and 
the efficacy of two-sample MR as a statistical method, phenome-wide MR can be an effective method 
to test a large number of exposure-outcome associations; the results of which can be used to prioritise 
and inform downstream hypotheses and analyses. The two-sample MR framework allows for analyses 
of this scale, in that it can be used to test both the association of a genetically instrumentable exposure 
across all potential outcomes, or conversely test the association of all instrumentable exposures for a 
given outcome (with available genetic data). 
 
This phenome-wide approach may provide novel insights into disease aetiology that may not 
have been captured using previous hypothesis-driven approaches. However, it is important to 
replicate any putative findings from the phenome-wide search in an independent data set. As large 
GWAS and consortia are becoming more prevalent, the number of studies and exposure-cancer 
associations that can be analysed using a two-sample MR framework will increase in quantity and 
power over time. 
 
Two Step Mendelian Randomization 
 As mentioned in 2.2.3 – Genetics of epigenetics, methylation at specific loci can be 
instrumented by mQTLs. Building on two-sample MR, two-step MR is an extension of the MR 
framework which allows for appraisal of causality of molecular intermediates [126]. Firstly, the 
association between an exposure and intermediate is established using a traditional MR approach 
(e.g. a genetic IV for smoking is regressed against methylation levels at the AHRR loci). Next, in a 
second step, an IV proxying the intermediate is regressed against the outcome of interest (e.g. an 
mQTL proxying methylation at AHRR is regressed against incidence of OPC). The IVs for each step 




2.3. Data and resources 
The analyses in this thesis predominately utilise genetic, epigenetic and phenotype data from 
Head and Neck 5000 (HN5000) and the OncoArray Consortium. Below, each resource is briefly 
introduced and described. Any chapter-specific resources are described in the relevant results 
chapter. 
 
2.3.1. Head and Neck 5000 (HN5000) clinical cohort study 
Between April 2011 and December 2014, 5511 individuals with HNC were recruited from 76 
centres across the UK [209]. All people with a new diagnosis of HNC were eligible to join the study and 
were recruited before or within a month of their cancer treatment commencing. Individuals with 
cancers of the pharynx, mouth, larynx, salivary glands and thyroid were included, while those with 
lymphoma, tumours of the skin or a recurrence of a previous head and neck cancer were excluded 
from the study. There were 119 exclusions between recruitment and our data release (v2.3) for the 
following reasons: withdrawn by study/ineligible (n = 72), patient choice withdrawal (n = 12), and not 
HNC (n = 35). Participants with OPC were selected from the wider pool of individuals (post-exclusion) 
in HN5000 (N: 5392) based on an ICD-10 coding (pathological where available, clinical if otherwise) of 
oropharynx (CO1, CO5, CO9, C10.0-2, C10.3, C10.8 and C10.9; N: 1909/5392), availability of OncoChip 
genotype data generated previously (N: 1034/1909), baseline questionnaire and data capture 
information (see below), and the availability of blood samples taken at baseline (prior to treatment; 
N: 448/1034).  
 
N.B. HN5000 OncoArray data is a subset of GWAS data from people of European descent with HNC and matched 
controls were obtained from the OncoArray Consortium GWAS of oral cavity and pharyngeal cancer. Therefore, 
information on how this data was derived will be described in section 2.3.2 – OncoArray Consortium - oral cavity 
and pharyngeal cancer GWAS. 
 
 Local research nurses obtained informed consent from individuals, which included agreement 
to collect, store and use biological samples; obtain samples of stored tissue; carry out genetic analyses 
and collect clinical information from hospital notes and mortality data through record linkage. Ethics 
approval for this study was granted by the National Research Ethics Committee (South West Frenchay 
Ethics Committee, reference 10/H0107/57, 5th November 2010) and approved by the research and 





Baseline data collection  
Participants completed a series of three self-administered questionnaires at baseline 
enquiring about: 1) social and economic circumstances, overall health and lifestyle behaviours; 2) 
physical and psychological health, well-being and quality of life; and 3) past sexual history and 
behaviours. Information on diagnosis, treatment and co-morbidity was recorded on a short data 
capture form using questions based on a national audit. Diagnoses were coded using the International 
Classification of Diseases (ICD) version 10 and clinical staging of the tumour was derived based on the 
American Head and Neck Society TNM staging. Research nurses collected a blood sample from all 
consenting participants. These were then sent to the study centre laboratory at ambient temperature 
for processing. The blood samples were centrifuged at 3500 rpm for 10 minutes and the buffy coat 
layer used for DNA extraction. Any additional samples from the same participant were frozen and 
stored at -80°C.  
 
Assessment of tobacco, alcohol and HPV infection  
Detailed information on tobacco and alcohol history was obtained at baseline via the self-
administered questionnaire. Participants were asked about their current smoking and drinking status 
and their use of tobacco and alcohol products prior to receiving their HNC diagnosis. Among smokers, 
information on age at smoking initiation and number of years of smoking was obtained. The 
questionnaire differentiated between use of cigarettes, hand-rolled cigarettes, cigars and smokeless 
tobacco, whereby a cigar was considered equivalent to four cigarettes. From this information, 
participants were dichotomised into ever and never smokers. Ever smokers were defined as those 
who smoked at the equivalent of at least 1 tobacco product a day per year, or ≥100 cigarettes in their 
lifetime. Never smokers were those who reported not smoking in any of the questions answered.  
 
Respondents were asked to report their average weekly alcohol consumption of a range of 
beverage types (wine, spirits, and beer/larger/cider) before they were diagnosed with cancer. From 
these measures, we derived an average intake of alcohol consumption in units per week.  
 
HPV serologic testing (HPV16 E6, E7, E1, E2, E4, and L1) was conducted at the German Cancer 
Research Center (DKFZ, Heidelberg, Germany) using glutathione S-transferase multiplex. Median 
fluorescence intensity (MFI) values were dichotomized to indicate HPV16 E6 seropositivity using a cut-
off of ≥ 1000 MFI. E6 seropositivity is known to be a marker of with a high sensitivity and specificity 





Study follow-up and survival  
Regular updates were received from the NHS Central Register (NHSCR) and the NHS 
Information Centre (NHSIC) notifying on subsequent cancer registrations and survival among cohort 
members in the Head and Neck 5000 study. Recruitment for the study finished in December 2014 and 
follow-up information on survival status was obtained on 30th September 2017, resulting in at least 
2.75 years of follow-up for all participants (median: 3.1 years; range: 2.75 to 4.9 years: inter-quartile 
range: 1.1 years).  
 
DNA methylation  
Introduction to the Illumina MethylationEPIC BeadChip 
The Illumina Infinium MethylationEPIC BeadChip (EPIC) is a bead-based array which can 
quantify CpG methylation levels at over 850,000 positions across the genome. In 2008, Illumina 
introduced their first BeadChip; the Human Methylation 27K (HM27) BeadChip, capable of quantifying 
methylation at 27,000 CpG sites across the genome. In 2011, Illumina released their Human 
Methylation 450K (HM450) BeadChip, drastically improving genome-wide methylation coverage to 
interrogate methylation at 450,000 CpG sites. The EPIC array was released in 2016 and is currently the 
largest commercially available methylation BeadChip, almost doubling the coverage of its 450K 
predecessor. Recent studies using platforms such as whole-genome bisulfite sequencing (WGBS; the 
entire genome methylation levels at a single-base resolution) have demonstrated that DNA 
methylation at regulatory enhancers can determine transcription and phenotypic variation, through 
modulation of transcription factor binding. Therefore, accurate quantification of DNA methylation at 
more regulatory regions is essential for our understanding of the role of DNA methylation in human 
development and disease. To this end, the EPIC BeadChip targets enhancer regions, possessing 90% 
of the existing coverage of the HM540, but with more than 350,000 CpGs at regions identified as 
enhancers by FANTOM5 and the ENCODE project. The EPIC array is therefore an extremely useful tool 
to further our understanding of DNA methylation mechanisms in human disease, particularly the DNA 
methylation landscape of distal regulatory elements.  
 
Data generation  
Following extraction, DNA from whole-blood samples were bisulphite-converted using the 




generated using the Infinium MethylationEPIC BeadChips (EPIC array) (Illumina, USA) according to the 
manufacturer protocol. The arrays were scanned using an Illumina iScan (version 2.3) by Bristol 
Bioresource Laboratories.  
Pre-processing and quality assurance 
Raw data files (IDAT files) were pre-processed using the R package meffil 
(https://github.com/perishky/meffil/) [210] to perform quality control (QC) and normalization [211]. 
From the initial 448 samples available, 8 samples did not pass QC; 2 samples with incorrect sex 
prediction based on autosomal DNA methylation, 3 samples with sex detection outliers, 1 sample with 
an outlier in predicted median methylated vs unmethylated signal, and 2 duplicate samples. An 
additional 32 individuals were subsequently removed from the analysis owing to pathological re-
classification, leaving 408 participants with DNAm data available. During QC, probe intensities were 
dye-bias and background corrected using the ‘noob’ method developed by Triche et al [212]. A total 
of 3674 probes were excluded, leaving 863,289 CpGs with which to perform analyses - 2704 probes 
were removed due to a high proportion of high detection p-values (>10% of samples with a  detection 
p-value > 0.1) and 970 CpGs had low bead numbers in a high proportion of samples (<3 beads in >10% 
samples). Following QC, functional normalization (originally developed by Fortin et al. [213]) was 
performed using the Meffil R package, which exploits control probes to separate biological variation 
from technical variation. Data were normalized using 6 control probe principal components derived 
from technical probes. During the normalization process, probe intensity quantiles were normalized 
between samples by fitting linear models to these 6 derived principal components. The resulting 
quantile residuals for each QC object were retained as a set of normalized quantiles and used in a 
second normalization step, where the raw probe intensities for each sample were adjusted to conform 
to its own set of normalized quantiles. After the second step had been completed for each sample, 
the resulting normalized DNAm data subsets were merged into a single dataset for analysis. 
Post-normalization, estimation of blood cell proportions, per sample, were estimated via the 
Houseman cellular composition prediction algorithm [214]. Reinius et al. 2012 [215] was used as a cell 
type reference to estimate proportions of neutrophils, natural killer cells, B cells, eosinophils, CD4T 
cells, CD8T cells and monocytes. 
 
2.3.2. OncoArray Consortium – oral cavity and pharyngeal cancer GWAS 
Introduction to the OncoArray platform 
The development of chip-based microarray technology has made GWAS increasingly viable and 




is a collection of thousands (usually hundreds of thousands) of wells, containing oligonucleotide (short 
nucleic acid polymers) probes which bind to unique SNPs considered to have biological relevance in 
the genome. In this thesis, large volumes of genetic data (1,034 individuals [case only] with OPC in the 
HN5000 study; 2,641 OPC cases, 6,585 controls in the OncoArray consortium HNC study – HN5000 is 
nested within the OncoArray HNC study) are used. All of these samples have been genotyped using 
the OncoArray BeadChip (OncoChip) microarray. Currently, the OncoChip array is perhaps the most 
cost-effective microarray for Cancer Epidemiology studies, interrogating almost 500,000 expert-
selected SNPs, notably including >200,000 cancer-specific genetic variants [216]. As mentioned above, 
OncoChip is a BeadChip; it contains wells filled with 3µm silicon beads, covered with oligonucleotide 
probes (rather than oligonucleotides bound directly to the chip surface), which provide a large surface 
area with a high density of probes for processed DNA to bind to.  
 
Oral cavity and pharyngeal cancer GWAS 
In 2016, Lessuer et al. published GWAS results using genetic data from the OncoArray 
Consortium oral cavity and pharyngeal cancer GWAS [149]. This study examined 12,619 individuals 
(6,034 cases, 6,585 controls) from Europe, North America and South America. Cancer cases comprised 
the following ICD codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9, C05.0-C06.9) oropharynx 
(C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), overlapping (C14 and combination of other 
sites) and 25 oral or pharyngeal cases with unknown ICD code (other). Samples were originally 
genotyped using aforementioned Illumina OncoArray platform (see 2.3.1 – OncoArray genetic data), 
designed for cancer studies by the OncoArray Consortium, part of the Genetic Associations and 
Mechanisms in Oncology (GAME-ON) Network. The majority of samples were genotyped as part of 
the oral and pharynx cancer OncoArray, with the exception of 2,476 shared controls (1,453 from the 
European cohort study and 1,023 from the Toronto study) that were genotyped at the Center for 
Infectious Disease Research (Seattle, Washington, United States), but as part of the Lung OncoArray. 
Genotype calls were made by the Dartmouth team in GenomeStudio software (Illumina, Inc.) using a 
standardized cluster file for OncoArray studies. A total of 2,641 cases and 6,585 controls were 
examined in relation to OPC as a specific HNC sub-type.  
 
Pre-processing 
Initial quality control steps and analyses were performed at the International Agency for the 
Research of Cancer (IARC), Lyon. After removing duplicates, related samples, samples with sex 




Imputation Server. Genotypes were pre-phased (i.e. their haplotypes were inferred) using SHAPEIT v2 
and imputed with Minimach v3 using the Haplotype Reference Consortium panel. After imputation, 
SNPs with an imputation quality (R2) lower than 0.7 were removed from the datasets.  
 
Statistical analysis 
Effect estimates for oral cavity and pharyngeal cancer risk were obtained after adjusting for age, 
sex and significant principal components for population stratification using R software (R version 
3.3.1). Results were calculated for geographic region of HNC (overall oral cancer and pharynx cancer, 
site-specific oral cancer and oropharyngeal cancer) were then combined using a fixed-effects inverse-
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In current scientific literature, epidemiological studies with a focus on oropharyngeal cancer 
(OPC) are uncommon and display marked homogeneity with respect to risk factors of interest [21, 48, 
83, 217-219]. However, OPC incidence is increasing globally, with affected demographics shifting to 
include younger individuals [11]. Populations affected by this cancer are changing, in part an artefact 
of a shifting causal landscape for OPC risk factors. Therefore, further research is required to determine 
how best to prevent and detect OPC in the first instance, and to reduce the elevated mortality and 
morbidity risks associated with OPC in those with late-stage cancer. 
 
Prior to using genetic and epigenetic data to augment understanding of OPC risk factors and 
prognostic factors, it is important to know which risk factors exist with good evidence of association 
with OPC and which risk factors exist with more limited evidence. Notably, the latter group may be 
important in terms of effect on OPC but may simply be understudied or under-reported in current 
literature. Once known, an understanding of the mechanisms that relate identified risk factors to 
health outcomes is crucial for discovery of potential drug targets and disease biomarkers and prevents 
duplication of effort (i.e. the attempt of investigating an already-established hypothesis). Finally, 
identifying the mechanistic pathway from a given risk factor to OPC allows consideration of potentially 
modifiable intermediates, thus offering the potential to identify new biomarkers and treatments to 
reduce risk and mortality of the disease. 
 
In this chapter, a novel application of the MELODI platform (www.melodi.biocompute.org) is 
employed (see below) to identify epidemiologically-relevant factors associated with OPC in current 
literature. In a systematic framework, putative risk factors found to be enriched in literature for OPC 
are discovered. These risk factors are then recursively investigated against OPC using MELODI’s 
standard framework [138] in an attempt to derive intermediates in addition to risk factors. Any 
derived intermediates could be important therapeutic targets to reduce risk or mortality of OPC. Of 
note, intermediates discovered this way could also be independent risk factors and would require 
downstream investigation in a causal inference framework. 
 
MELODI is an online literature-mining tool which employs the Semantic Medline Database 
(SemMedDB) [140] of predications to infer association between an exposure and outcome in scientific 
literature [138]. The use of SemMedDB predications allows for directionality to be established 
between exposure and outcome, and for overlapping mechanisms to come from independent articles 




another shows increased pancreatic function to be associated with type 2 diabetes. The link between 
high-calorie diet and type 2 diabetes could be overlooked by a typical PubMed search, but in MELODI 
would show a pathway from high-calorie diet to type 2 diabetes with increased pancreatic function as 
an intermediate). MELODI also removes background “noise” by performing an enrichment step of the 
“concepts” (see Methods) within a particular set of articles, aiding the reliability of any exposure-
outcome pathways discovered. Finally, MELODI contains a Neo4j graph database of all available 
literature in PubMed. Unlike traditional databases which store data in rows, columns, and tables, 
Neo4j has a flexible structure which saves the relationships that connect data. With Neo4j, each data 
record, or “node”, contains directional links to all the nodes it is connected to. For example, if Bob is 
friends with Jane, a node called “Bob” would point directly to a node called “Jane” through a stored 
relationship. This network of nodes connected by relationships is a graph. Most other databases, 
including more recent node SQL types, don't save relationship data directly; they can create 
connections by searching a separate data structure called an index, but this process has to be repeated 
to find each connection, which is a time-intensive computational step. Accordingly, traditional 
databases tend to be inherently slower than Neo4j for relationship-intensive queries, particularly with 
large amounts of data such as PubMed literature. Neo4j avoids repeated index lookups because its 
native storage layer is a connected graph. The MELODI Neo4j graph contains data from every PubMed 
abstract, which has been systematically parsed for SemMedDB predicates. This allows the entire 
PubMed database (and its search engine) to be implemented in the creation of custom article “search 
sets”. A “search set” is the information and relationships shared by articles relating to a search term 
of interest. 
 
Here, a novel application of the MELODI tool for the hypothesis-free identification of 
epidemiological risk factors for OPC present in scientific literature was used: if a search set containing 
PubMed articles pertaining to OPC (or indeed, any outcome) is compared against itself (rather than a 
unique second search set), MELODI provides a results output which can identify enriched associations 
(and therefore potential risk factors) associated with it. Typically, MELODI is used to compare 
information across two search sets to discover intermediates. The output consists of a table of subject-
PREDICATE-object pathways, attempting to find enriched concepts in the search set. This set of results 
helps to identify risk factors (as mentioned above) which are both directly associated with OPC (intra-
publication: a risk factor has been directly discovered by the author of the paper i.e. smoking causes 
OPC. Smoking is therefore a risk factor for OPC), and 1 step removed from the outcome but potentially 




may form a causal pathway e.g. one author discovers that oral sex leads to HPV infection, another 
discovers that HPV infection leads to OPC. Oral sex may therefore be a risk factor for OPC). 
 
3.2. Methods 
3.2.1. Risk factor retrieval 
Within MELODI, SemMedDB data is available for all PubMed articles, in both “triple” and 
“concept” form, for those published on or before 30th June 2018. SemMedDB “concepts” are indexing 
articles similar to MeSH terms [220], derived from the Unified Medical Language System (UMLS) 
Metathesaurus [141] and describing the content of a journal article. SemMedDB “triples” are a pair of 
“concepts” (as before) linked by a “PREDICATE” derived from the UMLS Semantic Network [221]. 
These “triples” have been obtained for PubMed literature through use of the UMLS-based program, 
SemRep [222], and downloaded into MELODI’s database via the SemMedDB repository. Rindflesch 
and Fiszman [222], who developed SemRep, use the following example to show how their program 
extracts SemMedDB “triples”: 
 
  
As evidenced above, SemRep can parse sentences from journal article abstracts, returning 
refined predications which can be used to generate hypotheses. In the risk factor retrieval stage of 
this chapter, SemMedDB “triples” (rather than “concepts”, of which there would be tens of thousands, 
with less precise associations due to a lack of directionality) were retrieved using the MELODI 
platform, in relation to OPC. MELODI returns predications that are present in PubMed literature, 
between two search sets of articles, greater than expected by chance. However, if a search set 
pertaining to OPC is compared against itself, the MELODI program will return a list of overlapping, 
The sentence in (1) extracts the predications in (2): 
 
1. We used hemofiltration to treat a patient with digoxin overdose that was complicated by 
refractory hyperkalemia. 
 
2. Hemofiltration-TREATS-Patients  
Digoxin overdose-PROCESS_OF-Patients  





enriched SemMedDB “triples” from within the single set of articles. As of 25/10/2018, a PubMed 
search set of 14,831 articles pertaining to OPC - “oropharynx cancer OR oropharyngeal cancer OR OPC 
OR OPSCC OR oropharyngeal squamous cell carcinoma OR oropharynx squamous cell carcinoma” - 
was assessed for enriched predications. From this search set, 5,797 overlapping “triples” (referred to 
herein as a pathway) were retrieved. 
 
From all UMLS Sematic Network predicates available in the OPC search set, the predicates of 
’CAUSES’, ‘PREDISPOSES’ and ‘ASSOCIATED_WITH’ described potential evidence of a causal 
epidemiological relationship between retrieved risk factors and OPC, whereas others (e.g. 
LOCATION_OF, IS_A, PART_OF) did not. These 3 predicates were therefore used to filter the resultant 
5,797 potential pathways to 1,551 – if any of the overlapping “triples” contained one of these 
predicates, it was kept and others removed. Next, the search set was refined to those with a ‘CAUSES’, 
‘PREDISPOSES’ or ‘ASSOCIATED_WITH’ predicate prior to one of the only two concepts in the UMLS 
Metathesaurus which uniquely describes oropharyngeal cancer (either PREDICATE-”malignant 
neoplasm of oropharynx”, or PREDICATE-“oropharyngeal squamous cell carcinoma”), producing a final 












After risk factors were obtained for OPC, MELODI was implemented according to its original 
function; to mine enriched literature objects to derive intermediates. By comparing a search set of 
each retrieved risk factor against the OPC search set, respectively, intermediates for risk factor-OPC 
associations may be discovered, where available. Search strategies for risk factors (see Results) were 
generated using current systematic review literature as reference. HPV vaccine and HPV infection 
were aggregated in a search term that more broadly encapsulated both terms. The following four 
search strategies were employed: 
 
Alcohol 
 Search strategy: alcohol* OR alcoholic beverage OR alcohol consumption OR alcohol drinking 
OR alcohol use OR alcohol intake OR alcoholism OR alcohol abuse OR ethanol* OR ethanol 
concentration 
Returning a search set of 495,565 articles 
Reference: Simou et al. 2018 [223]  
 
Smoking 
Search strategy: cigarette OR smoking OR smoke OR tobacco OR snus OR snuff OR 
"environmental tobacco smoke” OR “passive smoking” OR “smoking cessation" OR "betel nut" OR bidi 
OR pipe OR cigar 
Returning a search set of 321,171 articles 
Reference: Aune et al. 2018 [224] 
 
HPV infection 
Search strategy: papillomavirus infections/epidemiology[MeSH Terms] OR papillomavirus 
infections/etiology[MeSH Terms] OR papillomavirus infections/transmission[MeSH Terms] OR 
"papillomaviridae"[MeSH Terms] OR HPV[Text Word] OR papillomavir*[Text Word] OR papilloma 
virus*[Text Word] 
Returning a search set of 47,399 articles 








 Search strategy: “sexual behaviour” OR sexual partner* OR sexuality OR “oral sex” OR 
orogenital* OR “sexual activity” 
Returning a search set of 151,688 articles 
Reference: Marston and King 2006 [226] 
  
As mentioned previously, MELODI contains information on both SemMedDB “concept” and 
“triple” predications. In the case of retrieving intermediates, “concepts” were examined. In contrast 
to the risk factor retrieval stage, “concepts” are more appropriate for intermediate retrieval as they 
are less frequently reported in epidemiological literature and may be as easily inferred by SemRep in 
journal abstracts. Enriched concepts were restricted to those of interest to molecular epidemiology; 
those that were modifiable, those that were molecular intermediates, or those that were able to be 
proxied by genetic loci to appraise causality (Table 3.1). Following identification of these enriched 
concepts, potential intermediates were manually screened for evidence of mediation of OPC risk. 
  
Table 3.1 - Inclusion and exclusion terms for SemMedDB concepts of interest to molecular epidemiology 
Included concepts Excluded concepts 




Human Fish Professional or 
Occupational Group 
Bacteria Body Location or 
Region 
Individual Behaviour Finding Qualitative concept 
Biologically active 
substance 
Body Part, Organ, or 
Organ Component 




Carbohydrate Body Space or Junction Intellectual product Organism 
Function 
Research device 
Fungus Cell component Laboratory Procedure Organism Tissue 
Gene Cell Mental process Organization Therapeutic or 
Preventive Procedure 
Hormone Clinical attribute Mental or Behavioural 
Dysfunction 
Organ or Tissue 
Function 
 
Lipid Daily or Recreational 
Activity 














Element, Ion, or 
Isotope 
Embryonic structure Plant  
Virus Health care activity Family Group Population Group  
3.3. Results 
Two hundred and ten “triples” were found to be enriched in the OPC search set, from which 
5 unique risk factors for OPC were identified: alcohol consumption (# triples = 17), HPV infection (# 
triples = 99), HPV vaccination (# triples = 77), oral sex (# triples = 1) and smoking (# triples = 16). For 
each respective risk factor, over 30 SemMedDB concepts were found to be enriched, including 
pharmacological, gene region and molecular intermediates. See below for details of enriched concepts 
per risk factor. 
HPV 
HPV infection was responsible for the majority of enriched literature associations (n = 99/210). 
All triples returned from this literature mining approach described HPV as causing (“CAUSES”) OPC; 
there were no triples described HPV predisposing (“PREDISPOSES”) or being associated 
(“ASSOCIATED_WITH”) with the disease. The HPV vaccine was also uniquely associated with OPC, 
present in 77 triples; 56 triples were “ASSOCIATED_WITH” OPC, 21 contained the “CAUSES” predicate. 
 
From the retrieval of enriched literature intermediates between HPV infection (a search was 
constructed encompassing both; see methods) and OPC, there were 35 potential intermediates: 10 
amino acid, peptide, or protein, 5 biologically active substances, 1 carbohydrate, 1 fungus, 5 gene 
regions, 3 hormones, 7 pharmacologic substances and 3 viruses (see Table 3.2). 
 
Table 3.2 - Potential intermediate factors between HPV and OPC 
Category Intermediate # Articles in 
HPV search set 




peptide, or protein 
Cyclin D1|CCND1  42 13 11 
Epidermal Growth Factor Receptor  84 38 22 
Interferon-beta|EREG|ESR1  21 3 0 
Interferons  196 2 1 




Interleukin-4  39 4 0 
Recombinant Interferon-gamma|CALR  7 3 0 
Retinoblastoma Protein|RB1  285 4 21 
Superoxide Dismutase  12 5 0 
Tumour Necrosis Factor-alpha  64 17 1 
Biologically active 
substance 
Cholesterol  3 6 0 
Nitric Oxide  85 19 0 
Sodium Chloride  38 24 0 
Triglycerides  2 3 0 
Zinc  20 4 0 
Carbohydrate Ascorbic acid 13 2 0 
Fungus Saccharomyces cerevisiae 83 10 0 
Gene CDKN2A 626 34 201 
EGFR 42 12 10 
MMP8 8 6 4 
SERPINB3 113 51 49 
TP53 1425 67 69 
Hormone Estradiol 40 1 0 
Estrogens 81 4 0 
Hydrocortisone 6 3 0 
Pharmacologic 
substance 
Cetuximab  38 58 30 
Cyclosporine 33 12 0 
Dexamethasone 28 14 0 
Fluconazole 1 60 0 
Hydrogen Peroxide 28 7 0 
Indomethacin 20 3 0 
Morphine 2 4 0 
Virus Hepatitis C virus 49 3 1 
Herpesvirus 4, Human 191 57 15 
Human Papillomavirus 13350 901 901 
 
Alcohol 
Seventeen triples were returned pertaining to alcohol consumption and OPC risk from this 
analysis (17/88 triples). All 17 described alcohol consumption predisposing (“PREDISPOSES”) OPC, 





From the retrieval of enriched literature intermediates between alcohol consumption and 
OPC, there were 74 potential intermediates: 22 amino acid, peptide, or protein, 1 bacteria, 9 
biologically active substances, 1 carbohydrate, 2 fungi, 6 gene regions, 8 hormones, 1 neuroreactive 
substance or biogenic amine, 20 pharmacologic substances and 4 viruses (see Table 3.3). 
 
Table 3.3 - Potential intermediate factors between alcohol consumption and OPC 
Category Intermediate 
# Articles in alcohol 
search set 






Cyclin D1 80 18 6 
Epidermal Growth Factor Receptor 107 54 6 
Interferons 292 3 0 
Interleukin-1 beta 744 9 0 
Interleukin-4 234 3 1 
Leptin 356 4 0 
NF-kappa B 587 6 0 
Recombinant Interferon-
gamma|CALR 
15 3 0 
Retinoblastoma Protein 1 20 21 6 
Superoxide Dismutase 1273 4 1 




Cholesterol 1891 5 1 
Nitric Oxide 1590 19 0 
Sodium Chloride 2837 23 1 
Zinc 700 3 1 
Carbohydrate Fluorodeoxyglucose 5 17 0 
Fungus 
Candida albicans 256 45 0 
Saccharomyces cerevisiae 5136 10 0 
Gene 
CA2 963 22 0 
CDKN2A 94 212 23 
EGFR 17 21 1 
IGHE 116 1 0 
TNFRSF6B 20 22 0 
TP53 479 116 20 
Hormone 
Adrenal Cortex Hormones 852 12 1 
Estradiol 637 1 0 




Glucocorticoids 392 3 0 
Hydrocortisone 545 2 1 
Insulin 970 3 0 
Progesterone 373 6 0 





Norepinephrine 969 11 0 
Pharmacologic 
substance 
Amifostine 5 11 0 
Angiotensin-Converting Enzyme 
Inhibitors 
184 1 0 
Argipressin 339 109 1 
Aripiprazole 53 25 0 
Bleomycin 82 48 1 
Carboplatin 18 71 1 
Cetuximab 7 85 3 
Cilostazol 12 44 1 
Cisplatin 222 258 6 
Cyclosporine 253 11 1 
Dexamethasone 439 14 0 
Docetaxel 64 42 1 
Fluconazole 59 60 0 
Fluorouracil 119 118 2 
Hydrogen peroxide 1495 7 0 
Iron 1237 4 0 
Inamrinone 7 11 0 
Morphine 799 4 0 
Paclitaxel 244 51 1 
Phosphodiesterase Inhibitors 63 23 0 
Virus 
Hepatitis C virus 2079 3 1 
Herpesvirus 4, Human 42 68 4 
Human papillomavirus 199 780 134 






There were 16 triples pertaining to tobacco smoking and OPC risk in this analysis. 14 triples 
described tobacco predisposing (“PREDISPOSES”) OPC and 2 triples described tobacco being 
associated with (“ASSOCIATED_WITH”) OPC. There were no triples describing tobacco causing 
(“CAUSES”) OPC.  
 
From the retrieval of enriched literature intermediates between smoking and OPC, there were 
74 potential intermediates: 17 amino acid, peptide, or protein, 1 bacteria, 6 biologically active 
substances, 1 carbohydrate, 2 fungi, 5 gene regions, 8 hormones, 2 neuroreactive substance or 
biogenic amine, 19 pharmacologic substances and 3 viruses (see Table 3.4). 
 
Table 3.4 - Potential intermediate factors between smoking and OPC 
Category Intermediate # Articles in 
smoking search 
set  







Angiotensin II 72 6 0 
ATP8A2 163 15 0 
Collagen 283 6 0 
Gamma-Aminobutyric Acid 116 4 0 
Interleukin-1 beta 438 9 0 
Interleukin-4 147 2 2 
Leptin|LEP 254 4 0 
Myelin Basic Proteins 8 36 0 
NF-kappa B 246 6 0 
Phosphoric diester hydrolase 18 31 0 
Recombinant Interferon-gamma|CALR 11 3 0 
Retinoblastoma Protein|RB1 25 20 7 
Somatotropin 52 1 0 
Substance P 113 1 0 
Superoxide Dismutase 433 4 1 
Tumor Necrosis Factor-alpha 481 16 2 




Calcium 702 9 1 
Nitric Oxide 829 17 2 
Phospholipids 213 3 0 




Triglycerides 1156 1 2 
Zinc 320 3 1 
Bacteria Neisseria meningitidis 9 43 0 
Carbohydrate Ascorbic Acid 774 2 0 
Fungus Candida albicans 24 45 0 
Saccharomyces cerevisiae 700 10 0 
Gene CA2 163 22 0 
EGFR 221 18 4 
SERPINB3 69 81 19 
TNFRSF6B 29 22 0 
TP53 939 103 33 
Hormone Adrenal Cortex Hormones 906 13 0 
Estradiol 268 1 0 
Estrogens 658 3 1 
Glucocorticoids 211 3 0 
Hydrocortisone 247 2 1 
Insulin 368 3 0 
Progesterone 129 6 0 
Testosterone 398 1 0 




Dopamine 483 17 0 
Norepinephrine 185 11 0 
Pharmacologic 
substance 
Amifostine 4 11 0 
Argipressin 68 111 0 
Aripiprazole 19 25 0 
Bleomycin 92 48 1 
Carboplatin 40 71 1 
Cetuximab 28 76 12 
Cisplatin 163 246 18 
Clotrimazole 1 12 0 
Cyclosporine 64 12 0 
Dexamethasone 143 14 0 
Docetaxel 33 40 3 
Fluconazole 8 60 0 
Fluorouracil 38 115 5 




Indomethacin 57 3 0 
Iron 406 4 0 
Morphine 86 4 0 
Nystatin 2 11 0 
Paclitaxel 45 48 4 
Virus Hepatitis C virus 274 2 2 
Herpesvirus 4, human 68 67 5 
Human papillomavirus 687 704 210 
Human papillomavirus 16 130 113 21 
 
Oral sex 
Oral sex had a single SemMedDB triple found to be associated with OPC risk. This triple 
showed oral sex to predispose OPC risk, rather than having a “CAUSES” or “ASSOCIATED_WITH” 
predicate linking it to the disease. 
 
From the retrieval of enriched literature intermediates between oral sex and OPC, there were 
74 potential intermediates: 19 amino acid, peptide, or protein, 9 biologically active substances, 1 
carbohydrate, 2 fungi, 5 gene regions, 8 hormones, 1 lipid, 2 neuroreactive substance or biogenic 
amine, 13 pharmacologic substances and 6 viruses (see Table 3.5). 
 
Table 3.5 - Potential intermediate factors between oral sex and OPC 
Category Intermediate # Articles in oral 
sex search set 
# Articles in 
OPC search set 
Overlap 
Amino acid, peptide, 
or protein 
Adiponectin 3 1 0 
Amino Acids 58 13 0 
Angiotensin II 15 6 0 
ATP8A2 13 15 0 
Collagen 16 6 0 
Epidermal Growth Factor Receptor 3 60 0 
Gamma-Aminobutyric Acid 88 4 0 
Human papillomavirus antibody 6 6 1 
Interferons 55 3 0 
Interleukin-1 beta 21 9 0 
Interleukin-4 9 4 0 




NF-kappa B 3 6 0 
Phosphoric diester hydrolase 10 31 0 
Retinoblastoma Protein|RB1 1 27 0 
Somatotropin 31 1 0 
Substance P 24 1 0 
Superoxide Dismutase 10 5 0 
Tumour Necrosis Factor-alpha 21 18 0 
Biologically active 
substance 
Calcium 31 10 0 
Cholesterol 55 6 0 
Fatty Acids 21 4 0 
Nitric Oxide 117 19 0 
Phospholipids 2 3 0 
Plasmids 14 10 0 
Sodium Chloride 186 24 0 
Triglycerides 28 3 0 
Zinc 16 4 0 
Carbohydrate Ascorbic Acid 15 2 0 
Fungus Candida albicans 13 45 0 
Saccharomyces cerevisiae 36 10 0 
Gene CA2 8 22 0 
CDKN2A 8 233 2 
EGFR 2 21 1 
IGHE 4 1 0 
TP53 11 136 0 
Hormone Adrenal Cortex Hormones 48 13 0 
Estradiol 984 1 0 
Estrogens 1249 4 0 
Glucocorticoids 95 3 0 
Hydrocortisone 151 3 0 
Insulin 37 9 0 
Progesterone 925 6 0 
Testosterone 2005 1 0 




Dopamine 370 17 0 








12 1 0 
Argipressin 13 15 0 
Bleomycin 7 49 0 
Cetuximab 1 88 0 
Cisplatin 9 264 0 
Cyclosporine 9 12 0 
Dexamethasone 30 14 0 
Fluconazole 8 60 0 
Fluorouracil 13 120 0 
Hydrogen Peroxide 3 7 0 
Indomethacin 25 3 0 
Iron 9 4 0 
Morphine 75 4 0 
Virus Hepatitis C virus 731 4 0 
Herpesvirus 4, human 39 72 0 
Human Papillomavirus 1567 823 91 
Human papillomavirus 16 158 123 11 
Human papillomavirus 18 37 8 0 
Human papillomavirus 6 46 11 0 
 
3.4. Discussion 
From this systematic retrieval of OPC risk factors and intermediates between OPC and risk 
factors, 5 phenotypes appear to be highly enriched in current PubMed literature: alcohol 
consumption, tobacco use, HPV infection, the HPV vaccine and sexual behaviour (namely oral sex). 
Intermediate SemMedDB concepts relating to pharmacological substances, specific gene regions and 
select molecular intermediates (e.g. hormones, amino acids) were also explored to augment the 
results from MELODI. 
 
Quantifying HPV risk in observational literature 
Although many journal articles quantify the prevalence of HPV within populations of 
individuals with OPC, very few attempt to quantify the risk of developing OPC from HPV infection. The 
largest of the few studies that does estimate risk of HPV infection on OPC incidence examines OPC 




cohort [227]. The study uses seropositivity of HPV16 E6 oncoproteins as a marker of current oncogenic 
infection. Of 135 OPCs, 88 showed HPV16 E6 seropositivity vs 47 showing HPV16 E6 seronegativity, 
with 1,599 controls (9 HPV16 E6 seropositive, 1590 HPV16 E6 seronegative). The odds ratio of having 
OPC given HPV16 E6 a seropositive status was 274 (95% CI: 110 to 681); a huge risk increase vs 
seronegative controls. Such evidence appears to support the predications obtained for HPV on OPC 
risk. 
 
Quantifying alcohol risk in observational literature 
The effect of alcohol consumption on OPC risk has been investigated by many observational 
epidemiological studies. In a large meta-analysis of 52 alcohol-OPC (combined as oral cavity and 
pharyngeal cancer) studies [17], alcohol consumption was split into frequency categories. Light (RR: 
1.13; 95% CI: 1.00 to 1.26), moderate (RR: 1.83 95% CI: 1.62 to 2.07) and heavy (RR: 5.13; 95% CI: 4.31 
to 6.10) consumption of alcohol all conferred an increased risk of these cancers vs never drinking. 
Furthermore, a study examining alcohol consumption in cancers of the pharynx found similar evidence 
[228]. Versus non/occasional drinking, light (OR: 1.39; 95% CI: 1.02 to 1.89), moderate (OR: 2.87; 95% 
CI: 1.91 to 4.30) and heavy drinking (OR: 5.70; 95% CI: 3.61 to 9.02) showed significant increase in risk 
of OPC. As with HPV, the effect of alcohol consumption on OPC risk from the studies above show 
consistent evidence supporting the SemMedDB triples obtained from this analysis – alcohol 
consumption is positively associated with OPC risk. 
 
Quantifying smoking risk in observational literature 
As with alcohol consumption, smoking has been investigated with respect to OPC risk in large, 
multi-centre meta-analyses of observational studies. In large meta-analyses of pharyngeal cancer, 
both current vs never smoking and former vs never smoking show marked effects on cancer risk [229] 
(current vs never RR: 6.76, 95% CI: 2.86 to 15.98, N studies = 7; former vs never smoking RR: 2.28, 95% 
CI: 0.95 to 5.50, N studies = 3). Similarly, current smoking was associated with cancer risk (OR: 5.83; 
95% CI: 4.50 to 7.54) for oral cavity and oropharyngeal cancer combined in the Alcohol-Related 
Cancers and Genetic Susceptibility in Europe (ARCGSE) project; a multicentre case-control study in 10 
European countries pertaining to over 4000 individuals [15]. Finally, a prospective study conducted by 
the International Head and Neck Cancer Epidemiology (INHANCE) consortium from 1981-2007, with 
over 3,800 cases and 18,000 controls [49] found ever vs never smoking in OPC to be associated with 




epidemiological studies appear to provide good evidence for the SemMedDB predications relating to 
an association between smoking and OPC risk.  
 
Quantifying oral sex risk in observational literature 
In the only meta-analysis of oral sex and oral cancer, six case‐control studies and one cross‐
sectional study, relating to 5,553 individuals, indicated that there was no significant association 
between oral sex and risk of oral cancer (OR: 1.15; 95% CI 0.86 to 1.54; P: 0.33) [230]. The authors of 
this meta-analysis suggest that oral sex is a “risk behaviour” that could lead to HPV infection, which in 
turn could cause OPC, rather than that oral sex is an independent risk factor for oral cancer.  
 
Example oral sex hypothesis network 
 The most associated intermediate (by overlap in PubMed literature) between OPC and oral 
sex is HPV. Sexual behaviour is an established risk factor for HPV-related OPC [231], with lifetime 
number of oral sex partners the factor most strongly associated with OPC [232]. When compared with 
patients with non-HPV-related OPC squamous cell carcinoma, patients with HPV-related OPSCC tend 
to be younger (aged <60 years) and do not have a history of sustained smoking and drinking [233]. 
Additionally, a higher percentage of them are men (in most regions), and report more oral sex partners 
and a higher socioeconomic status [231]. It is entirely plausible and generally accepted that differences 
in sexual behaviour could explain some of the differences in risk-attributable fractions observed across 
regions and across decades for HPV-positive OPC; demographics with more oral sex partners result in 
an increased number of high-risk HPV infections [234], resulting in a higher frequency of HPV-driven 
OPC [21]. 
  
Common intermediates between risk factors 
From these results, it is clear that research needs to be undertaken to disentangle the causal 
pathways of the risk factors returned by MELODI. Between alcohol consumption, smoking, HPV 
infection and oral sex, there is considerable correlation. The risk factors retrieved by MELODI could 
represent an over-arching “risk-taking” phenotype which is difficult to disentangle from its constituent 
factors. This interpretation is also supported by the discovery of dopamine as an intermediate for each 
of alcohol consumption, smoking and HPV infection; dopamine agonists have been shown to lead to 
impulse control disorders and pathological gambling [235, 236]. It may be that smoking, alcohol and 




reported in response to smoking [237] and alcohol consumption [238], but not for HPV infection. An 
alternative explanation that cannot be discounted in this analysis is that dopamine levels affect risk of 
smoking, alcohol consumption and sexual behaviour (leading to HPV infection), which in turn affect 
risk of OPC, highlighting a limitation of SemMedDB “concepts” vs “triples” – whilst use of “concepts” 
allows for recovery of a greater number of potential intermediates, directionality cannot be 
established between risk factor and outcome.  
 
 In observational literature, it has long been established that smoking and alcohol are highly 
correlated [25]. Alcohol and sexual activity are also correlated [239] – with a greater number of sexual 
partners, oral sex and propensity for HPV infection are generally more frequent in heavier/more 
frequent drinkers [231]. The shifting prevalence of HPV-driven OPC affecting younger individuals (<45 
years old) seen in literature likely reflects the change in sexual (and social) behaviour in those 
demographics, more than it reflects a fundamental change in how sustained alcohol consumption, 
HPV infection or sustained smoking cause OPC. A key pitfall of observational epidemiological studies 
is the inability to isolate the effect of a single phenotype on disease risk. For each risk factor “triple” 
seen in the results section of this chapter, the other 4 are always considered intermediates by multiple 
studies. Confounding, reverse causation and many other epidemiological biases cannot be accounted 
for in observational study designs, adding to the necessity to establish true causal risk factor-OPC 
estimates. Mendelian randomization (MR) is a method that could overcome these limitations; by 
genetically-proxying phenotypes in a causal inference framework, direction of effect is established 
(genetic information is fixed at conception, thus reverse causation is not possible) and confounding is 
typically overcome (genetic information is inherited at random during meiosis, thus population 
distribution of genotypes should be naturally “randomized”).  
 
Furthermore, 200 of the 210 intermediates were shared between at least two of the risk 
factors retrieved by MELODI and, when examining the literature mentioning smoking, alcohol 
consumption and oral sex indexing concepts, the vast majority of articles returned investigate all three 
concepts as risk factors. Solely using the approach detailed in this chapter, it is unclear whether 
smoking, alcohol and HPV do indeed describe a singular “risk-taking” phenotype, where each risk 
factor mediates the others. However, more likely is that these “mediations” are an artefact of a 
saturation of published articles examining the three risk factors on OPC risk simultaneously, with 
SemRep parsing the abstracts of these articles to describe independent risk factors as cofactors for 




risk factors/hypotheses (rather than highlighting combinations of established risk factors in different 
populations), prevents this data-driven approach from generating more hypotheses. 
 
Exemplar data-driven hypothesis network using enriched predications 
 As an exemplar, overlapping intermediates have been combined (where possible) into a 
hypothesis “network”, sharing common biological pathways. It should be noted, all intermediates 
discovered via MELODI will be used as an evidence base for analyses in latter chapters in this thesis.  
 
The amino acid, peptide or protein showing the largest degree of overlap between HPV and 
OPC in PubMed literature was the epidermal growth factor receptor (EGFR) protein. In vitro literature 
suggests that HPV16 oncoproteins (an artefact of HPV16 infection, transmitted through oral sex) 
regulate the translocation of β-catenin via the activation of EGFR [240]. There is a correlation seen 
between HPV-positive OPC, levels of E5 and E6 oncoprotein and decreased membrane EGFR. 
Furthermore, lower membrane EGFR has been shown to be significantly associated with disease-free 
and overall survival. However, whilst lower membrane EFGR is associated with survival, activation of 
this receptor can cause translocation of β-catenin from the membrane to the nucleus of a cell, which 
is strongly associated with lymph node metastases [240]. It is therefore hypothesised that HPV-
positive OPC, whilst associated with better survival than HPV-negative OPC, promotes early lymph 
node (and potentially distant) metastatic disease via activation of EGFR and subsequent translocation 
of β-catenin, through its E5 and E6 oncoproteins [241]. These findings also establish β-catenin as a 
distinct biomarker for HPV-positive OPC. Contrarywise, smoking and alcohol have been reported to 
increase expression of membrane EGFR [241-243], potentially explaining part of the decreased 
survival in more “traditional” OPC (caused by sustained tobacco and alcohol consumption) compared 
to HPV-driven OPC [11]. 
 
TP53 shared the most “gene” indexing articles between HPV and OPC search sets. TP53 is a 
well-established oncogene in a pan-cancer context with many associated biological pathways [244]. 
In the case of HPV-positive OPC, one of the many roles TP53 plays is to dysregulate the induction of 
hBD3 expression in human oral epithelial cells and oral cancer cell lines via HPV16 E6 when compared 
to E6 from non-oncogenic HPV types [245]. The hBD3 peptide is an epithelial cell-derived antimicrobial 
and immunoregulatory peptide that, under normal conditions, acts to defend mucosal surfaces from 
microbial challenges [246]. Clinically confirmed HPV-positive head and neck cancers overexpress 




and activate tumour-associated macrophages in the tumour microenvironment through hBD3, 
contributing to cancer progression [245]. As such, hBD3 may be a therapeutic target for OPC. 
 
 The pharmacologic substance with the most overlap between HPV and OPC search sets in this 
analysis was cetuximab – an EGFR monoclonal antibody used to prevent overexpression of EGFR in 
HNC patients in conjunction with radiotherapy. Interestingly, cetuximab seems to show inferior 
efficacy in HPV-positive OPC compared to HPV-negative OPC, potentially an artefact of decreased 
expression of membrane (due to translocation to the nucleus; see above) EGFR seen in those with 
HPV. As proof of principle of these connected hypotheses, recently, cisplatin has been advocated 
above cetuximab due to marked overall (77·9% [95% CI: 73·4 to 82·5] in the cetuximab group versus 
84·6% [95% CI: 80·6 to 88·6] in the cisplatin group) and progression-free survival (5-year progression-
free survival: cetuximab 67·3% [95% CI: 62·4 to 72·2] vs cisplatin 78·4% [95% CI: 73·8 to 83·0]) seen in 
a trial of 849 individuals with HPV-positive OPC, comparing the two chemotherapeutic agents [97, 98].  
 
Strengths 
The method outlined in this chapter is a rapid, systematic approach to obtain risk factors 
relating to an outcome of interest. In the context of epidemiology, when attempting to generate novel 
hypotheses or relationships, advanced data mining methodology is becoming increasingly important. 
Systematic, automated approaches offer enormous potential to assist in identification of existing 
evidence and prioritization of mechanisms to investigate, examining vast amounts of publication data 
using pre-calculated literature objects, such as SemMed predications. The scale and size of high-
throughput data mining techniques simply cannot be matched by manual effort. 
 
A key strength of using MELODI is that it can appraise intermediates between a risk factor and 
OPC. Results obtained from this approach provide the number of individual studies relating to a certain 
indexing concept for each of two search sets, whilst also providing an estimation of shared literature 
(i.e. an article describing both concepts simultaneously, greater than chance) between concepts. 
Shared literature represents existing evidence of an intermediate between a risk factor and OPC, 
whilst no shared literature could indicate a novel pathway. From the combined results across all risk 
factors, 71 intermediates showed evidence of association with OPC from published literature, with 
139 intermediates showing no previous evidence. By simultaneously estimating the degree of 
evidence for existing risk factor pathways and deriving novel hypotheses for appraisal, MELODI is less 




systematic review); traditional methods typically cannot link a risk factor and outcome which are a 
step removed from each other on a causal pathway, whereas MELODI can. 
 
Limitations 
The resolution of SemMedDB triples and the inclusion of a PREDICATE between concepts 
allows for directionality (proposed by the author of an article in an abstract) to be established between 
potential risk factor/intermediate and OPC when one is inferred. However, the efficacy of retrieval of 
SemMedDB concepts and triples from literature is largely dependent on how an abstract has been 
parsed by the SemRep program. As mentioned previously, SemRep infers predications from PubMed 
article abstracts. As such, an article would have to explicitly state that a risk factor was associated with 
OPC risk in its abstract for a triple to be inferred (e.g. “mouthwash was associated with increased risk 
of oropharyngeal squamous cell carcinoma in our analysis”). Combined with MELODI filtering results 
to remove background noise, risk factors and intermediates actually associated with OPC risk, but rare, 
unique, or phrased in a unique way, would likely be filtered out of the results of a search set 
comparison. This is a key limitation of this method; it is evidenced by a small number of 
epidemiologically-relevant triples returned for a small number of already well-established risk factors, 
in the case of OPC. Despite the lack of discovery of novel modifiable risk factors, those that have been 
retrieved by MELODI explain a significantly high proportion of the variance explained of OPC risk, 
validating this method of literature mining. 
 
In observational literature, many articles investigating risk factors relating to OPC tend to 
combine HNC subtypes. Whilst HNCs are proximal to each other, they are not always aetiologically 
similar. For example, Epstein-Barr virus is associated with nasopharyngeal cancer, whilst unassociated 
with other HNC cancer sub-types. Equally, HPV16 seems to have a much more significant association 
with OPC than any other HNC sub-type [247]. Combining HNCs raises two key issues for the method 
presented in this chapter; the first is that SemRep may not infer the association of a risk factor with 
OPC if it is grouped ambiguously, the second is that SemRep may infer an association that is not 
genuine for the same reason. Whilst MELODI filters out background noise and “triples” were filtered 
to only include those relating to OPC uniquely, it cannot be ruled out that some OPC risk predications 
were either not genuine, or simply missed. 
 
An important limitation of any literature-based tool is that the published literature may be a 




proportion of negative findings are never published, and groups often publish many related papers 
with similar ideas discussed in the abstract. In addition, the algorithms used to produce the 
SemMedDB data and the humans used to assign the MeSH terms may introduce unconscious bias. 
Using more flexible agnostic methods such as those mentioned above would enable the use of other 
publicly available data sets, alleviating some of the bias associated with published literature. Even so, 
MELODI is always going to give a biased representation of what is really known about a topic since it 
is based on published literature. However, the alternative to a computational approach is manual 
curation, which is impossible at this scale and potentially prone to much greater bias. As long as the 
caveats and limitations are understood, then the output of this kind of approach can still be valuable 
and provide reliable hypotheses. 
 
A key limitation of this analysis is that it was restricted to PubMed literature prior to 30th June 
2018. Whilst PubMed at this timepoint contains over 27.8 million articles 
(www.melodi.biocompute.org.uk), it does not encapsulate the entirety of scientific literature. Other 
biomedical literature repositories may contain information regarding OPC risk, such as Scopus, which 
contains over 69 million records [248]. However, whilst Scopus is a larger database, PubMed (including 
MEDLINE) is the default repository for biomedical articles and is currently the only database parsed 
for SemMedDB data [140], making it the only database available for use with this method.  
3.5. Conclusion 
In summary, MELODI provides a means of systematically interrogating vast amounts of 
literature data at a speed manual curation simply cannot match. Automated, systematic retrieval of 
risk factors and intermediates for downstream investigation, using pre-calculated literature objects, 
is extremely effective for rapid hypothesis generation. For the purposes of this thesis, gene and 
protein intermediate findings are of particular interest, as they may be able to be incorporated (using 
quantitative trait loci) into a Mendelian randomization framework to assess robust causality. 
Additionally, the list of risk factors and intermediates provide a robust evidence base and comparison 
for future chapters, where data-driven approaches will be incorporated to agnostically retrieve 
intermediates. It should be noted that this approach is not without weaknesses. Specifically, it is 
reliant on correct parsing of literature abstracts by SemRep, and the MELODI enrichment step will 
filter out any unique OPC risk factors if they are present in literature “less than chance”. In this respect, 
MELODI is overly conservative. However, for the purposes of deriving a robust evidence base from 
which to compare future analyses, it is a suitable method of risk factor and intermediate retrieval from 
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In this chapter, 17,449 phenotypes proxied by 647,283 genetic variants are examined in 
relation to oropharyngeal cancer risk in an MR-PheWAS framework. Exposure data is combined into 4 
broad groups: metabolites, immune cell traits, UK Biobank traits (see 4.2.1 – Phenotype grouping for 
an explanation of trait origins) and non-Biobank traits. Sensitivity analyses are conducted to ensure 
that any key assumptions of MR methodology are not violated. Finally, results surpassing a stringent 
FDR correction for multiple testing are then explored in current literature to ascertain biological 
plausibility. A relaxed p-value threshold is given to exposures pertaining to exposures (smoking, 
alcohol consumption, oral sex and HPV infection) presented in Chapter 3.  
 
Marked geographic and temporal differences in distribution and pattern of OPC indicates that 
a large proportion of these cancers are potentially avoidable. However, the nonspecific nature of OPC 
symptoms results in a high frequency of late-stage diagnoses and underscores the need for an 
effective screening programme with robust risk stratification. Tobacco smoking, alcohol consumption, 
and viral infection are among the major risk factors for OPC, with tobacco smoking and alcohol 
consumption reported as having synergistic effects on this disease. However, these reports are based 
on observational epidemiological studies, which are prone to unmeasured or residual confounding 
and reverse causation, precluding robust causal inference. Furthermore, conventional epidemiological 
studies often test a narrow set of hypotheses using prior subject knowledge, typically based on other 
observational studies. Whilst essential, hypothesis-driven approaches can constrict a field of research, 
and preoccupation with previously-hypothesised risk factors for a given disease can introduce 
publication bias [249], preventing both the identification of novel risk factors and de-prioritization of 
non-causal associations. 
 
Mendelian randomization (MR) is a well-established type of instrumental variable (IV) analysis 
that addresses some of the shortcomings of conventional observational studies by using genetic 
anchors to appraise the causal relevance of exposures on disease [250-254]. It is an increasingly 
recognised and powerful tool for identifying causes of a broad spectrum of outcomes, including cancer 
[255, 256]. Traditional MR studies focus on hypothesized exposure-outcome combinations, often 
using phenotype data collected on all participants in a single sample. Two-sample MR, using summary-
level data from published genome-wide association studies (GWASs), greatly extends the scope of the 
approach [125], allowing causal appraisal of hypothesized exposure-outcome associations using gene-
exposure and gene-disease associations collected in separate studies [257-261]. Further, the two-




to-many, many-to-1 or many-to-many exposure-outcome combinations, in an approach known as a 
MR phenome-wide association study (MR-PheWAS) [262, 263].  
 
Here, MR-PheWAS was used to screen the phenome for potential causes of OPC. Our aims 
were twofold: to identify potentially novel causes of OPC that may not have been captured using 
previous epidemiological approaches, and to prioritise hypotheses identified in current literature. 
 
4.2. Methods 
4.2.1. Data preparation 
OPC data 
GWAS data from people of European descent with OPC and matched controls were obtained 
from the International Head and Neck Cancer Epidemiology Consortium (INHANCE; 12 studies; 6034 
cases, 6585 controls). Cancer cases comprised the following ICD codes: oral cavity (C02.0-C02.9, C03.0-
C03.9, C04.0-C04.9, C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), 
overlapping (C14 and combination of other sites) and 25 oral or pharyngeal cases with unknown ICD 
code (other). The samples were originally genotyped using Illumina OncoArray, designed for cancer 
studies by the OncoArray Consortium, part of the Genetic Associations and Mechanisms in Oncology 
(GAME-ON) Network.  The majority of samples were genotyped as part of the oral and pharynx cancer 
OncoArray, with the exception of 2,476 shared controls (1,453 from the European cohort study and 
1,023 from the Toronto study) that were genotyped at the Center for Infectious Disease Research 
(Seattle, Washington, United States), but as part of the Lung OncoArray. Genotype calls were made 
by the Dartmouth team in GenomeStudio software (Illumina, Inc.) using a standardized cluster file for 
OncoArray studies. 
 
Initial quality control steps and analyses were performed at the International Agency for the 
Research of Cancer (IARC), Lyon. After removing duplicates, related samples, samples with sex 
discrepancy and population outliers, genotype imputation was performed using the Michigan 
Imputation Server [264]. Genotypes were pre-phased (i.e. their haplotypes were inferred) using 
SHAPEIT v2 [265] and imputed with Minimach v3 [266] using the Haplotype Reference Consortium 
panel [267]. After imputation, SNPs with an imputation quality (R2) lower than 0.7 were removed from 
the datasets. Effect estimates for OPC risk were obtained after adjusting for age, sex and significant 




calculated, at IARC, for site of OPC (overall oral cancer and pharynx cancer, site-specific oral cancer 
and oropharyngeal cancer) were then combined using a fixed-effects inverse-variance approach 
implemented in PLINK [268].  
 
Genetic instruments for phenotypes  
Two-sample MR was conducted using the TwoSampleMR R package [269], in R version 3.5.1. 
Genetic data on cognitive, anthropometric, metabolic, immune and behavioural phenotypes were 
obtained from the MR-Base database of harmonised GWAS summary data (Figure 4.1). Those 
phenotypes possessing robust genetic proxies (defined as P<5e-8) with which to conduct MR analyses 
were considered for further analysis (N=21,158). Duplicate (N=477) and non-European studies (N=16) 
were excluded from the analysis at this stage, leaving 21,074 potential phenotypes for analysis. 
Genetic instruments for each phenotype were single-nucleotide polymorphisms (SNPs) independently 
associated with the phenotype of interest after linkage disequilibrium (LD) clumping (radius = 
10,000kb; r2 = 0.001). For each identified SNP, the reported effect size was expressed as a one standard 
deviation (SD) increase in the level of the phenotype per risk allele, along with the standard error (SE). 
In the case of a binary phenotype (e.g. presence or absence of coronary heart disease), the reported 
effect size was expressed as a log odds ratio (OR). For studies in which the genetic effects were not 
originally reported in SD units of the phenotype, these were recalibrated according to the mean and 
SD reported in the original study and, if appropriate, weighted for sample size across the different 
studies contributing to the meta-analysed GWAS for a phenotype. For each genetic variant associated 
with the identified phenotypes, effect-estimates and SEs were then extracted from the summary 
genetic data for OPC. Phenotypes without genetic variants at P< 5x10-8 (N = 2,540) were excluded from 
analysis. To harmonise the data, effect alleles in the OPC summary data were coded to reflect the 
phenotype increasing allele, using allele frequencies to resolve strand ambiguities for palindromic 
SNPs (A/T or C/G). Those phenotypes that did not have genetic variants in the OPC GWAS were 
excluded (N = 669; not imputed in the dataset), resulting in a final list of 17,449 phenotypes on which 







 Phenotypes were grouped into 4 categories: metabolites, immune traits, UK Biobank traits, 
and traits not defined by the other categories (defined as “standard”, non-UK Biobank, immune or 
metabolite traits). Metabolic traits included those from Shin et al. [270], Kettunen et al. [271], 
Lemaitre et al. [272], Guan et al. [273], Wu et al.[274], Mozaffarian et al. [275], Dastani et al. [276], 
Paterson et al. [277] and Kilpelainen et al. [278], corresponding to 383 phenotypes. Metabolites were 
grouped due to their vast numbers, highly correlated nature and the rising significance of the 
metabolome’s effect on disease in literature. Immune traits consisted of phenotypes from Roederer 
et al. [279], who examined the genetic contribution to different proportions of immune cell subtypes. 
Immune traits (N = 24) were grouped separately due to their highly correlated nature and due to the 
Figure 4.1 - Flowchart detailing phenotype extraction process for MR-PheWAS. Phenotypes were extracted from MR-Base 




large proportion of attributable risk of OPC given to HPV infection. UK Biobank traits consisted of 
16,930 phenotype instrumental variables (IVs) generated by the Integrative Epidemiology Unit at the 
University of Bristol, UK and by Neale Laboratories in Boston, Massachusetts. Both institutes 
conducted GWAS using pipelines incorporating the PHEnome Scan Analysis Tool (PHESANT). PHESANT 
was created to systematically perform PheWAS in UK Biobank, automating the coding of UK Biobank 
variables and testing their association with genetic information. Where possible, all phenotypes were 
converted into normally-distributed quantitative or binary categorical variables and GWAS models 
were adjusted for principal components, sex, age, age2, sexage and sexage2. Binary traits were 
regressed using BOLT-LMM; a linear mixed-model approach which accounts for relatedness and 
population stratification. BOLT-LMM outputs betas as an absolute risk difference, therefore to allow 
for estimation of log odds ratios, beta values from UK Biobank binary phenotype GWAS were 
converted prior to MR using the following formulae: 
 









Where 𝛽𝐵𝑂𝐿𝑇 is the BOLT-LMM output beta 
 




Where 𝑆𝐸𝐵𝑂𝐿𝑇 is the BOLT-LMM standard error 
 
Non-Biobank traits consisted of 112 phenotypes. This grouping of phenotypes contained 
neurological, anthropometric and disease traits, including common modifiable epidemiological 
phenotypes such as body mass index, smoking and educational attainment.  
 
 Finally, phenotypes pertaining to alcohol consumption, smoking, sexual activity and HPV 
infection (see Box 4.1) were investigated in a separate analysis due to existing observational 
epidemiological evidence of association with OPC from MELODI (see Chapter 3). For these 
phenotypes, a multiple-testing correction was not necessary (see 1.2.2); they were treated as 








The following phenotypes were matched with risk factors found to be enriched in current 
epidemiological literature by MELODI. From each broad category of phenotypes in this analysis, the 
keywords “smok*”, “ciga*”, “alc*”, “drink*”, “beer”, “wine”, “spirit*”, “sex*”, “intercourse”, “HPV” 
and “papillomavirus” were used to systematically retrieve potential phenotype matches. Where 
similar phenotypes were retrieved, the IV with the largest sample size or largest number of SNPs was 
used, resulting in 13 phenotypes being extracted from the UK Biobank dataframe of exposures. 
 
Phenotype #SNPs Matching phenotype 
Age first had sexual intercourse 189 Sexual activity 
Average weekly beer plus cider intake 20 Alcohol consumption 
Average weekly champagne plus white wine intake 4 Alcohol consumption 
Average weekly red wine intake 17 Alcohol consumption 
Average weekly spirits intake 4 Alcohol consumption 
Current tobacco smoking 34 Smoking 
Ever smoked 77 Smoking 
Lifetime number of sexual partners 61 Sexual activity 
Nondependent abuse of alcohol 64 Alcohol consumption 
Nondependent abuse of tobacco 15 Smoking 
Pack years of smoking 10 Smoking 
Papillomavirus as the cause of diseases classified to other chapters 3 HPV infection 
Past tobacco smoking 92 Smoking 
 
 
4.2.2. Statistical analysis 
Mendelian randomization analyses  
We used fixed-effects inverse-variance weighted (IVW) [280, 281] MR analyses when the 
number of SNPs available to instrument a phenotype was greater than 1. IVW is an established, 
reliable MR analysis method when using summary genetic data with phenotype instruments 
containing multiple SNPs [125]. For phenotypes instrumented by a single SNP, we derived Wald ratio 
effect estimates [125, 282]. Results were expressed as odds ratios (ORs) with a corresponding 95% 




confidence interval (CI) per 1 standard deviation (SD) increase in continuous traits (e.g. height), and 
as ORs with 95% CI per a doubling in odds for binary traits (e.g. type 2 diabetes). 
 
Multiple testing correction 
To account for the large multiple testing burden accrued by the MR-PheWAS, analysis p-values 
were adjusted via the Benjamini-Hochberg FDR correction [169]. An FDR-adjusted p-value of 0.05 was 
used to determine results with strong statistical evidence to support an association between a 
phenotype and OPC.  
 
Sensitivity analyses 
MR-Egger regression [283] was used as a sensitivity analysis to detect bias due to horizontal 
pleiotropy in the causal estimates. Horizontal pleiotropy is where a genetic variant affects the 
outcome via a different biological pathway from the phenotype under investigation and is a violation 
of a key assumption of MR. MR-Egger regression performs a weighted linear regression of the SNP-
disease and SNP-phenotype associations, the intercept of which is not constrained to the origin and 
can therefore be used to detect and estimate the magnitude of horizontal pleiotropy [283]. Due to 
the lack of constraint to the origin, deviation from the origin in an MR-Egger regression may suggest 
the effect of the SNP is operating via a separate pathway. MR-Egger regression relies on the existence 
of at least three SNPs to estimate a linear relationship. Additionally, we used MR Robust Adjusted 
Pleiotropy Score (MR-RAPS) to detect the presence of the many weak instruments bias.  
  
4.3. Results 
All phenotype-OPC associations below an FDR-corrected p-value of 0.05 can be seen in Table 
4.1. Results are described in more detail, per grouping, below. 
 
Metabolite trait grouping 
Using a conservative FDR p-value correction for multiple testing, of the 383 metabolite traits 
analysed, none of our results showed a corrected p-value of association below 0.05. All results from 






Table 4.1 - Phenotype associations with OPC displaying sufficient evidence of association below an FDR-corrected p-value of 
0.05. 95% confidence intervals (95% CI) and p-values are shown for each phenotype, in addition to the number of SNPs used 
in the IV, the variance explained by the IV in the phenotype of interest and the broad phenotype grouping the exposure 
belongs to in this analysis. OR: Inverse-variance weighted odds ratio for the effect of the exposure on incidence of OPC. Units 
are standardised - continuous traits are in standard deviation units; binary traits are in log odds units. 
Phenotype OR 95% CI FDR P-value Variance 
explained 
#SNPs Grouping 
Alcohol consumed (binary) 10.4 4.8 to 22.6 1.42 x10-5 1.24% 1 UK Biobank 
Former alcohol drinker 
(binary) 
11.7 5.2 to 26.6 1.42 x10-5 1.23% 1 UK Biobank 
Alcohol drinker status: never 
(binary) 
5.0x10-21 8.5x10-28 to 3.0x10-14 1.42 x10-5 1.03% 1 UK Biobank 
Red wine intake (units/wk) 178.1 31.6 to 1002.8 1.42 x10-5 2.35% 1 UK Biobank 
Alcohol (units/wk) 154.6 28.8 to 830.6 1.42 x10-5 1.67% 1 UK Biobank 
Non-cancer illness code, self-
reported: bronchiectasis 
(binary) 
0.55 0.45 to 0.68 7.54 x10-5 2.00% 2 UK Biobank 
Ischemic stroke (binary) 5.21 2.47 to 11.0 1.76 x10-3 2.93% 1 Non-Biobank 
Treatment/medication code: 
flecainide (binary) 
1.29 1.16 to 1.43 4.10 x10-3 2.00% 2 UK Biobank 
Treatment/medication code: 
sotalol (binary) 
1.55 1.27 to 1.89 0.027 1.00% 1 UK Biobank 
Qualifications: College or 
University degree (binary) 
0.72 0.61 to 0.83 0.027 1.29% 244 UK Biobank 
PCT where patients GP was 
registered: SWALE PCT 
(binary) 
1.00 1.002 to 1.007 0.027 2.11% 114 UK Biobank 
Age first had sexual 
intercourse (years) 
0.44 0.30 to 0.64 0.037 2.07% 189 UK Biobank 
Operative procedures - main 
OPCS: P09.1 Biopsy of lesion 
of vulva (binary) 
1.72 1.33 to 2.22 0.040 1.00% 1 UK Biobank 
Age at first live birth (years) 0.23 0.11 to 0.46 0.040 2.02% 34 UK Biobank 
Diagnoses - main ICD10: 
D64.9 Anaemia, unspecified 
(binary) 
2.77 1.71 to 4.48 0.041 1.01% 1 UK Biobank 




Figure 4.2 - Volcano plot showing the odds ratio derived from MR analyses of 383 metabolic phenotypes against incident OPC across the x-axis and a corresponding MR analysis p-value (-log10 scale) on the y-axis. Units are 
standardised - continuous traits are in are in standard deviation units, whereas binary traits are in log odds units. Small red points denote analyses with an unadjusted p-value < 0.05. Large red points denote analyses with a 




Immune trait grouping 
None of the 24 immune traits investigated showed any evidence of association with OPC 
below our FDR correction. Results of all immune trait phenotype-OPC associations can be seen in 
Figure 4.3.  
 
UK Biobank trait grouping 
 Fourteen of the 16,930 UK Biobank traits analysed showed evidence of association with OPC 
incidence below the FDR multiple testing threshold. Of these findings, 8 analyses were proxied by a 
single SNP, hence sensitivity analyses could not be conducted. The other 6 analyses were conducted 
using an IVW regression and allowed for 1 or more sensitivity analyses to be performed. Of the 
phenotypes below PFDR = 0.05, alcohol consumption appeared to show dramatic ORs for OPC incidence 
(alcohol consumed OR = 10.4; former alcohol drinker OR = 11.7; alcohol drinker status: never OR = 
5.0x10-21; red wine intake OR = 178.1; alcohol OR = 154.6). However, none of these findings allowed 
for sensitivity analyses due to single genetic proxies per phenotype. Age at first sexual intercourse and 
age at first live birth both showed inverse associations with OPC incidence (age first had sexual 
intercourse OR = 0.44; age at first live birth OR = 0.23). Both of these phenotypes possessed >1 genetic 
proxy, and both had consistent directions of effect between IVW, MR Egger and MR-RAPS analyses 
(age first had sexual intercourse IVW OR = 0.44; Egger OR = 0.60; RAPS OR = 0.42 | age at first live 
birth IVW OR = 0.23; Egger OR = 0.11; RAPS OR = 0.22). The magnitude of effect differed for both these 
phenotypes for the MR Egger findings, though low statistical power for Egger may explain these 
discrepancies.  
 
Non-Biobank trait grouping 
Of the non-Biobank phenotypes, 2 traits showed evidence of association at an FDR-corrected 
p-value < 0.05. Ischemic stroke showed a strong positive association with OPC (OR: 5.22; 95% CI: 2.47 
to 11.05; PFDR: 1.8x10-3). This phenotype was instrumented by a single SNP, hence corresponds to a 
Wald ratio estimate. Weight showed a negative association with OPC (OR: 0.42; 95% CI: 0.25 to 0.70; 
PFDR: 0.046) Weight was instrumented by 8 SNPs, thereby was estimated using the IVW method. 
Additionally, high grade serious ovarian cancer showed a positive association with OPC at a suggestive 
FDR-corrected p-value < 0.1 (OR: 1.24; 95% CI: 1.08 to 1.43; PFDR: 0.09). All results for this grouping are 




Figure 4.3 - Volcano plot showing the odds ratio derived from MR analyses of 24 immune phenotypes against incident OPC across the x-axis and a corresponding MR analysis p-value (-log10 scale) on the y-
axis. Units are standardised - continuous traits are in are in standard deviation units, whereas binary traits are in log odds units. Small red points denote analyses with an unadjusted p-value < 0.05. Large red 





Figure 4.4 - Volcano plot showing the odds ratio derived from MR analyses of 112 “standard” (non-UK Biobank) phenotypes against incident OPC across the x-axis and a corresponding MR analysis p-
value (-log10 scale) on the y-axis. Units are standardised - continuous traits are in are in standard deviation units, whereas binary traits are in log odds units. Small red points denote analyses with an 




Phenotypes possessing observational epidemiological evidence (MELODI) 
 Of the 13 phenotypes matched to MELODI risk factors for OPC, 5 showed an FDR adjusted p-
value of association below 0.05 (Table 4.2).   
 
Table 4.2 - Association between MELODI-derived risk factors and OPC risk. OR: odds ratio, CI: confidence interval 
Phenotype OR 95% CI P-value #SNPs 
Age first had sexual intercourse 0.44 0.30 to 0.64 2.4 x10-5 189 
Current tobacco smoking 11.1 2.35 to 52.3 2.4 x10-3 34 
Average weekly beer plus cider intake 21.5 2.87 to 161.8 2.8 x10-3 20 
Ever smoked 1.46 1.06 to 2.00 0.02 77 
Lifetime number of sexual partners 2.31 1.03 to 5.12 0.04 61 
Past tobacco smoking 0.71 0.46 to 1.08 0.11 92 
Nondependent abuse of alcohol 1.00 0.99 to 1.01 0.21 64 
Average weekly red wine intake 2.22 0.24 to 20.9 0.48 17 
Papillomavirus as the cause of diseases classified 
to other chapters 
1.03 0.94 to 1.12 0.54 3 
Average weekly spirits intake 0.21 0.0 to 38.4 0.55 4 
Pack years of smoking 0.89 0.36 to 2.17 0.79 10 
Nondependent abuse of tobacco 1.00 0.98 to 1.02 0.87 15 
Average weekly champagne plus white wine 
intake 
0.80 0.01 to 44.3 0.91 4 
 
4.4. Discussion 
We undertook an MR-PheWAS of the association of 17,449 phenotypes with OPC, across 4 
broad groupings, pertaining to cognitive, anthropometric, clinical, metabolic, immune and 
behavioural phenotypes. We provide evidence that 16 of the 17,449 phenotypes we tested were 
associated with OPC, pertaining to alcohol consumption, sexual behaviour, disease, medication use, 
weight and educational attainment.  
 
The inverse association seen between weight and risk of OPC is concurrent with findings from 
conventional observational studies investigating body fatness on the disease [80, 81, 219, 284, 285]. 
Across these studies, ORs were consistently above 2.0 for any measure of lower body fatness against 




[284]. In this PheWAS, elevated weight is associated with a ~2.3-fold decrease in OPC risk. Results did 
not change substantially in sensitivity analyses that made allowance for violations of MR assumptions, 
thus are compatible with a true inverse association between weight and risk of OPC. Findings for other 
body fatness phenotypes almost exclusively show the same inverse direction of association with OPC 
although do not reach the FDR adjusted p-value threshold used for filtering. In a study assessing weight 
loss at time of diagnosis in HNC patients, it was found that 20% of all HNC patients suffered from 
weight loss of either >5% in a month or >10% in 6 months [286]. Other studies examining weight loss 
report prevalence varying from 31% to 57% [287-289]. Weight loss has been linked to presence of 
typical HNC symptoms such as dysphagia/passage difficulties, loss of taste/aversion and loss of 
appetite, appearing to be particularly frequently observed in hypopharyngeal, oropharyngeal and 
supraglottic laryngeal cancer [286]. Thus, our finding of weight being inversely associated with OPC 
may be interpreted as “lack of weight loss” being inversely associated with OPC. Alternatively, it has 
been hypothesised that HNC patients may suffer from the anorexia-cachexia syndrome [290]; where 
elevated cytokine production in those with HNC [291, 292] cause a loss of taste and appetite. The 
inverse association of weight with OPC may also proxy for a lack of anorexia-cachexia syndrome; 
further investigation into this phenomenon is required to disentangle these phenotypes. 
 
Dramatic findings were observed between genetically-proxied alcohol phenotypes and risk of 
OPC. ORs for these phenotypes ranged from 10.4 to 178.1 for alcohol intake traits, indicating that, as 
observational literature suggests, alcohol consumption is a significant risk factor for OPC. However, 
given a distinct lack of sensitivity analyses for these phenotypes, the robustness of the MR analyses is 
unclear and definitive causal inference cannot be made as a result. The top 5 phenotype-OPC 
associations were: alcohol consumed, former alcohol drinker, alcohol drinker status: never, red wine 
intake and alcohol. These phenotypes were all proxied by the same single SNP, rs1229984, evidenced 
by the exact same p-value for each of their associations. This SNP encodes a form of the alcohol 
dehydrogenase, ADH1B, gene that significantly reduces the clearance rate of alcohol from the liver 
[293], providing biological plausibility for the discovery of rs1229984 from multiple alcohol-related UK 
Biobank GWAS. However, we can only state that this locus displays a profound effect on OPC 
incidence; we cannot assert true causality of any of these phenotypes without more well-defined IVs 
to proxy them, and without additional sensitivity analyses. Amongst phenotypes possessing 
observational evidence of association with OPC from MELODI, average weekly beer plus cider intake 
showed a markedly elevated OR for risk of OPC (OR: 21.5; 95% CI: 2.87 to 161.8). This phenotype was 
proxied by 20 SNPs, thus sensitivity analyses be conducted alongside the IVW MR regression. Despite 




x104; 95% CI: 89.1 to 1.05 x107) and MR-RAPS (OR: 14.4; 95% CI: 3.40 to 61.2) confidence intervals 
resulted in a lack of evidence for horizontal pleiotropy or weak instrument bias, respectively.  
 
 Educational attainment (Qualifications: College of University degree) was found to be one of 
the more robust results in this analysis. The phenotype was proxied by 244 genetic variants, showing 
little evidence of bias via multiple weak instruments (IVW OR: 0.72; 95% CI: 0.61 to 0.83 | MR-RAPS 
OR: 0.71; 95% CI: 0.61 to 0.83) and little evidence of horizontal pleiotropy (MR Egger OR: 0.92; 95% 
CI: 0.33 to 1.14). Therefore, there is sufficient evidence in this analysis to suggest a robust causal 
association between genetically-proxied educational attainment and OPC risk. One potential 
explanation for this finding could be that educational attainment typically describes a large amount of 
variance in socio-economic position (SEP); a proposed driver of OPC risk in observational 
epidemiological literature and compound measure of risk factor exposure for many diseases. Amongst 
other behaviours, elevated SEP has been shown to correspond to a decreased proportion of heavy 
smoking and alcohol consumption in European population [294]; both well-established as causal risk 
factors for OPC in observational epidemiological literature.  
 
Findings pertaining to sexual behaviour agree with current observational literature. Increasing 
age at first sexual intercourse showed an inverse association with OPC. On the contrary, increasing 
lifetime number of sexual partners showed a positive association with OPC. In a cancer case/healthy 
control study, Schwartz et al. found a significant increase in OPC risk among men (OR: 3.4; 95% CI: 1.5 
to 7.5) if their age at first regular intercourse (defined as ≥ 3 times per month) was <18 years old [295]. 
The authors also found that the risk of oral cancer in males increased if the number of opposite-sex 
partners was ≥15 (vs a single partner) (OR: 2.3; 95% CI: 1.1 to 5.0). Findings were adjusted for age, 
smoking and alcohol consumption. Additionally, D’Souza et al. found that being ≤17 years at first 
sexual intercourse showed a significant increase in the risk of HPV16-positive OPC (OR: 2.1; 95% CI: 
1.1 to 3.6) after adjustment for gender, tobacco use, alcohol use, dentition and toothbrushing and 
family history of HNC [23]. This study also found that a high lifetime number of vaginal sex partners 
(≥26 vs 0–5) was associated with a significantly greater risk of OPC among men (OR: 3.1; 95% CI: 1.5 
to 6.5). Dahlstrom et al. found that patients with OPC were significantly more likely than patients with 
other head and neck cancers to have had ≥10 lifetime sexual partners (OR: 39.2; 95% CI 8.2 to 187.3), 
with a trend of increasing risk of OPC with an increasing number of lifetime sexual partners (P < 0.01) 
after adjustment for age, sex, ethnicity, smoking and income [296]. Finally, a pooled analysis study by 




cancer of the oropharynx (OR: 1.63; 95% CI: 1.22 to 2.18, and OR: 1.25; 95% CI: 1.01 to 1.54, 
respectively) [297].  
 
The summary statistics used in this analysis were not stratified by sex. Therefore, the effect 
estimates seen between ovarian cancer and OPC, and vulvar lesions and OPC are potentially biased 
towards the null. By not being able to restrict these analyses to women, the true causal effect of these 
phenotypes on OPC are likely diluted by the presence of male genetic information. Observationally, in 
support of the positive association of ovarian cancer with OPC seen in this analysis, complications of 
women treated for ovarian cancer with pegylated liposomal doxorubicin (PLD) include oral squamous 
cell carcinoma and leucoplakia [298]. Liposomes have been shown to accumulate in skin and mucous 
membranes and release doxorubicin and its metabolites over time. The prolonged exposure to 
doxorubicin is presumed to be the cause of an increased rate of secondary oral malignancies. 
However, it should be noted that numbers of individuals exhibiting these symptoms are rare. 
Additionally, the findings from this MR-PheWAS should not be interpreted as a direct causal effect of 
ovarian cancer on OPC, or a direct effect of vulvar lesions on OPC. More likely, it is shared genetic 
architecture translating in the same direction to affect the risk between a genetic predisposition to 
both these phenotypes and OPC, respectively. 
 
Mechanistic evidence for findings 
Flecainide and sotalol are both drugs used to suppress abnormally high heart rates and 
arrhythmias. Arrhythmias are common in those with alcoholism, thus both findings may be proxying 
alcoholism if enough of the population from UK Biobank taking these medications were alcoholics. 
Cardiovascular disease is also significantly associated in those with HNC as a direct result of the patient 
demographics for this cancer; older individuals, smokers, sustained high alcohol consumption. The 
flecainide and sotalol findings may also be proxying a population of individuals more likely to exhibit 
risk behaviours for OPC. Sotalol has been shown in observational literature to decrease prostate 
cancer risk, though to the best of our knowledge, has not been examined with respect to OPC or HNC 
risk. No evidence in current epidemiological literature appears to investigate the effect of flecainide 
on OPC or (more generally) HNC. 
 
Strengths  
The association of a multitude of phenotypes with an uncommon cancer type were appraised 




level data; a particularly valuable method when the outcome of interest is rare (as in the case of OPC), 
or when the capacity to investigate phenotypes in single studies is limited. For example, given limited 
power and sample size due to the cost of metabolomic platforms, many metabolites would unlikely 
have been investigated in relation to OPC risk in observational studies. However, since genetic 
instruments for a multitude of metabolites have been obtained in previous studies with large sample 
sizes [270, 271], the two-sample MR framework allows these data to be harnessed to appraise the 
causal effect of the metabolome on health and disease. 
 
Few other MR studies exist for the same OPC outcome as this analysis, and none utilise an 
MR-PheWAS framework. Pastorino et al. [299] examined the effect of adult height on combined HNC 
in a sample of ~5,000 Europeans. However, this MR analysis did not stratify their outcome by HNC 
subtype, thus the increase in risk observed between height and HNC (OR: 1.14; 95% CI: 0.99 to 1.32) 
may reflect a heterogeneity between subtypes, with one particular subtype biasing the true direction 
or magnitude of effect of another subtype. In this MR-PheWAS analysis, height showed an OR of height 
against OPC of over double that reported by Pastorino (OR: 2.33; 95% CI: 2.02 to 2.68), suggesting the 
presence of subtype heterogeneity in a combined HNC sample in their paper. The negation of potential 
HNC subtype heterogeneity in this analysis is a key strength as it reduces sources of bias. Kachuri et 
al. [300] also investigated HNC in an MR framework, this time against leukocyte telomere length. They 
found an inverse effect of telomere length on HNC (OR: 0.90; 95% CI: 0.70 to 1.05) using a novel IV for 
this phenotype. The present analysis could not investigate the effect of telomere length due to not 
possessing an IV for it, therefore could not assess the effect of telomere length on the OPC subtype 
rather than HNC combined.  
 
This analysis serves to illustrate a method that may shed light on phenotype-disease 
associations otherwise untested in the literature, whilst also appraising the association of phenotypes 
purportedly associated with disease in observational epidemiological literature using an MR 
framework. That some of the phenotypes identified in this study have already been highlighted in the 
literature strengthens the validity of the MR-PheWAS approach in identifying potentially causal 
phenotype-disease associations. MR-PheWAS can be extended to other outcomes to help prioritise 
potentially modifiable phenotypes for investigation in further observational, animal, MR, and cell 
studies. Having prior evidence for an association between a subset of a large panel of phenotypes (as 





As more GWAS are published, the number of hypotheses available for investigation using this 
method will steadily increase. Additionally, continued publication of GWAS of molecular intermediates 
such as those of the proteome, epigenome and transcriptome will allow for more detailed hypotheses 
of causal mechanisms to be generated, revealing intermediate pathways through which a phenotype 
could lead to disease. 
 
Limitations  
One limitation of the approach applied here is that not all possible phenotypes have genetic 
instruments or have not yet been curated in MR-Base (as seen for telomere length above). Therefore, 
some potentially associated phenotypes (e.g. HPV infection, oral sex) with OPC could not be appraised. 
Additionally, multiple phenotypes could only be proxied by a single SNP, negating the utilisation of 
sensitivity analyses and consequently restricting the evidence of causal association to suggestive at 
best. Conducting MR analysis with genetic IVs of ≥3 SNPs would allow a greater degree of certainty to 
be placed on the causality of a phenotype-OPC association, as it would increase the reliability of MR-
Egger and MR-RAPS. 
 
Due to the multiple testing burden of this analysis, there was potential for false-negative 
findings (i.e. true causal effects that we dismissed because they did not surpass our statistical 
threshold for further evaluation). To remain conservative in such a broad approach, only phenotypes 
that surpassed a strict FDR correction in the main analysis are presented. On the other hand, the MR 
approach may identify false positive findings, particularly if there is a horizontal pleiotropic effect of a 
genetic instrument on the outcome, which was evident for some of the phenotypes identified here.  
 
A limitation of the approach applied here is a significant risk of false negative findings due to 
a lack of granularity afforded by using summary genetic data. As summary genetic data reflects the 
average genetic association across all individuals with OPC in the OncoArray study, this will include 
both those who have an HPV-driven OPC and those who do not. However, HPV-driven and non-HPV-
driven OPC are recognised as distinct clinical entities and may have different factors predisposing 
them, respectively. Accordingly, with the outcome genetic data reflecting the average effect between 
the two entities, the results shown in this chapter may be biased towards the null, potentially missing 
important sub-type-specific (HPV-driven vs not) causal effects. It appears from the results that alcohol, 
smoking, body weight and sexual activity display a marked effect on OPC generally and are either not 
subject to, or able to overcome, any bias towards the null. However, any factors which do not have 




aetiology. This is particularly the case for HPV-driven OPC, where perhaps the only known predisposing 
factor for the disease is sexual history. Given that exposure to the high-risk HPV 16 and 18 sub-types 
is near-universal and incidence of HPV-driven OPC is currently increasing, knowledge of predisposing 
factors to the disease may prevent a large proportion of cases. This is notably important whilst the UK 
(and much of Europe) waits for the current time lag of vaccination programs to affect HPV-driven OPC 
incidence. An MR-PheWAS of HPV-driven OPC could be conducted similarly to how one has been 
conducted in this chapter – summary GWAS data would be extracted for a large number of exposures, 
then applied in a robust MR framework to summary genetic outcome data for HPV-stratified OPC 
incidence. The caveat of obtaining HPV-driven OPC summary genetic data is that a GWAS would 
require careful consideration of a control group; sexual history, geographic location and cultural 
experiences are all key factors for a cancer that is predisposed by sexual history. For younger 
individuals, matched controls based on e.g. university attendance and sexual history may optimal; for 
older individuals, matching based on long-term friendship groups (where possible) may best capture 
and match sexual behaviour, sex, age and “traditional” risk factor exposure (smoking, alcohol 
consumption and, to a degree, body weight). 
 
4.5. Conclusion 
Results from this MR-PheWAS of OPC show clear trends around phenotype groupings. Weight 
appears to be robustly associated with OPC risk. This finding is perhaps an artefact of not losing 
weight; weight loss appears to consistently preclude OPC in epidemiological literature and is also one 
of the nonspecific risk factors for the disease highlighted in Chapter 1. Alcohol consumption 
phenotypes show extreme effect sizes on OPC incidence, often showing ORs above 10, even with IVs 
possessing 20 SNPs (as is the case with red wine consumption). Whilst robust causality cannot be 
definitively stated with the alcohol IVs instrumented with a single SNP, rs1229984, associated with the 
ALDB1 gene, provides biological plausibility for their association with the alcohol phenotype. Alcohol 
consumption affects OPC with a consistently large direction of effect in the results of this chapter. 
Sexual behaviour, determined by MELODI to be observationally associated with OPC, appeared to 
show corresponding directions of effect to those reported in epidemiological literature; the more 
sexual partners one has, the higher the risk of OPC; the older one is at first age of intercourse, the 
lower the risk of OPC. Unfortunately, HPV16 or HPV18 infection could not be instrumented in this 
analysis. Current tobacco smoking and having ever smoked were also associated with increased OPC 




causal association, investigation of biological pathways and molecular intermediates (such as DNA 





C H A P T E R  5 .  D N A  M E T H Y L A T I O N  A S  A  M E D I A T O R  O F  O P C  






Observationally, smoking, alcohol and HPV16 infection are reported to affect both incidence 
and prognosis of OPC in classic epidemiological literature [19, 26, 217, 301]. Smoking and, to a lesser 
extent, heavy drinking at time of diagnosis are associated with increased incidence and poor prognosis 
of OPC [217, 302, 303]. Interestingly, HPV16 infection, while being a risk factor for OPC incidence, has 
been associated with improved prognosis for the disease [76, 304-306].  
 
Given that the vast majority of OPC is thought to be associated with prolonged exposure to 
one or more of smoking, alcohol consumption and HPV16 infection [14], insight into prognostic 
pathways related to these phenotypes will be of notable value for risk stratification and intervention 
strategies for the disease. Methylation, due to its proximity to the genome and utility as an exposure 
indicator, can be used to highlight gene expression pathways between prognostic factor exposure and 
mortality. Additionally, by investigating the causality of methylation as an intermediate between 
prognostic factor exposure and mortality in those with OPC, evidence for novel, disease-specific, 
potentially druggable therapeutic targets between each exposure and mortality may be discovered. 
 
Whilst methylation associated with smoking and alcohol have both been extensively 
investigated in epidemiological literature in healthy populations [182, 307], in the context of OPC, only 
methylation associated with HPV infection has been investigated [308]. Methylation associated with 
mortality in the context of OPC has not currently been investigated in epidemiological literature.  
 
In this chapter, whole-blood-based genome-wide DNA methylation in HN5000 is examined in 
relation to the main prognostic factors reported in epidemiological literature for OPC, and in relation 
to overall OPC mortality. DNA methylation patterns associated with the prognostic factors of smoking 
(ever vs never), alcohol (units per week) and HPV16 infection (proxied by HPV16 E6 seropositivity) are 
identified through EWAS and DMR analysis, in addition to those associated with ~3-year mortality 
(dead vs alive at a median 3.1 years [range: 2.75 to 4.9 years; inter-quartile range: 1.1 years] post-
follow-up from participant recruitment to study). Shared DNA methylation patterns between 
prognostic factors and mortality are then investigated. Finally, causal analyses are conducted within a 
novel MR framework to establish whether these overlapping methylation patterns between 






5.2.1. Study population 
Participants for this analysis were selected from a wider pool of individuals (post-exclusion) in 
HN5000 [209, 309] (N:5392), based on an ICD-10 coding (pathological where available, clinical if 
otherwise) of oropharynx (CO1, CO5, CO9, C10.0-2, C10.3, C10.8 and C10.9; N:1909/5392), availability 
of OncoChip genotype data [149] (N:1034/1909), baseline questionnaire and data capture 
information, and the availability of Illumina MethylationEPIC BeadChip data from blood taken at 
baseline, prior to treatment; N:448/1034. The HN5000 cohort structure and enrolment is described in 
detail in Chapter 2 section 1.5. 
 
Phenotype definitions 
Smoking, alcohol consumption and HPV16 infection 
Detailed information on tobacco and alcohol history were obtained at baseline via a self-
administered questionnaire. Participants were asked about their current smoking and drinking status 
and their use of tobacco and alcohol products prior to receiving their HNC diagnosis. Among smokers, 
information on age at smoking initiation and number of years of smoking was obtained. The 
questionnaire differentiated between use of cigarettes, hand-rolled cigarettes, cigars and smokeless 
tobacco, whereby a cigar was considered equivalent to four cigarettes. From this information, 
participants were dichotomised into ever and never smokers. Ever smokers were defined as those 
who smoked at the equivalent of at least 1 tobacco product a day per year, or ≥100 cigarettes in their 
lifetime. Never smokers were those who reported not smoking in any of the questions answered. 
Respondents were also asked to report their average weekly alcohol consumption of a range of 
beverage types (wine, spirits, and beer/larger/cider) before they were diagnosed with cancer. From 
these measures, an average intake of alcohol consumption in units per week was derived; weekly units 
were estimated from volumes of each beverage type reported by respondent and divided by 7. 
 
HPV serologic testing (HPV16 E6, E7, E1, E2, E4, and L1) was conducted at the German Cancer 
Research Center (DKFZ, Heidelberg, Germany) using a glutathione S-transferase multiplex [310]. 
Median fluorescence intensity (MFI) values were dichotomized to indicate HPV16 E6 seropositivity 
using a cut-off of ≥ 1000 MFI [227]. E6 seropositivity is known to be a marker of current HPV16 







Regular updates were received from the NHS Central Register (NHSCR) and the NHS 
Information Centre (NHSIC) notifying on subsequent cancer registrations and mortality among cohort 
members in HN5000. Recruitment for the study finished in December 2014 and follow-up information 
on mortality status was obtained on 30th September 2017, resulting in at least 2.75 years of follow-
up for all participants (median: 3.1 years; range: 2.75 to 4.9 years: inter-quartile range: 1.1 years).  
 
Other variables 
Surrogate variables were generated from the HN5000 DNA methylation data using the SVA R 
package [312] and attempt to generate variables to include in a model which explain the largest 
amount of variance, similar to the PCA analyses described in Chapter 2.2.2 “Confounding and GWAS 
precision”.  
 
DNA methylation data 
Illumina MethylationEPIC BeadChip-derived whole-blood DNA methylation data for 448 
individuals from HN5000 was available for this analysis as part of the work conducted in the Integrative 
Cancer Epidemiology Programme at the University of Bristol. Details of HN5000 methylation data 
extraction and quality control can be found in Chapter 2.3.1. 
 
Methylation quantitative trait loci 
Methylation quantitative trait loci were generated using MethylationEPIC BeadChip data from 
a quality-controlled subset of individuals (N: 5101) from the Generation Scotland: Scottish Family 
Health Study [313, 314]. 
 
Mortality GWAS data 
Prior to MR analysis of methylation against mortality being conducted (see section 1.2.2 
“Statistical analyses” below), instrumental variables (IVs) were derived, proxying CpG sites jointly 
identified with prognostic factors and mortality, consisting of mQTLs. Methylation quantitative trait 
loci used to instrument intermediate CpG sites were identified in the HN5000 OncoChip data. Analysis 
of the association of these sites with mortality was conducted using the SurvivalGWAS_SV program in 
a Linux shell script to run Cox proportional-hazards survival analyses with an additive dosage model 




censoring) in days as the time variable. Age at cancer diagnosis and sex were used as covariables in 
the model. For each SNP the log-hazard ratio (and standard error) per minor allele was reported. 
 
5.2.2. Statistical analyses  
Single-site epigenome-wide association analyses 
Epigenome wide association study (EWAS) analysis was conducted to identify associations 
between DNA methylation and 1) alcohol consumption 2) smoking status and 3) HPV16E6 
seropositivity. EWAS were conducted in meffil [210] using R (version 3.4.1), using a linear regression 
model of DNA methylation regressed on the prognostic factors, adjusting for age, sex, surrogate 
variables obtained by SVA and the other prognostic factors (e.g. for alcohol intake, adjusting for 
smoking and HPV16E6 seropositivity; for smoking, alcohol intake and HPV16 E6 seropositivity).  
 
Of the 443 individuals who passed QC (see Chapter 2.3.1 – Head and Neck 5000: DNA 
Methylation), the number of individuals with complete phenotype data for alcohol intake, smoking 
status and HPV16E6 seropositivity with which to conduct an EWAS was 408 as of the 2018, version 2.3 
release of HN5000 data. All samples possessed information on mortality status.  
 
EWASs for mortality from recruitment (last participant recruited December 2014) – 
September 2017 (or time of censoring; whichever occurred first) was conducted using Cox 
proportional-hazards models using code adapted from the meffil R package. Two models were 
assessed: Model 1, adjusting for age, sex and surrogate variables obtained by SVA, and Model 2, 
adjusting for age, sex, surrogate variables obtained by SVA, HPV16 E6 seropositivity, smoking status 
and alcohol intake. Model 1 was run to assess overlap with prognostic factors by not adjusting for 
them; Model 2, by adjusting for prognostic factors, would provide mortality-specific hits independent 
of them. Death from any cause was used as the failure variable and time to death (or censoring) in 
days as the time variable.  
 
Due to the large number of tests conducted in the EWAS, a Bonferroni correction was 
employed to derive a conservative p-value threshold of 5.7 x10-8 (0.05/862491 independent tests), 
determining those sites showing strong evidence of association with each prognostic factor of interest 
or mortality, respectively. The alpha value calculated for the Illumina 450K array was also employed 





Differentially-methylated region analyses 
Following each EWAS, DMR analysis was conducted, using the dmrff R package [186]. This 
analysis identified regions (> 1 CpG site per region) enriched for low P-values (P<0.05), corrected for 
dependencies between other CpG sites in the DMR and adjusted for multiple testing. 
 
Generation Scotland methylation quantitative trait loci 
DNA methylation can be influenced by genetic sequence variations, such that individual 
genotypes at a given locus may result in different patterns of DNA methylation due to allele-specific 
methylation [198, 317, 318]. Such sites, called methylation quantitative trait loci (mQTLs), can 
influence the methylation pattern across an extended genomic region [317], and can be used as a 
proxy for methylation levels in a Mendelian randomization (MR) framework [126].  
To generate mQTLs, methylation data from a quality-controlled subset of individuals (N: 5101) 
from the Generation Scotland: Scottish Family Health Study who had undergone EPIC array DNA 
methylation profiling, described previously [314], were used. Following measurement of DNA 
methylation, normalization was performed using the R package minfi [213], producing M-values [319] 
for downstream analysis. Briefly, linear mixed modelling was used to remove potential effects from 
technical factors, adjusting for both fixed and random effects. Fixed effects included: the top 50 
principal components of control probe intensities (explaining 99% of variation in control probe 
intensities) [320], clinic centre for blood draw appointment, processing batch, year of clinic visit, and 
sentrix position (position of the sample on EPIC array slide). Random effects included: blood draw 
appointment date and sentrix ID (EPIC array slide). The model converged successfully for 712,595 sites. 
Outliers from this normalisation with residualized-M-values more than five interquartile ranges from 
the nearest quartile were removed [321].  
A GKFSC model [322, 323] was then fitted to derive mQTLs from the normalised data, including 
5 matrices as random effects, and other covariates as fixed-effects. The matrices were: G (a genomic 
relationship matrix), K (a kinship relationship matrix) [324, 325], F (an environmental matrix 
representing nuclear-family-member relationships), S (an environmental matrix representing full-
sibling relationships) and C (an environmental matrix representing couple relationships) [322, 323]. 
Covariates (as fixed effects) included: age, age2, gender, estimated cell counts, season of clinic visit, 
appointment time of the day and appointment day of the week. The model successfully converged in 





Generation of instrumental variables for DMRs 
Prior to MR analysis being conducted (see “Mendelian randomization” below), instrumental 
variables (IVs) were generated, proxying CpG sites identified concurrently in analyses of each 
prognostic factor and mortality. Where possible, DMRs (P < 0.05) were identified for each prognostic 
factor, and DMRs located in the survival analysis which spanned the same regions (Model 1 – 
unadjusted for prognostic factors; P < 0.05). CpG sites present in both DMRs were retained. 
 
Next, using the summary genetic data for mQTLs from Generation Scotland, all mQTLs 
proxying any CpG site per DMR grouping (MAF >0.05; P < 5x10-8) were extracted. From this list, 
instruments were generated by LD pruning iteratively; first taking all mQTLs associated with the 
sentinel CpG (defined as the CpG in each DMR with the lowest p-value) and LD pruning with an r2 of 
0.01. Then, the second most-associated CpG in the DMR was identified; all mQTLs associated with this 
CpG which were not associated with the previous, more-associated CpG were extracted. The 
remaining mQTLs were clumped and combined with mQTLs proxying the sentinel CpG. This process 
was repeated for each CpG within a DMR. Clumping and mQTL extraction were conducted using R 
3.4.1, with the TwoSampleMR R package [269]. 
 
In order to account for mQTL proxies influencing methylation at multiple CpG sites, a meta-
analysis of mQTL-CpG effects was conducted. Per DMR, the metafor R package [326] was used to 
meta-analyse each mQTL effect (beta) on methylation levels at each CpG, using a restricted maximum 
likelihood (REML) model, adjusting for pairwise correlation between the CpG sites proxied by each 




Following identification of shared methylation patterns between prognostic factors and OPC 
survival, two-sample MR was utilised in an attempt to ascertain whether methylation was a true causal 
intermediate, or rather concurrently associated with a prognostic factor and survival. In the first 
sample, mQTL-DMR effect estimates (βGP) from Generation Scotland were used; in the second 
sample, mQTL-survival estimates (βGD) from HN5000. For each mQTL, the log HR per unit (β) increase 
in DNA methylation was calculated by the formula βGD/βGP (Wald ratio). Standard errors were 
approximated by the delta method. Where multiple mQTLs were available for one DMR, these were 
combined in a fixed effects meta-analysis after weighting each ratio estimate by the inverse variance 




mQTLs, genetic correlation was adjusted for. An online platform, LDMatrix [327], was used to generate 
a genetic correlation matrix (using the 1000 Genomes reference standard) of mQTLs, which was 
included as a covariate in each MR regression analysis [328]. Wald ratios were calculated for CpGs 
proxied by a single mQTL and IVW MR estimates were calculated when multiple mQTLs were available 
to proxy a CpG.  
 
Sensitivity analyses 
In addition to the main analysis detailed above, multivariable MR Egger [329, 330] analysis 
was conducted as an assessment of IV heterogeneity. Sensitivity MR analyses were conducted by 
calculating the log HR per unit increase in DNA methylation for the sentinel CpG within each DMR 
analysed. Other prognostic factors for mortality include stage and comorbidity. Mortality EWAS were 
conducted with these covariates included and found the effect size remained largely unaffected by 
the addition of stage and comorbidity. Therefore, the EWAS of mortality was conducted without stage 
and comorbidity as covariates. Finally, where possible, multivariable MR Egger analysis was conducted 
on a subset of independent SNPs for each DMR as a sensitivity analysis for using multivariable MR 
Egger with correlated SNPs in the main analysis.  
 
5.3. Results 
5.3.1. Sample characteristics 
Baseline characteristics of samples with epigenetic data, compared to all HNC and OPC 
samples in HN5000 are shown in Table 1. Notably, the proportion of those with OPC under the age of 
60 is higher than those with other sub-types of HNC and the degree to which those with OPC differ to 
other HNC sub-types with respect to HPV16 E6 seropositivity (an established biomarker of current 
HPV16 infection) is substantial. Table 5.1 shows that the demographics of those who were selected to 
have their methylation patterns typed were sufficiently representative of others with the OPC sub-
type in HN5000 with respect to exposure to prognostic factors, albeit not necessarily representative 








Table 5.1 - Comparison of patient demographics in OPC samples selected for methylation data extraction, all samples in 
HN5000 identified as OPC, and all samples in HN5000 
Variable OPC in HN5000 with methylation 
data and complete phenotype 
data (N=408) 





ICD group (% oropharynx) 100 100 35.4 
Sex (% female) 27.0 21.9 27.2 
Age (% <60) 58.4 52.4 42.7 
Smoking (% never smoked) 27.1 28.0 24.6 
Alcohol (% non-drinker) 25.9 26.6 28.4 
HPV16 E6 (% negative) 33.3 32.3 72.0 
Survival (% died, prior to 30/09/2017) 26.2 24.2 28.0 
 
5.3.2. Epigenome-wide association analyses 
Epigenome-wide association study of smoking 
The single-site EWAS of ever vs never smokers revealed 52 CpG site associations annotated to 
27 unique gene regions, or loci (P<5.7x10-8, Bonferroni-adjusted p < 0.05 for 862,491 tests) (Figure 
5.1). CpG site cg05575921, which annotates to the AHRR gene region, was most strongly associated 
(P< 1.48x10-40) and also showed the largest effect size of -29.5% difference in methylation between 
ever and never smokers. Forty-nine of the associated CpG sites had lower DNA methylation in ever 
smokers, with a mean difference in methylation of -8.3% (SD: 5.1%, range: -29.5% to -2.2%). The three 
remaining CpG sites had higher methylation in smokers, with a mean difference of 7.7% (SD: 4.2%, 
range: 4.7% to 12.6%). Table 5.2 provides the complete list of all CpGs that were differentially 
methylated below a multiple testing threshold of P:2.4x10-7 (the alpha for the Illumina 450K BeadChip, 
a predecessor of the EPIC array, common in epidemiological literature, which can assay >450,000 CpG 
sites compared to >850,000 on the EPIC array). Of the results presented in this table, 37.5% (24/64 









Figure 5.1 - Manhattan plot of EWAS results from a comparison of ever vs. never smoking, showing CpG sites within DMRs in 
red. Each dot represents a single CpG site, plotting –log10(p) (y-axis) against the genomic position of the CpG site (x-axis). 
The horizontal red line is at P<5.7x10-8 and represents the value below which methylation was deemed to be significantly 
associated with smoking. 
 
Table 5.2 - Genome-wide differentially-methylated CpG sites associated with smoking status below a multiple testing 
threshold of P < 5.8e-08. Results are adjusted for age, sex, surrogate variables obtained by SVA, alcohol consumption and 
HPV16E6 seropositivity 
CpG P-value Beta Chromosome Position Gene annotation 
cg05575921 1.48E-40 -0.295 chr5 373378 AHRR 
cg21566642 4.94E-32 -0.170 chr2 233284661 - 
cg01940273 9.48E-29 -0.123 chr2 233284934 - 
cg14391737 4.87E-27 -0.152 chr11 86513429 PRSS23 
cg03636183 1.09E-24 -0.132 chr19 17000585 F2RL3 
cg23771366 2.82E-19 -0.071 chr11 86510998 PRSS23 
cg26703534 8.96E-19 -0.072 chr5 377358 AHRR 
cg21911711 8.47E-18 -0.101 chr19 16998668 F2RL3 
cg17739917 1.13E-15 -0.116 chr17 38477572 RARA 
cg19572487 2.09E-15 -0.085 chr17 38476024 RARA 




CpG P-value Beta Chromosome Position Gene annotation 
cg16841366 3.48E-14 -0.104 chr2 233286192 - 
cg25001882 5.40E-14 -0.045 chr14 78619077 - 
cg03329539 8.04E-14 -0.084 chr2 233283329 - 
cg23576855 1.04E-13 -0.213 chr5 373299 AHRR 
cg18110140 1.09E-13 -0.103 chr15 75350380 - 
cg09935388 1.19E-13 -0.185 chr1 92947588 GFI1 
cg05086879 2.89E-13 -0.089 chr22 39861490 MGAT3 
cg15187398 6.57E-13 -0.070 chr19 2093896 MOBKL2A 
cg22812571 1.68E-12 -0.093 chr2 233286229 - 
cg11660018 7.90E-12 -0.058 chr11 86510915 PRSS23 
cg26271591 1.80E-11 -0.070 chr2 178125956 NFE2L2 
cg21611682 2.80E-11 -0.062 chr11 68138269 LRP5 
cg02583484 3.45E-11 -0.042 chr12 54677008 HNRNPA1 
cg09945032 8.34E-11 -0.042 chr3 38871019 - 
cg23161492 1.24E-10 -0.058 chr15 90357202 ANPEP 
cg00045592 2.10E-10 -0.084 chr1 160714299 SLAMF7 
cg21161138 3.76E-10 -0.098 chr5 399360 AHRR 
cg04414766 5.53E-10 0.126 chr3 22412963 - 
cg06421013 1.13E-09 -0.079 chr20 19194143 SLC24A3 
cg06644428 1.18E-09 -0.073 chr2 233284112 - 
cg09338374 1.96E-09 0.059 chr22 39888390 - 
cg07986378 2.44E-09 -0.064 chr12 11898284 ETV6 
cg07069636 8.63E-09 -0.043 chr16 30671749 - 
cg00475490 1.04E-08 -0.030 chr11 86517110 PRSS23 
cg19965693 1.15E-08 -0.064 chr2 163175743 IFIH1 
cg10691866 1.31E-08 -0.075 chr7 65817282 TPST1 
cg17287155 1.51E-08 -0.034 chr5 393347 AHRR 
cg11866539 1.83E-08 0.047 chr2 135033075 MGAT5 
cg25305703 2.46E-08 -0.069 chr8 128378218 - 
cg01901332 2.47E-08 -0.065 chr11 75031054 ARRB1 




CpG P-value Beta Chromosome Position Gene annotation 
cg12956751 2.93E-08 -0.037 chr2 233246922 ALPP 
cg15342087 3.11E-08 -0.032 chr6 30720209 - 
cg07741821 3.46E-08 -0.060 chr7 26577897 KIAA0087 
cg23337648 3.82E-08 -0.040 chr11 47546192 CELF1 
cg12075928 4.56E-08 -0.060 chr8 141801307 PTK2 
cg10012530 4.57E-08 -0.036 chr2 129073706 HS6ST1 
cg13633560 4.68E-08 -0.060 chr11 76380921 LRRC32 
cg05934812 4.68E-08 -0.056 chr5 334322 AHRR 
cg23110422 4.83E-08 -0.044 chr21 40182073 ETS2 
cg10788371 5.54E-08 -0.046 chr11 76381040 LRRC32 
cg25558667 6.93E-08 -0.154 chrX 10075110 WWC3 
cg07995927 7.85E-08 -0.063 chr2 161995135 TANK 
cg05284742 9.43E-08 -0.045 chr14 93552128 ITPK1 
cg12803068 1.14E-07 0.124 chr7 45002919 MYO1G 
cg01431482 1.29E-07 -0.056 chr1 2989085 PRDM16 
cg12876356 1.41E-07 -0.154 chr1 92946825 GFI1 
cg05460226 1.44E-07 -0.093 chr17 8804279 PIK3R5 
cg26361535 1.45E-07 -0.064 chr8 144576604 ZC3H3 
cg25845814 1.71E-07 -0.040 chr14 74224613 MIR4505 
cg00310412 1.72E-07 -0.037 chr15 74724918 SEMA7A 
cg14580211 1.92E-07 -0.073 chr5 150161299 C5orf62 
cg12919873 1.99E-07 -0.088 chr21 38929815 - 
 
In the differentially methylated region (DMR) analysis of ever vs never smoking, 166 unique 
DMRs containing 617 measured CpGs and mapping to 156 gene regions were identified (Figure 5.1). 
The DMR with the strongest association contained 3 measured CpGs (cg21566642, cg01072057 and 
cg13903162) and was located at Chr2:233284661-233285290, an intergenic CpG island on 2q37.1 







Epigenome-wide association study of alcohol 
The EWAS of alcohol consumption revealed 3 CpG site associations annotated to 3 unique 
genes (P<5.7x10-8) (Figure 5.2). The association with the smallest p-value was cg06690548 (P:8.3x10-
16), annotating to the SLC7A11 gene region. This CpG site also showed the largest effect size of -0.10% 
difference in methylation per unit increase in alcohol. All results below the 450K array multiple testing 
threshold of 2.4x10-7 are shown in Table 5.3. Of the results presented in this table, 40% of the CpGs 
(2/5 CpGs) were present on the EPIC array but not it’s 450K predecessor. 
Figure 5.2 - Manhattan plot of EWAS of alcohol consumption, showing CpG sites within DMRs in red. Each dot represents the 
EWAS result for a single CpG site, plotting –log10(p) (y-axis) against the genomic position of the CpG site (x-axis). The 
horizontal red line is at P<5.7x10-8 and represents the value below which CpG sites were considered to have good evidence of 
association with alcohol consumption. 
 
Table 5.3 - Genome-wide differentially-methylated CpG sites associated with alcohol consumption below a multiple testing 
threshold of P < 5.8e-08. Results are adjusted for age, sex, surrogate variables obtained by SVA, smoking status and HPV16E6 
seropositivity 
CpG P-value Beta Chromosome Position Gene annotation 
cg06690548 3.14E-15 -0.0010 chr4 139162808 SLC7A11 
cg12397071 1.25E-08 0.0004 chr2 166983534 SCN1A 
cg03137071 1.32E-08 -0.0005 chr8 49496369 - 
cg06088069 8.61E-08 -0.0002 chr14 75895604 JDP2 




In the DMR analysis of alcohol consumption, 40 unique DMRs containing 238 measured CpGs and 
mapping to 34 gene regions were identified (Figure 5.2). The DMR with the smallest P value was a 
region containing 2 CpGs (cg06690548 and cg13903162) found at Chr4:139162808-139163020 (P:1.45 
x10-10), annotating to the SLC7A11 gene region.  
 
Epigenome-wide association study of HPV 
In the EWAS analysis of HPV16 E6 seropositivity, no CpGs passed the multiple testing p-value 
threshold (P<5.7x10-8) (Figure 5.3). At a suggestive threshold of 2.4x10-7, only 1 CpG site (cg26738437; 
P:1.3x10-7) was found, annotating to the CCL16 gene. This probe is not found on the 450K array. 
Methylation at this site was on average 2.3% lower in HPV16 E6 seropositive participants than 
controls.  
 
In the DMR analysis of HPV16 E6 seropositivity, 31 unique DMRs pertaining to 158 CpGs and 
annotating to 38 gene regions were identified (Figure 5.3). The most associated DMR was a region of 
13 CpGs found at Chr5:110062343-110062838 (P:4.10x10-6), annotating to the TMEM232 gene region.  
 
Figure 5.3 - Manhattan plot of EWAS of HPV16E6 seropositivity, showing CpG sites within DMRs in red. Each dot represents 
the EWAS result for a single CpG site, plotting –log10(p) (y-axis) against the genomic position of the CpG site (x-axis). The 
horizontal red line is at P<5.7x10-8 and represents the value below which CpG sites were considered to have good evidence of 






Epigenome-wide association study of OPC survival 
Model 1 
In the single-site analysis of survival (adjusting for age, sex and surrogate variables obtained 
by SVA [312]), three CpGs mapping to three unique loci showed association with survival below a 
multiple testing p-value threshold (P<5.7e-8) (Figure 5.4).  One CpG site showed lower methylation in 
those who died vs were alive during follow-up. This site was also the most strongly associated with 
survival in the survival analysis, annotating to PAQR3 and showed the largest effect size among top 
hits (cg25864218; β [difference in methylation between those that were dead vs alive before 30th 
September 2017]: -2.54%; P: 1.04e-9). Two sites showed higher methylation in those who died vs were 
alive during follow-up in the analysis, annotating to DNAH11 (cg07377396; β: 0.49%; P: 3.39e-8) and 
MYBPC1 (cg12151015; β: 0.11%; P: 7.51e-9). The mean difference in methylation in these sites was 
0.3% (SD: 0.27%, range: 0.11% to 0.49%). All results below a suggestive multiple testing threshold of 
2.4e-7 are shown in Table 5.4. Of the results presented in this table, 47% (7/15) were CpG probes 
specific to the EPIC array. 
 
Figure 5.4 - Manhattan plot of EWAS of survival (model 1 – not adjusted for smoking, alcohol consumption and HPV16E6 
seropositivity), showing CpG sites within DMRs in red. Each dot represents the EWAS result for a single CpG site, plotting –
log10(p) (y-axis) against the genomic position of the CpG site (x-axis). The horizontal red line is at P<5.7x10-8 and represents 







Table 5.4 - Genome-wide differentially-methylated CpG sites associated with ~3-year survival below a multiple testing 
threshold of P < 5.8e-08. Results are adjusted for age, sex and surrogate variables obtained by SVA 
CpG Beta P-value Chromosome Position Gene annotation 
cg25864218 -2.54 1.04E-09 chr4 79860686 PAQR3 
cg12151015 0.11 7.51E-09 chr12 102010848 MYBPC1 
cg07377396 0.49 3.39E-08 chr7 21788428 DNAH11 
cg15036595 -0.16 6.00E-08 chr11 125818934 - 
cg03093995 1.21 6.51E-08 chr9 114393414 DNAJC25-GNG10 
cg17679548 -0.46 7.11E-08 chr19 39353395 - 
cg18236982 -0.15 1.27E-07 chr1 236065291 - 
cg00338391 0.76 1.28E-07 chr7 1283981 - 
cg11337053 -0.15 1.50E-07 chr1 232651485 SIPA1L2 
cg09853393 -0.10 1.73E-07 chrX 67995409 - 
cg14504586 -0.64 1.81E-07 chr9 134744872 MED27 
cg19019403 -0.24 1.96E-07 chr12 31899879 - 
cg02927174 1.01 2.30E-07 chr8 116681088 TRPS1 
cg20046119 0.15 2.31E-07 chr8 145981207 ZNF251 
cg13071729 0.27 2.31E-07 chr1 201617443 NAV1 
 
In the DMR analysis of survival, 142 unique DMRs pertaining to 805 CpGs and annotating to 
153 gene regions were identified (Figure 5.4). The DMR with the lowest p value was a region of 10 
CpGs found at Chr17:33814297-33814897 (P:5.26e-21), annotating to the CDK16 gene region. 
 
Model 2 
In the single-site analysis of survival using Model 2 (adjusting for age, sex, surrogate variables 
obtained by SVA, HPV16E6 seropositivity, smoking status and alcohol intake), 6 CpGs annotated to 4 
unique loci showed a p-value of association below the multiple testing threshold (P<5.7e-8) (Figure 
5.5). Three of the 6 CpGs passing multiple testing correction showed lower methylation in those who 
died vs were alive during follow-up in the analysis, while the other 3 showed higher methylation. Of 
the 3 sites showing lower methylation, the mean difference in methylation between those that were 
dead vs alive after ~3-year follow-up was -0.07% (SD: 0.05%, range: -2.54% to -0.16%). For the 3 sites 
showing higher methylation, the mean difference in methylation was 0.31% (SD: 0.31%, range: 0.11% 




region. This CpG site also showed the largest effect size of -2.5% difference in methylation between 
those who are dead vs alive. Other CpGs passing the multiple testing correction which were annotated 
to genes included MYBPC1 (cg12151015; β: 0.11%; P: 2.59e-8), GRIN2A (cg08204867; β: -0.16%; P: 
2.87e-8), and IL15 (cg26269613; β: 0.67%; P: 5.34e-8). Two CpGs showed an association with survival 
in both models: cg12151015 (annotating to MYBPC1) and cg25864218 (annotating to PAQR3). All 
results below a suggestive multiple testing threshold of 2.4e-7 are shown in Table 5.5. Interestingly, of 
the results presented in this table, all 23 associated CpGs were present on the EPIC array but not the 
450K predecessor. 
 
Figure 5.5 - Manhattan plot of EWAS of survival (model 2 – adjusted for smoking, alcohol consumption and HPV16E6 
seropositivity), showing CpG sites within DMRs in red. Each dot represents the EWAS result for a single CpG site, plotting –
log10(p) (y-axis) against the genomic position of the CpG site (x-axis). The horizontal red line is at P<5.7x10-8 and represents 
the value below which CpG sites were considered to have good evidence of association with survival. 
 
Table 5.5 - Genome-wide differentially-methylated CpG sites associated with ~3-year survival below a multiple testing 
threshold of P < 5.7e-08. Results are adjusted for age, sex, surrogate variables obtained by SVA, smoking status, alcohol 
consumption and HPV16E6 seropositivity 
CpG Beta P-value Chromosome Position Gene annotation 
cg25864218 -2.45 1.22E-08 chr4 79860686 PAQR3 
cg27551718 -0.14 1.99E-08 chr19 39572000 - 
cg12151015 0.11 2.59E-08 chr12 102010848 MYBPC1 




CpG Beta P-value Chromosome Position Gene annotation 
cg18604947 0.16 2.99E-08 chr22 19609793 - 
cg15036595 -0.16 3.72E-08 chr11 125818934 - 
cg26269613 0.67 5.34E-08 chr4 142558451 IL15 
cg03093995 1.19 6.13E-08 chr9 114393414 DNAJC25 
cg17679548 -0.48 7.86E-08 chr19 39353395 - 
cg04444399 -0.31 9.02E-08 chr10 8302797 - 
cg18236982 -0.16 1.13E-07 chr1 236065291 - 
cg00338391 0.75 1.21E-07 chr7 1283981 - 
cg13071729 0.29 1.24E-07 chr1 201617443 NAV1 
cg11588423 -0.20 1.28E-07 chr6 29578191 GABBR1 
cg19019403 -0.24 1.57E-07 chr12 31899879 - 
cg22769651 -0.49 1.70E-07 chr14 59594615 - 
cg20046119 0.15 1.73E-07 chr8 145981207 ZNF251 
cg15334209 -0.25 2.00E-07 chr2 5986281 - 
cg13987792 -0.23 2.08E-07 chr12 132431451 - 
cg09853393 -0.11 2.12E-07 chrX 67995409 - 
cg01555270 -1.24 2.23E-07 chr19 41945599 ATP5SL 
cg05278651 -0.11 2.24E-07 chr1 220533602 - 
cg07377396 0.46 2.26E-07 chr7 21788428 DNAH11 
 
In the DMR analysis of survival (model 2), 157 unique DMRs pertaining to 874 CpGs and 
annotating to 177 gene regions were identified (Figure 5). The DMR with the lowest p value was a 
region of 12 CpGs found at ChrX: 47077168- 47077877 (P:1.08e-21), annotating to the CDK16 gene 
region.  
 
5.3.3. DMR overlap between OPC risk factors and survival 
Eighteen unique CpGs overlapped between all smoking DMRs and survival DMRs (survival 
EWAS model 1). These CpGs belonged to 3 unique DMRs (annotated to GFI1, SPEG and PPT2); five 
CpGs overlapped between all alcohol DMRs and survival (EWAS Model 1) DMRs, all pertaining to a 
single DMR (annotated to KHD3CL). No CpGs overlapped at the p-value threshold for HPV DMRs and 




Of the 18 CpGs which overlapped between smoking and survival, 15 possessed mQTL proxies 
in the Generation Scotland summary data with which to conduct MR (see Methods). Of the 5 CpGs 
which overlapped between alcohol and survival, 3 possessed mQTL proxies in the Generation Scotland 
summary data (Table 5.6).  
 
Table 5.6 - Genetic instrumental variables (IVs) used in Mendelian randomization analyses to assess epigenetic mediation 
between prognostic factors and ~3-year survival. The final # SNPs denotes genetic IVs which both proxy a CpG and where the 
same position is available in the genome-wide association study of 3-year mortality 















































































cg19146112 N/A N/A 
4 
cg27237745 rs488114 Y 




cg16074228 rs564533 Y 
 
5.3.4. Mendelian randomization: DNA methylation - OPC survival  
Tables 5.7-5.9 and Figure 5.6 show the results MR analyses for the association of mQTL-
proxied DNA methylation, at CpG sites associated with smoking and survival, with 3-year survival in 
HN5000. In these analyses, there appears to be some evidence for a potential causal effect of 
decreased DNA methylation on survival at the SPEG gene locus (Table 5.7; Chr2:22035443-22036041; 




seen between smoking and decreased survival at this gene region. The GFI1 (Table 5.8) and PPT2 
(Table 5.9) gene regions appear to show no consistent evidence of a causal effect of DNA methylation 
on survival. Multivariable MR Egger analysis using independent SNPs (multivariable MR Eggerindependent: 
a sensitivity analysis for using multivariable MR Egger with correlated SNPs in the main analysis) could 
only be conducted at the SPEG locus, as other regions did not have sufficient independent SNPs as 
proxies. Fewer than 3 SNPs greatly reduces the accuracy of MR Egger; therefore, it was only used in 
analyses with 3 or more SNP proxies. Multivariable MR Eggerindependent showed a similar effect estimate 
to normal multivariable MR Egger at this locus, albeit with larger confidence intervals, suggesting the 
confidence interval for normal multivariable MR Egger is likely to be overly precise in this analysis. 
 
Table 5.7 - Mendelian randomization (MR) analysis results, assessing epigenetic mediation between smoking status and ~3-
year survival at the SPEG gene (chromosome 2:220325443-220326041). The number of SNPs per analysis are shown, in 
addition to the inverse- variance weighted (IVW) and multivariable MR Egger MR results. IVW and MR Egger results are 
adjusted for genetic correlation between mQTLs are reported as hazard ratios (HR) with 95% confidence intervals (CI). The 
SPEG locus was the only in our analyses to possess >2 independent SNPs and is therefore the only with multivariable MR Egger 
analysis conducted on this independent subset in addition to all DMR CpGs. 
Region (gene) MR Method SNPs HR 95% CI P 
All DMR CpGs 
Chr2:220325443-220326041 (SPEG) IVW  17 1.28 1.14 to 1.43 2.12x10-05 
Chr2:220325443-220326041 (SPEG) MR Egger 17 1.28 1.18 to 1.38 4.04x10-10 
Sentinel CpG only 
cg06084174 (SPEG) IVW 3 1.14 0.90 to 1.45 0.29 
CpGs with independent SNPs 
cg19179241 and cg14890311 MR Egger 4 1.27 0.78 to 2.08 0.34 
 
 
Table 5.8 - Mendelian randomization (MR) analysis results, assessing epigenetic mediation between smoking status and ~3-
year survival at the GFI1 gene (chromosome 1:92946132-92947588). The number of SNPs per analysis are shown, in addition 
to the inverse-variance weighted (IVW) and multivariable MR Egger MR results. IVW and MR Egger results are adjusted for 
genetic correlation between mQTLs are reported as hazard ratios (HR) with 95% confidence intervals (CI). 
Region (gene) MR Method SNPs HR 95% CI P 
All DMR CpGs 
Chr1:92946132-92947588 (GFI1) IVW  8 0.74 0.60 to 0.93 7.9x10-03 
Chr1:92946132-92947588 (GFI1) MR Egger 8 2.65 0.77 to 9.12 0.12 
Sentinel CpG only 





Table 5.9 - Mendelian randomization (MR) analysis results, assessing epigenetic mediation between smoking status and ~3-
year survival at the PPT2 gene (chromosome 6:32120895-32120907). The number of SNPs per analysis are shown, in addition 
to the inverse-variance weighted (IVW) and multivariable MR Egger MR results. IVW and MR Egger results are adjusted for 
genetic correlation between mQTLs are reported as hazard ratios (HR) with 95% confidence intervals (CI). 
Region (gene) MR Method SNPs HR 95% CI P 
All DMR CpGs 
Chr6:32120895-32120907 (PPT2) IVW 8 0.82 0.52 to 1.30 0.40 
Chr6:32120895-32120907 (PPT2) MR Egger 8 1.68 0.27 to 10.38 0.58 
Sentinel CpG only 




Figure 5.6 - Forest plots showing SNP-specific and overall IV Hazard ratio estimates (95% CI) for Mendelian randomization 






Table 5.10 and Figure 5.7 show the results of the associations of mQTL-proxied DNA 
methylation, at CpG sites associated with alcohol and survival with 3-year survival in HN5000. In the 
analysis, there appears to be no consistent evidence for a causal effect of DNA methylation on survival 
at the KHD3CL gene locus (Chr6:74072255-74072376).  
 
Table 5.10 - Mendelian randomization (MR) analysis results, assessing epigenetic mediation between alcohol consumption 
and ~3-year survival at the KHD3CL gene (chromosome 6:74072255-74072376). The number of SNPs per analysis are shown, 
in addition to the inverse-variance weighted (IVW) and multivariable MR Egger MR results. IVW and MR Egger results are 
adjusted for genetic correlation between mQTLs are reported as hazard ratios (HR) with 95% confidence intervals (CI). 
Region (gene) MR Method SNPs HR 95% CI P 
No clumping of final instrument, meta-analysis of mQTLs 
Chr6:74072255-74072376 (KHD3CL) IVW  4 1.17 0.70 to 1.97 0.55 
Chr6:74072255-74072376 (KHD3CL) MR Egger 4 0.89 0.27 to 2.98 0.85 
Sentinel CpG only 
cg19146112 (KHD3CL) Wald ratio 1 1.17 0.54 to 2.53 0.68 
 
Figure 5.7 - Forest plot showing the SNP-specific and overall IV Hazard ratio estimates (95% CI) for Mendelian randomization 







EWAS analyses were conducted, identifying CpG sites and DMRs associated with smoking and 
alcohol consumption, but not with HPV infection. Six CpGs were also found to be associated with 
survival at 3 years post-diagnosis. Twenty-three CpGs at 4 DMRs were identified in both analyses of 
risk factor and of survival. It is hypothesised that for these CpG sites, DNA methylation could mediate 
part of the association between risk factor and OPC survival. MR analysis was conducted to test this 
hypothesis and preliminary evidence was found to support this mediation pathway between smoking 
and OPC survival at the SPEG gene locus. 
 
In relation to smoke exposure, the results include several previously reported loci, notably 
those mapping to AHRR and PRSS23. The effect size seen in the EWAS for cg05575921 (29.5%) is 
markedly stronger than the largest published smoking EWAS analysis; Joehanes et al [182] report 18% 
lower methylation in current smokers compared to those who have never smoked (P: 4.60e-26). A 
potential explanation for this finding could be that the analysis was conducted in a case-only setting 
where smoking is one of the predominant risk factors for HNC and smoking intensity is likely to be 
higher in HN5000 smokers compared to non-cancer smoking populations. A lookup of the top smoking 
CpG sites (P < 5.7e-8) was completed using the EWAS Catalog (http://www.ewascatalog.org/) online 
tool to compare whether the effect sizes were consistently stronger than other published smoking 
EWAS findings (Table 5.11). Of the 52 sites below a multiple-testing correction, 20 had not been 
previously reported in published EWASs. The other 32 CpG sites which had previously been reported 
in the literature showed consistently larger effect estimates in response to smoking in the analysis 
compared to a weighted mean (weighted by sample size) of published EWAS beta values.   
 
Using the same EWAS Catalog resource, an attempt was made to determine whether 
associations below the multiple testing threshold were stronger than previously published results for 
all EWAS conducted in this analysis (Table 5.11). All 5 associations found in the alcohol consumption 
analysis had not been previously reported in published EWAS of alcohol consumption; this is probably 
because they are not measured on the 450K array. SLC7A11, the gene annotated to the top CpG site 
associated with alcohol consumption, is essential for glutathione synthesis, a component of the 
KEAP1-NRF2-CUL3 axis, and strongly associated with poor prognosis in The Cancer Genome Atlas 






Table 5.11 - Lookup of CpG sites in the MRCIEU EWAS Catalog across all EWAS analyses below a Bonferroni p-value threshold 
of 5.7e-08. Betas for all studies reporting beta values are calculated as a weighted mean, weighted by sample size 
Phenotype CpG name Gene 
annotation 








Alcohol  cg06690548 SLC7A11 -0.0010 3.14E-15 Y NA NA 
Alcohol  cg12397071 SCN1A 0.0004 1.25E-08 Y NA NA 
Alcohol  cg03137071 - -0.0005 1.32E-08 Y NA NA 
Alcohol  cg06088069 JDP2 -0.0002 8.61E-08 Y NA NA 
Alcohol cg20871826 CAMKK1 0.0002 1.04E-07 Y NA NA 
Smoking cg05575921 AHRR -0.295 1.48E-40 N -0.191 30 
Smoking cg21566642 - -0.170 4.94E-32 N -0.191 19 
Smoking cg01940273 - -0.123 9.48E-29 N -0.107 22 
Smoking cg14391737 PRSS23 -0.152 4.87E-27 Y NA NA 
Smoking cg03636183 F2RL3 -0.132 1.09E-24 N -0.132 19 
Smoking cg23771366 PRSS23 -0.071 2.82E-19 N -0.055 14 
Smoking cg26703534 AHRR -0.072 8.96E-19 N -0.076 15 
Smoking cg21911711 F2RL3 -0.101 8.47E-18 Y NA NA 
Smoking cg17739917 RARA -0.116 1.13E-15 Y NA NA 
Smoking cg19572487 RARA -0.085 2.09E-15 N -0.039 17 
Smoking cg25189904 GNG12 -0.136 2.30E-15 N -0.050 21 
Smoking cg16841366 - -0.104 3.48E-14 Y NA NA 
Smoking cg25001882 - -0.045 5.40E-14 Y NA NA 
Smoking cg03329539 - -0.084 8.04E-14 N -0.044 15 
Smoking cg23576855 AHRR -0.213 1.04E-13 N -0.146 12 
Smoking cg18110140 - -0.103 1.09E-13 Y NA NA 
Smoking cg09935388 GFI1 -0.185 1.19E-13 N -0.076 19 
Smoking cg05086879 MGAT3 -0.089 2.89E-13 Y NA NA 
Smoking cg15187398 MOBKL2A -0.070 6.57E-13 N -0.029 11 
Smoking cg22812571 - -0.093 1.68E-12 Y NA NA 
Smoking cg11660018 PRSS23 -0.058 7.90E-12 N -0.038 18 
Smoking cg26271591 NFE2L2 -0.070 1.80E-11 N -0.032 10 




Phenotype CpG name Gene 
annotation 








Smoking cg02583484 HNRNPA1 -0.042 3.45E-11 N -0.026 15 
Smoking cg09945032 - -0.042 8.34E-11 Y NA NA 
Smoking cg23161492 ANPEP -0.058 1.24E-10 N -0.040 12 
Smoking cg00045592 SLAMF7 -0.084 2.10E-10 Y NA NA 
Smoking cg21161138 AHRR -0.098 3.76E-10 N -0.053 18 
Smoking cg04414766 - 0.126 5.53E-10 Y NA NA 
Smoking cg06421013 SLC24A3 -0.079 1.13E-09 Y NA NA 
Smoking cg06644428 - -0.073 1.18E-09 N -0.04 16 
Smoking cg09338374 - 0.059 1.96E-09 Y NA NA 
Smoking cg07986378 ETV6 -0.064 2.44E-09 N -0.029 9 
Smoking cg07069636 - -0.043 8.63E-09 N -0.017 9 
Smoking cg00475490 PRSS23 -0.030 1.04E-08 Y NA NA 
Smoking cg19965693 IFIH1 -0.064 1.15E-08 Y NA NA 
Smoking cg10691866 TPST1 -0.075 1.31E-08 N -0.031 10 
Smoking cg17287155 AHRR -0.034 1.51E-08 N -0.027 10 
Smoking cg11866539 MGAT5 0.047 1.83E-08 Y NA NA 
Smoking cg25305703 - -0.069 2.46E-08 N -0.035 9 
Smoking cg01901332 ARRB1 -0.065 2.47E-08 N -0.030 11 
Smoking cg25949550 CNTNAP2 -0.022 2.79E-08 N -0.020 17 
Smoking cg12956751 ALPP -0.037 2.93E-08 Y NA NA 
Smoking cg15342087 - -0.032 3.11E-08 N -0.032 18 
Smoking cg07741821 KIAA0087 -0.060 3.46E-08 Y NA NA 
Smoking cg23337648 CELF1 -0.040 3.82E-08 Y NA NA 
Smoking cg12075928 PTK2 -0.060 4.56E-08 N -0.033 13 
Smoking cg10012530 HS6ST1 -0.036 4.57E-08 N -0.011 4 
Smoking cg13633560 LRRC32 -0.060 4.68E-08 N -0.015 5 
Smoking cg05934812 AHRR -0.056 4.68E-08 Y NA NA 
Smoking cg23110422 ETS2 -0.044 4.83E-08 N -0.021 7 




Phenotype CpG name Gene 
annotation 








Survival Model 1 cg25864218 PAQR3 -2.54 1.04E-09 Y NA NA 
Survival Model 1 cg12151015 MYBPC1 0.11 7.51E-09 Y NA NA 
Survival Model 1 cg07377396 DNAH11 0.49 3.39E-08 Y NA NA 
Survival Model 1 cg15036595 - -0.16 6.00E-08 Y NA NA 
Survival Model 1 cg03093995 DNAJC25-
GNG10 
1.21 6.51E-08 Y NA NA 
Survival Model 1 cg17679548 - -0.46 7.11E-08 Y NA NA 
Survival Model 1 cg18236982 - -0.15 1.27E-07 Y NA NA 
Survival Model 1 cg00338391 - 0.76 1.28E-07 Y NA NA 
Survival Model 1 cg11337053 SIPA1L2 -0.15 1.50E-07 Y NA NA 
Survival Model 1 cg09853393 - -0.10 1.73E-07 Y NA NA 
Survival Model 1 cg14504586 MED27 -0.64 1.81E-07 Y NA NA 
Survival Model 1 cg19019403 - -0.24 1.96E-07 Y NA NA 
Survival Model 1 cg02927174 TRPS1 1.01 2.30E-07 Y NA NA 
Survival Model 1 cg20046119 ZNF251 0.15 2.31E-07 Y NA NA 
Survival Model 1 cg13071729 NAV1 0.27 2.31E-07 Y NA NA 
Survival Model 2 cg13071729 NAV1 0.29 1.24E-07 Y NA NA 
Survival Model 2 cg05278651 - -0.11 2.24E-07 Y NA NA 
Survival Model 2 cg18236982 - -0.16 1.13E-07 Y NA NA 
Survival Model 2 cg04444399 - -0.31 9.02E-08 Y NA NA 
Survival Model 2 cg15036595 - -0.16 3.72E-08 Y NA NA 
Survival Model 2 cg19019403 - -0.24 1.57E-07 Y NA NA 
Survival Model 2 cg12151015 MYBPC1 0.11 2.59E-08 Y NA NA 
Survival Model 2 cg13987792 - -0.23 2.08E-07 Y NA NA 
Survival Model 2 cg22769651 - -0.49 1.70E-07 Y NA NA 
Survival Model 2 cg08204867 GRIN2A -0.16 2.87E-08 Y NA NA 
Survival Model 2 cg17679548 - -0.48 7.86E-08 Y NA NA 
Survival Model 2 cg27551718 - -0.14 1.99E-08 Y NA NA 
Survival Model 2 cg01555270 ATP5SL -1.24 2.23E-07 Y NA NA 




Phenotype CpG name Gene 
annotation 








Survival Model 2 cg18604947 - 0.16 2.99E-08 Y NA NA 
Survival Model 2 cg25864218 PAQR3 -2.45 1.22E-08 Y NA NA 
Survival Model 2 cg26269613 IL15 0.67 5.34E-08 Y NA NA 
Survival Model 2 cg11588423 GABBR1 -0.20 1.28E-07 Y NA NA 
Survival Model 2 cg00338391 - 0.75 1.21E-07 Y NA NA 
Survival Model 2 cg07377396 DNAH11 0.46 2.26E-07 Y NA NA 
Survival Model 2 cg20046119 ZNF251 0.15 1.73E-07 Y NA NA 
Survival Model 2 cg03093995 DNAJC25 1.19 6.13E-08 Y NA NA 
Survival Model 2 cg09853393 - -0.11 2.12E-07 Y NA NA 
 
In the EWAS of 3-year survival none of the 15 (model 1) or 23 (model 2) reported associations 
have previously been reported in published studies of OPC survival. Both survival EWAS models gave 
a top hit annotating to the PAQR3 gene. Aberrant promotor methylation at this gene has been shown 
to be associated with prostate cancer [333], with the gene itself being an established tumour 
suppressor [334]. Within the context of HNC, PAQR3 has been associated with tumorigenesis in 
oesophageal cancer [335, 336], although currently no literature has examined whether this gene 
affects oropharyngeal cancer specifically.   
 
A limitation of the ~3-year survival EWAS is that it was conducted using whole-blood-based 
DNA methylation rather than tumour tissue-based methylation. Whole-blood methylation acts as a 
robust “biosocial archive” of exposure, but lacks the specificity to detect local, tumour-based 
epigenetic change. Accordingly, there may be valuable CpG sites undiscovered in this analysis which 
better characterise OPC survival and predict prognosis in tumour tissue. Furthermore, many whole-
blood-based methylation changes in response to cancer survival are likely associated with immune 
response or inflammation, which are almost certainly confounded by cell composition effects rather 
than a direct epigenetic effect. However, whole-blood-based EWAS may also report associations 
which are not explained by cell composition effects, making it still a valuable tissue to assay; one that 
is also comparatively inexpensive and non-invasive to obtain and process versus tumour tissue. 




cell composition effects themselves and their potential interactions with other processes may prove 
a particularly lucrative avenue to explore. 
 
The consistent direction of effect between MR Egger, MR Eggerindependent and Burgess IVW 
estimates for the SPEG locus provide us with greater confidence that the IV is reliable and that there 
is sufficient statistical power to demonstrate preliminary evidence for a causal association with 
decreased survival. Expression of the SPEG gene shows specificity to vascular smooth muscle cells – 
the major cell type in blood vessel walls, in which smoking has been shown to produce abnormal 
function throughout the human body [337]. Functional annotations show the SPEG gene to be 
essential for cardiac function in particular, with deficiency of this gene reported to result in heart 
failure [338]. A lookup in the BIOS QTL Browser (https://genenetwork.nl/biosqtlbrowser/) confirms 20 
cis-expression quantitative trait methylations (eQTMs) showing evidence of correlation between gene 
expression and methylation at this locus in whole blood, though further work evaluating tissue-specific 
expression is required. People with head and neck squamous cell carcinoma (HNSCC) have an elevated 
risk of non-HNSCC mortality that persists over their lifetime. Among people with HNSCC, the 5-year 
incidence of non-cancer mortality is 13% [339], with a high baseline risk of cardiovascular disease 
compared to matched controls [340, 341]. 
 
This is currently the first EWAS study investigating oropharyngeal cancer survival using a cox 
proportional-hazards model to investigate DNA methylation in relation to survival at ~3 years. A key 
strength of the study relates to the use of the EPIC array which profiles methylation at approximately 
twice as many CpG sites as its 450k predecessor. Across the EWASs of smoking, alcohol, HPV and both 
survival models, 39.4% of the CpG sites showing association at P<2.4e-7 were specific to the EPIC array 
(43/109). However, proportionally, the results suggest that associations are not enriched with the 
inclusion of novel enhancer region CpGs from the EPIC array. A one-sided Fisher’s exact test for 
enrichment of EPIC probes vs 450K probes in CpG sites below P: 2.4e-7 confirms this; P > 0.99, 
suggesting no evidence of enrichment. 
 
It should be noted that, despite being an established biomarker with high sensitivity (>93%) 
and specificity (>94%) for oral HPV16 infection [21], HPV16 E6 seropositivity may underestimate the 
number of individuals in the data with a current HPV16 infection. It has been reported that HPV can 
colocalise to biofilm (a community of immotile bacteria encased in a self-produced glycocalyx matrix) 
in tonsillar crypts, representing a reservoir of latent oncovirus undetected by the immune system 




evidence of infection at time of assessment. As such, the EWAS results for HPV16 infection may be 
biased toward the null. 
 
Collider bias may influence associations between the prognostic factors and progression in a 
case-only setting [343]. HPV, smoking and alcohol are all associated with OPC incidence; by only 
examining cases, incidence is conditioned on, potentially inducing an association between HPV, 
smoking, alcohol and any unmeasured confounding. Unmeasured, unknown, confounding cannot be 
adjusted for here, so if any unmeasured confounding is associated with survival, it may be that an 
association between a prognostic factor and survival is simply a result of the induced association of 
the prognostic factor and unmeasured confounding.  
 
Some of the MR analyses highlight potential violations of its methodological assumptions. 
Primarily, those analyses where the MR Egger estimate shows an opposite direction of effect to the 
IVW estimate (GFI1, PPT2, KHDC3L) could indicate an IV where one or more of the genetic variants 
proxying methylation is disproportionately skewing the effect in a certain direction (horizontal 
pleiotropy). However, for each of these analyses, the MR Egger intercept test of heterogeneity 
(explained elsewhere [329, 330]) spans 0 (GFI1 intercept: -0.25, 95% CI: -0.54 to 0.05, p-value: 0.10; 
PPT2 intercept: -0.18, 95% CI: -0.58 to 0.23, p-value: 0.40; KHDC3L intercept: 0.07, 95% CI: -0.09 to 
0.23, p-value: 0.37), indicating that directional pleiotropy is not causing the difference between the 
MR Egger and IVW estimates. A possible explanation of this finding, and one that cannot be ruled out, 
is that these analyses suffer from a type of bias known as weak instrument bias; a bias where the 
chance difference in confounders may explain more of the difference in phenotype between genotype 
subgroups than the instrument, thereby confounding the true causal estimate. Finally, in these three 
analyses, the true direction of effect cannot be determined with confidence, given that the confidence 
intervals span a null line of Y = 1; this is likely an artefact of low statistical power.  
 
One notable limitation of the MR analysis is that it is likely particularly conservative as overlap 
was assessed between prognostic factor DMRs and survival DMRs only if they surpassed the multiple 
correction threshold in both analyses. This approach was chosen (rather than to test corrected 
prognostic factor DMRs for association with all survival DMRs, only correcting for a number of tests 
equal to the number of prognostic factor DMRs) to improve confidence that regional methylation was 
associated with both a prognostic factor and survival. In order to reduce the possibility that regional 
methylation was only associated with a prognostic factor (and only spuriously associated with 






Within the context of OPC, novel epigenetic biomarkers from whole blood measured by the 
EPIC array were found to be associated with the prognostic factors of smoking and alcohol and with 
survival. Of these biomarkers, overlapping signals between prognostic factor and survival analyses 
were used in an MR framework to appraise the causal role of DNA methylation. Using a novel IVW 
approach, derived to investigate the causal effect of DNA methylation at DMRs against mortality for 
this project, a stretch of CpGs located within a DMR, found to be associated with smoking (located at 
Chr2:220325443-220326041; annotating to the SPEG gene), shows preliminary evidence of a causal 
effect on mortality (HR: 1.28, 95% CI: 1.14 to 1.43, P: 2.12x10-05). DNA methylation at this locus could 
potentially mediate some of the association between smoking and OPC survival. To strengthen the 
validity of these findings, replication analyses and a longer follow-up period in Head and Neck 5000 
are necessary. Additionally, conducting an EWAS of OPC-specific mortality (when possible) and 
applying may provide more sights with greater clinical relevance.  
 
Finally, the discovery of novel CpG sites associated jointly with prognostic factors (smoking 
and alcohol) and mortality, whilst not causal intermediates, highlight the potential of DNA methylation 
to be used as an objective predictor of prognostic-factor-specific mortality in those with OPC. By 
applying robust epigenetic signatures from EWAS in a weighted “methylation score” approach to 
predict phenotypes from OPC epigenetic data, DNA methylation may possess utility as an exposure 
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6.1. Introduction  
This chapter describes DNA methylation as a predictor of complex health and lifestyle factors 
in OPC and assesses its validity as a tool for phenotype prediction and risk stratification. Firstly, the 
chapter introduces four phenotypes (with robust EWAS data) reported to be associated with OPC 
prognosis in observational literature; two explaining a high fraction of attributable risk for OPC 
incidence (smoking and alcohol consumption) and two commonly associated with adverse outcomes 
(BMI and educational attainment). Secondly, epigenetic scores for the aforementioned phenotypes, 
from previously published EWAS, are applied to epigenetic data in HN5000. The predictive accuracy 
of these scores are assessed via area under a ROC curve. Finally, the prognostic value of epigenetically-
predicted phenotypes are determined by assessing their effect on 5-year survival using Cox 
proportional hazards regression models in HN5000. This chapter seeks to examine the clinical utility 
of epigenetic prediction in the case of OPC (above and beyond self-reported phenotypes), and to 
further investigate potential pathways associated with established phenotype-mortality relationships.   
 
Multiple examples of the utility of DNA methylation in trait prediction exist in the 
epidemiological literature. DNAm has been shown to serve as both a sensitive and specific biomarker 
of tobacco smoke exposure, with methylation status at one cytosine-phosphate-guanine (CpG) site in 
the aryl hydrocarbon repressor (AHRR) gene (cg05575921) having a predictive area under the receiver 
operating characteristic curve (AUC) for smoking status of 0.99 for current vs never smokers [344]. 
Moreover, previous studies have found that DNAm markers at smoking-related CpG sites, both 
individually and combined in “epigenetic scores” (methylation values derived from a weighted average 
of multiple CpG sites associated with a trait of interest), may have  potential for improving lung cancer 
risk and mortality prediction over and above self-reported smoking information [345-347]. Epigenetic 
scores of other lifestyle characteristics, including alcohol consumption, body mass index (BMI) and 
educational attainment, have recently been developed in large training datasets [348] and have been 
shown to independently explain relatively large degrees of phenotypic variance (up to 60%). These 
too have been shown to serve as predictors of disease outcomes, as well as all-cause mortality in 
general population-based cohort studies [346, 348-350].   
 
The utility of epigenetic predictors in estimating mortality risk in clinical cohorts of individuals 
diagnosed with disease has not been thoroughly investigated and epigenetic predictors may be able 
to reliably supplement prognostication. In the setting of a large prospective head and neck cancer 
cohort (the Head and Neck 5000 Study [209]), epigenetic and self-report data associated with four 




attainment, were used to assess whether externally-derived DNAm predictors could provide an 
accurate prediction of phenotype in a subset of participants with oropharyngeal tumours. 
Furthermore, the validity of these predictors was assessed against mortality, given that all of these 
factors have been shown to be related to HNC mortality in previous studies [351-357]. The 
methylation predictors were then compared with the self-reported measures for the four phenotypes 
in terms of their predictive ability. Though smoking is the only phenotype predicted here which shows 
evidence of possessing a causal epigenetic intermediate between phenotype and mortality (see 
Chapter 5), the phenotypes proxied by epigenetic scores are important factors in OPC prognosis and 
may be able to augment the resolution of existing phenotypic information to improve risk 
stratification. Moreover, in the absence of directly measured phenotypic information, DNA 
methylation predictors may provide reliable estimates of unmeasured phenotype.  
 
6.2. Methods 
Study population  
The study population for this analysis were individuals enrolled in the Head and Neck 5000 
clinical cohort study (HN5000). Full details of enrolment criteria, phenotype measurement and data 
availability for this study can be found in the Methods section of this thesis.  
 
Epigenetic risk score generation 
DNA methylation scores for alcohol consumption, smoking, BMI and educational attainment 
were generated based on independently identified CpG sites from the largest or most recent EWAS in 
epidemiological literature. Details of regression model, sample size, year of publication and number 
of CpGs for each EWAS used to derive epigenetic risk scores are shown in Table 6.1.  
 
DNA extracted from blood samples taken from 448 individuals from HN5000 were run on the 
Illumina Infinium EPIC array. Of these, 440 passed quality control (2 samples with incorrect sex 
prediction, 3 samples with sex detection outliers, 1 sample with an outlier in predicted median 
methylated vs unmethylated signal, 2 duplicate samples). An additional 32 individuals were 
subsequently removed from the analysis owing to pathological re-classification, leaving 408 
participants with DNAm data available (Figure 6.1).  The primary analysis included 364 individuals with 






Table 6.1 - Details of regression model, sample size, year of publication and number of CpGs for each EWAS used to derive 
epigenetic risk scores 
Phenotype Origin publication EWAS model # CpG sites 
Alcohol 
consumption 
“A DNA methylation 
biomarker of alcohol 
consumption” Liu et al. 
2018 [307] 
EWAS were conducted initially using linear 
models per cohort. Next, an inverse variance-
weighted random-effects model was used to 
meta-analyse 8 European-ancestry cohorts. 
CpGs from the meta-analysis were taken forward 
and included in a least absolute shrinkage and 
selection operator (LASSO) regression in an 
independent cohort, with four selection criteria 
used to select CpGs with predictive value of 
alcohol consumption 
Model 1: 5 
Model 2: 23 
Model 3: 78 
Model 4: 144 
“Epigenetic prediction of 
complex traits and 
death” McCartney et al. 
2018 [348] 
EWAS were conducted using a LASSO regression 
model with k-fold (k=10) cross-validation.  
450 
BMI “Epigenetic prediction of 
complex traits and 
death” McCartney et al. 
2018 [348] 
EWAS were conducted using a LASSO regression 
model with k-fold (k=10) cross-validation.  
1109 
“Bayesian reassessment 
of the epigenetic 
architecture of complex 
traits” Trejo Banos et al. 
2018 [358] 
EWAS were conducted using a Baysian 




“Epigenetic prediction of 
complex traits and 
death” McCartney et al. 
2018 [348] 
EWAS were conducted using a LASSO regression 
model with k-fold (k=10) cross-validation.  
373 
Smoking “Epigenetic Signatures of 
Cigarette Smoking” 
Joehanes et al. 2016 
[182] 
Linear mixed models were conducted, then 
combined in a random-effects model meta-
analysis. After meta-analysis, one set of CpGs 
was selected based on a Bonferroni p-value of 
P<1x10-7 (485,381 tests) and another was 
selected based on a genome-wide false discovery 










serum cotinine, and 
blood DNA methylation” 
Zhang et al. 2016 [359] 
An EWAS of cotinine concentration was 
conducted using median quantile regression, 
then CpG sites were individually validated 
against estimated average cigarettes per day 
using restricted cubic spline regression. Results 
were filtered by optimising AUCs derived from 
logistic regression for smoking status (current vs 
never; former vs never).  
4 
“Bayesian reassessment 
of the epigenetic 
architecture of complex 
traits” Trejo Banos et al. 
2018 [358] 
EWAS were conducted using a Baysian 




Figure 6.1 - Flow diagram of HN5000 participants included in the analysis *Data available for age, gender, TNM stage, HPV 






For each individual, methylation scores were calculated per individual in HN5000 as the 
product-sum of each CpG beta value from the respective EWAS in Box 1, multiplied by the normalised 
methylation value of the same CpG site in the HN500 MethylationEPIC data.  
 
6.2.1. Statistical analysis 
Associations of epigenetic scores with self-reported phenotypes 
 Linear regression analyses of epigenetic risk scores were performed against directly measured 
phenotype data (score ~ phenotype) to determine the variance of each phenotype explained by the 
methylation score attempting to predict that phenotype. The R-squared statistic generated by the 
“lm” function of the core Stats package in R (v3.4.1) was used as a measure of variance explained per 
model. R-squared statistics were derived as follows: 
 
𝑟2 =  
∑( ?̂?𝑖 − ?̅? )
2
∑( 𝑦𝑖 − ?̅? )
2
 
The r-squared value is the quotient of the variances of the fitted values and observed values of the dependent 
variable. For the equation above, let 𝑦𝑖  be the observed values of the dependent variable, ?̅? be the mean, and ?̂?𝑖  
be the fitted regression value 
 
The epigenetic prediction scores (derived using EWAS results from Table 6.1, in HN5000 
epigenetic data) explaining the greatest proportion of variance for each phenotype were taken 
forward as exposure variables in survival analyses. Furthermore, scores showing the greatest variance 
explained were considered the most predictive epigenetic risk scores of alcohol consumption, BMI, 
educational attainment and smoking, respectively. In these scores, the degree of variance explained 
was investigated further, to determine if it changed notably (that is, greater than additively) with the 
inclusion of a corresponding polygenic risk score as a variable in each epigenetic risk score model.  
 
Survival analyses 
All-cause mortality, defined as the time in days from study enrolment to date of death from 
any cause or the date of censorship (i.e., the last date of follow-up), was the failure variable in the 
survival analyses. Primary analyses included cases with complete data only (i.e. participants with 
complete data for all the covariates used in the adjusted models and epigenetic data available; 




of covariates on mortality. A test for nonproportional hazards using the Schoenfeld residuals was 
performed. Mortality risk was then assessed in relation to each of the directly measured phenotypes 
(i.e. self-reported smoking, alcohol drinking, BMI and education level), DNAm scores and polygenic 
scores using Cox proportional-hazards models. DNAm scores and polygenic scores were standardised 
(z-scored) to allow direct comparison. Hazard ratios (HRs) and 95% confidence intervals (CIs) for 
mortality were calculated for each standard deviation (SD) increase in score. For phenotypic measures, 
HRs represent the increase in mortality risk for current smokers versus never-smokers, hazardous to 
harmful drinkers versus non-drinkers or degree educated versus school educated individuals; BMI was 
treated as a continuous variable and therefore the HR represents the difference in mortality risk per 
unit increase in BMI. 
 
 To assess potential associations of directly measured phenotypes with mortality, three 
regression models were fitted: (1) a minimally adjusted model that controlled for age and sex; (2) a 
model that additionally adjusted for clinical factors (TNM stage, HPV status and comorbidity); and (3) 
a fully adjusted model that adjusted for the other directly-measured phenotypes of interest.  Owing 
to issues of missing data, models examining the associations of self-reported smoking, alcohol drinking 
and education with mortality were not adjusted for directly measured BMI (model 3) because this 
would have reduced the sample size, and therefore the statistical power. The aforementioned clinical 
factors were selected on the basis of the strength of prior evidence linking them with HNC survival. 
Higher TNM stage is consistently associated with poorer survival [360]. HPV positivity, despite being a 
risk factor for OPC (that is, tumors driven by HPV infection, in particular HPV16) confers a marked 
survival advantage to those with OPC without HPV-driven tumors [76]. Comorbidity greatly affects all-
cause mortality in both general populations and cancer populations [361, 362].  Finally, ethnicity was 
not included as a potential covariate in this study because the cohort is almost exclusively White 
British (97.1%). 
 
Four separate models were fit to examine the relationship between DNAm scores with 
mortality: (1) A minimally adjusted model that adjusted for age, sex, cell counts and batch effects 
(epigenetic scores); (2) a ‘clinical model’, as above; (3) a model that additionally adjusted for the 
corresponding directly-measured phenotype (e.g. models that examined the association of smoking-
related DNAm scores with mortality adjusted for self-reported smoking status) and 4) a model that 
additionally adjusted for the other directly measured phenotypes (excluding BMI to preserve sample 





As described above, it was decided a priori not to restrict the complete case analysis to 
participants with directly measured BMI data available due to the amount of missing data, as this 
would decrease the statistical power to detect an effect of our exposures on mortality.  Therefore, as 
a sensitivity analysis, the same dataset was analysed as above, but restricted to complete data for BMI 
(measured at baseline).  
 
Predictive accuracy of epigenetic risk scores against mortality 
 To assess the efficacy of epigenetic risk scores in prediction of mortality (that is, the accuracy 
with which the epigenetic risk scores for phenotypes could independently predict mortality, rather 
than directly affect it), ROC curves of epigenetic risk scores against our all-cause mortality variable 
were derived using the pROC R package [363]. Area under the ROC curves was computed using the 
trapezoidal rule. With all-cause mortality as the response variable, 3 ROC curves were generated per 
phenotype (alcohol consumption, BMI, educational attainment, smoking):  
 
1. Epigenetic risk score of the phenotype as the predictor 
2. Directly-measured phenotype as the predictor 
3. A generalized linear model combining both epigenetic risk score of the phenotype and the 
directly measured phenotype 
 
6.3. Results 
The baseline descriptive statistics of included participants are presented in Table 6.2. 
Descriptive statistics stratified by human papilloma virus (HPV) status in are shown in Table 6.3. 
Seventy-eight of the 364 individuals died during a median follow-up period of 5.3 years (IQR: 4.9-5.9). 
OPC associated with HPV has been established in literature as a different pathological subtype with 
improved prognosis, compared to the more “traditional” OPC associated with alcohol consumption 
and smoking [364]. The Kaplan-Meier survival curves for mortality based on the covariates of interest 










Table 6.2 - Baseline descriptive statistics of included participants (n=364), by gender, age at enrolment, TNM stage, HPV 
status, BMI, education, smoking and alcohol intake. Created by Rhona Beynon 
  Alive (n=273) Dead (n=91)  
Characteristic N Frequency N Frequency P-value 
Gender      
Male  209 76.6% 75 82.4%  
Female 64 23.4% 16 17.6% 0.242 
Age at enrolment      
< 44 20 7.3% 3 3.3%  
45 to 54 83 30.4% 22 24.2%  
55 to 64 113 41.4% 34 37.4%  
65 to 74 48 17.6% 22 24.2%  
75 + 9 3.3% 10 11.0% 0.016 
TNM stage      
Low (1-2) 39 14.3% 8 8.8%  
High (3-4) 234 85.7% 83 91.2% 0.176 
HPV status      
Negative 61 22.3% 48 52.7%  
Positive 212 77.7% 43 47.3% <0.001 
BMI group      
not overweight 73 38.0% 31 55.4%  
overweight or obese 119 62.0% 25 44.6% 0.021 
Comorbidity      
None 164 60.1% 34 37.4%  
Mild 73 26.7% 29 31.9%  
Moderate/Severe 36 13.2% 28 30.8% <0.001 
Education level      
School education 116 42.5% 45 49.5%  
College 111 40.7% 34 37.4%  
Degree 46 16.8% 12 13.2% 0.470 
Self-reported smoking status      
Never 96 35.2% 11 12.1%  
Former 140 51.3% 49 53.8%  
Current 37 13.6% 31 34.1% <0.001 
Self-reported alcohol intake      
Non-drinker 75 27.5% 22 24.2%  
Moderate  68 24.9% 15 16.5%  
Hazardous-harmful 130 47.6% 54 59.3% 0.119 
 
Abbreviations: BMI, body mass index; HPV, human papillomavirus; N, number.* Comorbidity was 
defined using the Adult Comorbidity Evaluation-27 (ACE-27) index [365]. For the purposes of analysis, 






Table 6.3 - Baseline descriptives of included participants as in table 6.2, stratified by HPV status. Created by Rhona Beynon 
 HPV-negative n=109 HPV-positive n=255   
Variable N Frequency N Frequency Total p-value* 
Gender       
Male  87 79.8% 197 77.3% 284  
Female 22 20.2% 58 22.7% 80 0.589 
Age at enrolment       
< 44 4 3.7% 19 7.5% 23  
45 to 54 27 24.8% 78 30.6% 105  
55 to 64 46 42.2% 101 39.6% 147  
65 to 74 23 21.1% 47 18.4% 70  
75 + 9 8.3% 10 3.9% 19 0.216 
TNM stage       
I 9 8.3% 7 2.7% 16  
II 17 15.6% 14 5.5% 31  
III 21 19.3% 31 12.2% 52  
IV 62 56.9% 203 79.6% 265 <0.001 
BMI group       
Not overweight (BMI ≤25) 43 39.4% 61 23.9% 104  
Overweight or obese (BMI >25) 66 60.6% 194 76.1% 260 0.003 
Comorbidity       
None 44 40.4% 154 60.4% 198  
Mild 35 32.1% 67 26.3% 102  
Moderate/Severe 30 27.5% 34 13.3% 64 <0.001 
Education level       
School education 50 45.9% 111 43.5% 161  
College 42 38.5% 103 40.4% 145  
Degree 17 15.6% 41 16.1% 58 0.918 
Self-reported smoking status       
Never 17 15.6% 90 35.3% 107  
Former 46 42.2% 143 56.1% 189  
Current 46 42.2% 22 8.6% 68 <0.001 
Self-reported alcohol intake      
 
Non-drinker 29 26.6% 68 26.7% 97  
Moderate  16 14.7% 67 26.3% 83  




Figure 6.2a - Kaplan-Meier survival curves based on demographic and clinical covariates. Created by Rhona Beynon 
 
 






Proportion of phenotypic variance explained for DNAm-based and genetic predictors. 
 A comparison of phenotypic variance explained by DNAm predictors can be found in Table 
6.4. Where available, the Bayesian-derived epigenetic risk scores [358] seemed to explain a higher 
proportion of variance than their LASSO and glm-derived counterparts. The Bayesian-derived 
epigenetic score explained the greatest proportion of variance for smoking, explaining 51.06% of 
phenotypic variance. The epigenetic risk score of educational attainment explained the least variance 
explained of our phenotypes, of 0.40%. 
 
Table 6.4 - Proportions of phenotypic variance explained by the epigenetic risk scores employed in this analysis 
Methylation score Variance explained in phenotype 
Smoking 
Trejo Bayesian (59 CpG sites) 51.06% 
AHRR (cg05575921) 48.96% 
McCartney LASSO (233 CpG sites) 44.33% 
Joehanes (Bonferroni) (2623 CpG sites) 39.08% 
Joehanes (FDR) (18,670 CpG sites) 22.71% 
Zhang (4 CpG sites) 5.15% 
Alcohol 
Liu Model 4 (144 CpG sites) 16.48% 
Liu Model 3 (78 CpG sites) 16.18% 
Liu Model 1 (5 CpG sites) 14.96% 
Liu Model 2 (23 CpG sites) 11.56% 
McCartney LASSO (450 CpG sites) 7.90% 
BMI 
Trejo Bayesian (144 CpG sites) 22.70% 
McCartney LASSO (1109 CpG sites) 21.05% 
Educational attainment 
McCartney LASSO (373 CpG sites) 0.40% 
 
 
Relationship between directly-measured phenotype and mortality 
A comparison of multivariable Cox proportional hazards outputs for minimally adjusted and 
fully adjusted models is presented in Table 6.5. In minimally adjusted models, smoking was positively 
associated with mortality (ever vs never smoking HR: 2.34, 95% CI=1.71, 3.21; p=1.21x10-07) while BMI 
appeared to be protective (HR per kg/m2: 0.93, 95% CI= 0.87, 0.99; p=0.028). There was weak evidence 
to suggest that alcohol consumption was related to mortality risk (hazardous-to-harmful drinking vs 
moderate-to-non-drinking HR:1.26, 95% CI=0.97, 1.64; p=0.089).  Educational attainment was not 
associated with mortality. The association of self-reported smoking status with all-cause mortality 





Relationship between DNAm scores and mortality 
All the epigenetic predictors were related to mortality in the minimally adjusted models (Table 
6.5), except for the BMI predictor derived by McCartney et al [348]. After adjusting for clinical factors 
and directly measured phenotypes (Table 6.6), only the smoking-derived DNAm scores developed by 
Joehanes et al (Bonferroni) and Zhang et al were associated with mortality risk (HRs: 1.36, 95% CI: 1.02 
to 1.82; p: 0.034 and 1.28, 95% CI: 1.02 to 1.61; p: 0.036, respectively). There was additional evidence 
of a relationship between AHRR methylation status and mortality in the imputed analysis, whereby a 
SD unit decrease in cg05575921 methylation (smoking is associated with hypomethylation at this loci) 
was associated with a 25% decrease in risk of death (HR: 0.75, 95% CI: 0.56 to 0.98; p: 0.044) in the 




Table 6.5 - Association of phenotypic and DNAm-based predictors of smoking, alcohol drinking, BMI and education with mortality. Created by Rhona Beynon 
 
Abbreviations:  N, number; HR, hazard ratio; ll, lower confidence interval; ul, upper confidence interval. *Directly measured phenotypes adjusted for age and gender; epigenetic scores adjusted 
for age, gender, cell counts and batch effects. **phenotypes additionally adjusted for clinical variables (TNM stage, HPV status and co-morbidity), and a combination of smoking, alcohol intake, 
education and BMI, as appropriate to the model; risk scores additionally adjusted for clinical variables, the corresponding phenotype predicted by the score of interest and the remaining directly 
measured phenotypes (excluding BMI). ‡ sample numbers vary due to missing BMI data.    
    Minimally adjusted*         Fully adjusted**     
Exposure  N HR ll ul p-value   N‡ HR ll ul p-value 
Directly measured phenotype 
Ever vs. never smoker 364 3.29 1.75 6.18 2.22E-04  364 2.21 1.14 4.30 0.019 
Hazardous to harmful drinker vs. not 364 1.62 1.06 2.49 0.027  364 1.34 0.86 2.09 0.202 
Higher education vs school education 364 0.81 0.54 1.22 0.320  364 0.87 0.57 1.31 0.503 
BMI  248 0.93 0.87 0.99 0.028  248 0.98 0.92 1.06 0.664 
DNAm score 
Smoking             
McCartney LASSO (233 CpG sites) 364 1.53 1.24 1.88 7.89E-05  364 1.20 0.94 1.52 0.144 
Trejo Bayesian (59 CpG sites)  364 1.70 1.37 2.11 1.49E-06  364 1.26 0.93 1.72 0.140 
AHRR (cg05575921) 364 0.59 0.48 0.74 1.72E-06  364 0.79 0.58 1.07 0.125 
Joehanes (FDR) (18760 CpG Sites)  364 1.70 1.34 2.15 1.27E-05  364 1.35 0.99 1.84 0.056 
Joehanes (Bonferroni) (2623 CpG Sites) 364 1.67 1.36 2.05 7.57E-07  364 1.38 1.04 1.83 0.025 
Zhang (4 CpG Sites) 364 1.48 1.16 1.88 1.48E-03  364 1.28 1.02 1.60 0.036 
Alcohol             
Liu (5 CpG sites)   364 1.32 1.10 1.57 2.50E-03  364 1.19 0.97 1.47 0.094 
Liu (23 CpG sites) 364 1.26 1.04 1.52 0.019  364 1.10 0.89 1.36 0.357 
Liu (78 CpG sites)   364 1.25 1.07 1.45 5.02E-03  364 1.20 0.99 1.45 0.067 
Liu (144 CpG sites) 364 1.24 1.07 1.44 5.31E-03  364 1.21 1.00 1.46 0.052 
McCartney LASSO (450 CpG Sites) 364 1.28 1.03 1.60 0.024  364 1.05 0.79 1.41 0.723 
BMI            
Trejo Bayesian (144 CpG Sites) 364 0.78 0.63 0.97 0.024   248 0.77 0.56 1.08 0.132 
McCartney LASSO (1109 CpG Sites) 364 0.85 0.68 1.06 0.146  248 0.77 0.57 1.04 0.093 
Education            




Table 6.6 - Multivariable Cox proportional hazards results for model 2 (clinical) and model 3 (respective phenotype). Created by Rhona Beynon 
    Model 2*   Model 3** 
Exposure  N HR ll ul p-value       
Directly measured phenotype           
Ever- vs. never-smoker 364 2.47 1.29 4.72 0.006           
Hazardous to harmful drinker vs. not 364 1.47 0.95 2.27 0.084           
Higher education vs. school education 364 0.81 0.53 1.22 0.306           
BMI 248 0.96 0.89 1.02 0.169           
DNAm score 
Smoking           
McCartney smoking (233 CpG sites) 364 1.34 1.07 1.67 0.011  1.05 0.79 1.41 0.726 
AHRR (cg05575921) 364 0.66 0.52 0.83 4.11E-04  0.79 0.58 1.07 0.125 
Joehanes (FDR) (18670 CpG sites) 364 1.59 1.22 2.08 6.11E-04  1.35 0.99 1.84 0.056 
Joehanes (Bonferroni) (2623 CpG sites) 364 1.59 1.26 2.00 9.82E-05  1.38 1.04 1.83 0.025 
Trejo Bayesian smoking (59 CpG sites) 364 1.51 1.2 1.91 4.34E-04  1.26 0.93 1.72 0.14 
Zhang (4 CpG sites) 364 1.38 1.1 1.74 6.26E-03  1.28 1.02 1.6 0.036 
Alcohol consumption           
Liu Model 1 (5 CpG sites) 364 1.25 1.03 1.51 0.023  1.19 0.97 1.47 0.094 
Liu Model 2 (23 CpG sites) 364 1.17 0.96 1.42 0.13  1.1 0.89 1.36 0.357 
Liu Model 3 (78 CpG sites)  364 1.25 1.05 1.49 0.014  1.2 0.99 1.45 0.067 
Liu Model 4 (144 CpG sites)  364 1.26 1.06 1.49 9.99E-03  1.21 1.00 1.46 0.052 
McCartney alcohol (450 CpG sites) 364 1.26 1.00 1.57 0.046  1.2 0.94 1.52 0.144 
BMI           
McCartney BMI (1109 CpG sites) 364 0.82 0.66 1.02 0.075  0.77 0.57 1.04 0.093 
Trejo Bayesian BMI (144 CpG sites) 364 0.77 0.61 0.97 0.025   0.78 0.56 1.08 0.132 
Educational attainment           
McCartney education (373 CpG sites) 364 0.87 0.67 1.11 0.26  0.87 0.68 1.12 0.27 
* Adjusted for age, gender, TNM stage, HPV status and comorbidity (plus cell count and batch effects for epigenetic (DNAm models)). ** additionally, adjusted for the respective directly-measured 




Predictive accuracy of epigenetic risk scores against mortality 
 Across all four phenotypes assessed, the AUC when DNAm risk scores (see Table 6.1) were 
used to predict mortality was greater than when directly-measured phenotype attempted to do the 
same (Figure 6.3). However, none of these findings were found to improve upon the predictive value 
of directly-measured phenotype to a level of statistical significance (Z-test p-value for comparison of 
epigenetic AUC and directly-measured AUC for: smoking = 0.19, alcohol = 0.41, BMI =  0.62, 
educational attainment = 0.49). When a generalized linear model of epigenetic risk score and 
corresponding directly-measured phenotype was used to predict mortality, AUC improved over 
directly-measured phenotype alone, but also below a level of statistical significance (Z-test p-value for 
combined epigenetic risk score and directly-measured phenotype AUC vs directly-measured 
phenotype AUC for: smoking = 0.30, alcohol = 0.38, BMI = 0.71, educational attainment = 0.26). The 
most predictive epigenetic risk score for mortality was that of smoking with an area under the curve 
(AUC) of 0.70. The weakest epigenetic risk score predictor of mortality was the educational attainment 




A summary of the baseline descriptive characteristics of participants included in the sensitivity 
analysis is provided in Table 6.7. When the analysis was restricted to participants with data available 
for BMI (Table 6.8), the results of models examining the association of self-reported phenotypes with 
mortality were broadly comparable; only self-reported smoking was associated on full adjustment.  
When the relationships of DNAm scores with mortality were examined, there was evidence that the 
alcohol-related DNAm scores developed by Liu et al. were associated with mortality, in addition to the 















Figure 6.3 - ROC curves detailing the predictive accuracy of epigenetic risk scores, directly-measure phenotype and a 
combination of the two, against 5-year mortality in HN5000.  ROC curves are provided for smoking, alcohol consumption, BMI 




Table 6.7 - Baseline descriptives of participants included in the sensitivity analysis (n=248). Created by Rhona Beynon 
  Alive (n=192) Dead (n=56)   
Characteristic N Frequency N Frequency p-value  
Gender       
Male  147 76.6% 45 80.4%   
Female 45 23.4% 11 19.6% 0.550 
Age at enrolment       
< 44 16 8.3% 1 1.8%   
45 to 54 61 31.8% 16 28.6%   
55 to 64 76 39.6% 17 30.4%   
65 to 74 32 16.7% 14 25.0%   
75 + 7 3.6% 8 14.3% 0.009 
TNM stage       
Low 29 15.1% 7 12.5%   
High 163 84.9% 49 87.5% 0.626 
HPV status       
Negative 43 22.4% 31 55.4%   
Positive 149 77.6% 25 44.6% <0.001 
BMI group       
not overweight 73 38.0% 31 55.4%   
overweight or obese 119 62.0% 25 44.6% 0.021 
Comorbidity       
None 119 62.0% 25 44.6%   
Mild 51 26.6% 18 32.1%   
Moderate/Severe 22 11.5% 13 23.2% 0.031 
Education level       
School education 84 43.8% 30 53.6%   
College 80 41.7% 20 35.7%   
Degree 28 14.6% 6 10.7% 0.414 
Self-reported smoking status       
Never 72 37.5% 7 12.5%   
Former 98 51.0% 29 51.8%   
Current 22 11.5% 20 35.7% <0.001 
Self-reported alcohol intake       
Non-drinker 53 27.6% 15 26.8%   
Moderate  47 24.5% 9 16.1%   




Table 6.8 - Results of the sensitivity analysis, restricted to those with complete data (including BMI). Created by Rhona Beynon 
    Minimally adjusted         Fully adjusted     
Exposure  N HR ll ul p-value   N HR ll ul p-value 
Directly measured phenotype 
Ever vs. never smoker 248 3.64 1.65 8.07 1.42E-03  248 2.47 1.07 5.73 0.035 
Hazardous to harmful drinker vs. not 248 1.48 0.86 2.56 0.16  248 1.24 0.70 2.21 0.46 
Higher education vs school education 248 0.74 0.44 1.25 0.26  248 0.94 0.54 1.64 0.84 
BMI  248 0.93 0.87 0.99 0.028  248 0.98 0.92 1.06 0.66 
DNAm score 
McCartney smoking 248 1.49 1.13 1.97 4.31E-03  248 1.32 0.97 1.81 0.076 
McCartney alcohol 248 1.31 0.98 1.76 0.067  248 1.04 0.71 1.51 0.85 
McCartney BMI  248 0.76 0.57 1.01 0.059  248 0.77 0.57 1.04 0.093 
McCartney Education  248 0.86 0.65 1.14 0.29  248 0.94 0.69 1.28 0.69 
Liu 5 CpG alcohol  248 1.36 1.08 1.73 9.39E-03  248 1.43 1.07 1.92 0.017 
Liu 23 CpG alcohol  248 1.33 1.03 1.72 0.029  248 1.33 0.98 1.80 0.068 
Liu 78 CpG alcohol  248 1.23 1.02 1.49 0.028  248 1.32 1.03 1.69 0.027 
Liu 144 CpG alcohol  248 1.22 1.01 1.46 0.037  248 1.29 1.02 1.63 0.036 
AHRR (cg05575921) 248 0.63 0.47 0.83 1.28E-03  248 0.89 0.60 1.32 0.55 
Joehanes 248 1.84 1.36 2.49 7.43E-05  248 1.59 1.09 2.32 0.012 
Joehanes strict 248 1.72 1.32 2.24 5.24E-05  248 1.50 1.06 2.12 0.022 
Zhang 248 1.41 1.04 1.91 0.029  248 1.33 1.00 1.77 0.047 
Bayes smoking 248 1.61 1.21 2.14 1.17E-03  248 1.12 0.75 1.67 0.58 
Bayes alcohol 248 0.76 0.59 0.99 0.045   248 0.77 0.56 1.08 0.13 
 
Abbreviations:  N, number; HR, hazard ratio; ll, lower confidence interval; ul, upper confidence interval. *Directly measured phenotypes adjusted for age and gender; risk scores adjusted for age, 
gender, cell counts and batch effects. **phenotypes additionally adjusted for clinical variables (TNM stage, HPV status, co-morbidity and BMI) and a combination of smoking, alcohol intake, 






Analyses were undertaken to attempt to define the predictive accuracy of epigenetic risk 
scores for smoking, alcohol drinking, BMI and educational attainment, in comparison with directly 
measured or self-reported phenotypes. These epigenetic scores were used to assess ~3-year mortality 
risk in a clinical cohort of individuals with oropharyngeal cancer. In all models, the epigenetic risk 
scores explaining the largest amount of phenotypic variance yielded similar mortality estimates to 
directly measured or self-reported phenotypes and may therefore provide a useful measure of these 
exposures in future epidemiological studies, particularly if directly measured phenotypic data is not 
available. 
 
Results from the fully-adjusted model show that phenotypically, smoking is the only trait 
strongly associated with mortality risk after adjustment for age, sex, TNM stage, HPV status, 
comorbidity, alcohol consumption and educational attainment (HR: 2.21, 95% CI: 1.14 to 4.30; P: 0.019 
for ever versus never-smokers). Similarly, when investigating DNAm risk scores, only smoking was 
associated with mortality after adjustment for the covariates above, cell counts and BeadChip ID for 
batch (Joehanes Bonferroni HR: 1.38, 95% CI: 1.04 to 1.83; P: 0.025, Zhang HR: 1.28, 95% CI: 1.02 to 
1.60; P: 0.036). Finally, it should be noted that alcohol consumption showed weak evidence of 
association with mortality (with similar magnitude to smoking analyses) both phenotypically (HR: 1.34; 
95% CI: 0.86 to 2.09; P: 0.202) and as an epigenetic risk score (HR: 1.21; 95% CI: 1.00 to 1.46; P: 0.052) 
when adjusting for the same covariates in our full-adjusted model. 
 
For the prediction of mortality using epigenetic scores, the two predictors that were derived 
using results from a Bayesian framework explained the most phenotypic variance, thus were 
employed over other epigenetic scores derived using a LASSO/linear mixed-effects regression. 
Interestingly, despite explaining the largest amount of phenotypic variance, neither Bayesian 
predictor was associated with mortality as strongly as the respective phenotypic measures. For 
smoking, the Joehanes Bonferroni epigenetic score was most strongly associated with mortality; for 
BMI, the McCartney LASSO epigenetic score was most strongly associated with mortality. One 
potential explanation for this finding is that the Bayesian scores are proxying characteristics of 
smoking and BMI which might not necessarily directly impact survival. However, whilst not affecting 
survival, the aspects of smoking that the Bayesian scores proxy may better predict the phenotype. An 
example of such a characteristic may be a susceptibility to social peer pressure [366, 367], though this 





In the minimally adjusted model, phenotypic BMI, epigenetic risk scores for alcohol and an 
epigenetic risk score for education all show an association with mortality. However, when adjusted 
for clinical covariates and co-adjusted for other phenotypes in the fully adjusted models, the 
associations attenuate. This observation may be explained by inadequately measurement of each of 
the above phenotypes. As such, in the minimally adjusted model, the above phenotypes may be 
closely associated with one or more of the covariates adjusted for in our fully adjusted model, and the 
observed association with mortality actually driven by the association of a covariate with mortality. 
Alternatively, the attenuation seen in the fully adjusted model results could reflect a true association 
masked by an inflated standard error due to addition of multiple covariates. A notable limitation of 
this analysis is the small sample size; in the survival analysis, it cannot be said with certainty that the 
observed change in effect size between models is a true attenuation. A larger sample size or 
independent replication is necessary to resolve this issue. 
 
This analysis has several strengths including the availability of MethylationEPIC epigenetic 
data and comprehensive mortality follow-up data in the same cohort, as well as the ability to adjust 
for multiple biological, clinical and lifestyle covariates, including HPV,  presents a major strength; it 
enables investigation of the association of methylation scores with mortality within a cancer cohort,  
a novel application of epigenetic prediction of phenotypes which may have clinical utility in the future. 
 
A notable limitation of the analysis is that all-cause mortality was used as the mortality 
phenotype. This was because cause-of death data was not available for all participants in the current 
HN5000 data release. Moreover, previous work has shown that the cause of death information on a 
death certificate is often inaccurate [368]. Whilst all-cause mortality will be impacted by cancer status, 
it will not show specificity to OPC.  Deaths could arise from competing causes such as cardiovascular 
disease, secondary cancer or age, preventing us from estimating phenotype risk on OPC-specific 
death. Interestingly, however, hazard ratio estimates are larger in this analysis compared to another 
study examining the association of epigenetic scores against mortality in a healthy population.  
McCartney et al. [348] report a HR of 1.29, 95% CI of 1.05 to 1.57 and P of 0.013 for their smoking 
epigenetic risk score (vs our smoking epigenetic score HR: 1.72; 95% CI: 1.21 to 2.45; P= 2.50 x10-03). 
All-cause mortality estimates in those with OPC likely reflects the effect of sustained heavy tobacco 
and alcohol use (a hallmark demographic of HNC populations), in addition to presence of cancer on 
mortality. The marked HR differences seen between those with and without OPC illustrate a need to 





 Another limitation is that sample sizes differ in models examining the effect of BMI on 
mortality risk, owing to missing data.  As a result, these models are not directly comparable to those 
estimating the mortality risk associated with smoking, drinking and education because the individuals 
included differ. However, the baseline descriptive statistics of participants included in the models did 
not appear to be different, presumably because BMI data was missing at random. If BMI had been 
included as a covariate in the fully adjusted models, this would have reduced the statistical power 
further, as shown by the loss of precision in sensitivity analyses (N = 248), which adjusted for directly-
measured BMI in all instances.  
6.5. Conclusion 
In summary, in the context of OPC, DNAm predictors are able to predict complex traits with a 
relatively high degree of variance explained for smoking, alcohol consumption and BMI; however, the 
educational attainment DNAm predictor did not display the same high degree of variance explained. 
Comparing the effect on mortality of both DNAm predictors and directly measured phenotype yielded 
similar results between the two, with methylation displaying similar effect sizes and variance 
explained of ~3-year mortality, across all traits assessed. Including genetic predictors as a covariate in 
our Cox regression analyses did not significantly affect our results. Findings suggest DNAm predictors 
can be used to supplement phenotypic prediction of mortality, potentially even providing reliable 
insight into smoking, alcohol consumption, BMI and educational attainment in situations where 











This body of work aimed to augment understanding of OPC by investigating aetiological factors 
and biological pathways with progressively greater granularity than had been available in the 
published literature. First, existing risk factors from observational epidemiological literature were 
collated. This was undertaken to form an evidence base from which to prioritise hypotheses and 
highlight potential gaps in current OPC research. The use of MELODI as a literature mining tool allowed 
for high-throughput retrieval and quantification of the proportion of all PubMed literature which 
mentioned an enriched, directional association from any pre-defined risk factor to OPC.  
 
Next, using a hypothesis-free approach, the causality of a vast number of phenotypes was 
appraised against risk of OPC in an MR-PheWAS framework. The purpose of this analysis was firstly to 
quantify the effect of established risk factors on OPC-specific risk (rather than OPC in combination 
with other HNC sub-types, as is currently prevalent in observational literature) using a robust causal 
inference method which can circumvent the innate biases of observational studies (namely 
confounding and reverse causation). Secondly, the MR-PheWAS was conducted to ascertain whether 
any novel, genetically-proxied phenotypes were associated with OPC risk outside of those already 
established. By utilising the vast scope and scale of published summary GWAS data in an MR approach, 
a comprehensive “scan” of the causal landscape of OPC could be achieved, investigating many 
previously untested associations between phenotype and OPC risk. 
 
Finally, DNA methylation has been established as an exposure indicator and causal molecular 
intermediate in epidemiological literature [369] EWAS, DMR and a novel 2-step MR approach were 
employed to assess whether risk factors for OPC affected disease aetiology via mediation by DNA 
methylation. Assessing mediation could provide novel therapeutic targets and biological pathways to 
prioritise, that is the methylation variable locus could be targeted as opposed to the risk factor itself 
to modulate OPC risk. Furthermore, ascertainment of DNA methylation patterns associated with OPC 
mortality or prognostic factors could shed insight into OPC progression pathways and allow for greater 
accuracy when stratifying OPC subgroups (such as HPV-IMU, HPV-KRT and HPV-negative OPC). This is 
of particular interest in light of unexpected de-escalation clinical trial findings for HPV-positive OPC 
[370]. Patient segmentation for entry into trials might be a fruitful strategy in future to increase the 
likelihood of success of new treatments and that DNA methylation biomarkers may be helpful to group 
patients in this way. Phenotypic prediction using DNA methylation also has clinical translation to 
circumvent bias in the self-report of relevant health behaviours or in the prediction of a missing 





Below, each chapter is discussed with respect to its contribution to wider epidemiological 
literature. Overall strengths and limitations of this thesis are then discussed, before exploration of 
future research directions informed by the work completed. 
7.1.2. Discussion 
Novel contributions to epidemiological literature and OPC aetiology 
Systematic retrieval of OPC risk factors enriched in epidemiological literature 
 The use of MELODI to retrieve risk factors for disease is a novel application of this platform. 
The use of SemMedDB “triples” to retrieve OPC risk factors (i.e. risk factor → PREDICATE → OPC) 
allowed for ascertainment of the degree of evidence, semantically, to which a risk factor was related 
to OPC risk (“associated with”, “predisposes” or “causes”). Furthermore, this method provided an 
evidence base of risk factors which reflected existing literature, albeit with “noise” filtered out through 
use of an enrichment step. Finally, MELODI provided large numbers of potential intermediates 
between smoking and OPC, alcohol and OPC, HPV and OPC, and oral sex and OPC. 
 
MR-PheWAS 
 MR is recognised as a robust causal inference method in epidemiological literature, to the 
degree that MR study findings have contributed evidence to IARC Monographs of cancer risk factors. 
Furthermore, MR-PheWAS have been able to establish novel risk factors for other cancers in peer-
reviewed epidemiological literature. Here, findings from 17,4449 phenotypes were largely in 
concordance with existing literature, finding a concentration of alcohol, sexual activity and smoking 
phenotypes to be most associated with risk of OPC. However, using a two-sample MR approach to 
interrogate OPC-specific risk is a key strength and novel contribution to epidemiological literature. 
Furthermore, MR is known to circumvent the issues of confounding and reverse causation typically 
seen in observational literature, thus provides new, robust evidence to augment the established 
effects of smoking, weight and sexual activity on OPC risk. The finding of weight as inversely associated 
with OPC risk provides greater evidence that the direction of effect for this observation may indeed 
be from low weight to OPC (ambiguous in observational literature due to study design), rather than 
an artefact of reverse causation (OPC causing a decrease in weight). Because genotype is inherited at 
conception, a genetically-proxied phenotype will always precede OPC in this framework. Finally, a key 
finding of this analysis which should not be overlooked is the number of findings which were not 




will not have previously been appraised against OPC risk. Such phenotypes will now have evidence for 
de-prioritisation (and a comparative effect estimate) in future risk factor studies. 
 
DNA methylation as a mediator of OPC prognostic factors and mortality 
 Due to its proximity to the genome, DNA methylation patterns can reveal important gene 
expression pathways for OPC aetiology. Epigenetic signatures have been established in 
epidemiological literature as exposure indicators and causal mediators for risk of multiple diseases, 
including OPC. However, DNA methylation patterns for OPC prognostic factors have not been 
investigated in a case-only context before and Illumina MethylationEPIC-derived signatures have not 
been investigated in relation to genome-wide OPC mortality. In 2017, Degli Esposti et al. investigated 
Illumina 450K for association with HPV status in HNSCCs, but this study combined oral, oropharyngeal, 
hypopharyngeal and laryngeal cancers. Given the uniquely-large effect of HPV on OPC, combining 
these cancer sites has potentially biased methylation findings unique to the OPC anatomical site 
towards the null. The specificity of HPV to OPC can be seen within this study when comparing the 
multidimensional scaling (MDS) plot generated for HNC anatomical site and MDS plot for HPV status 
(Figure 7.1); points describing samples with positive HPV status correlate almost perfectly with points 
describing the OPC subtype and not with oral cavity, hypopharyngeal and  laryngeal sites.  
 
 
Figure 7.1 – Adapted from Degli Eposti et al.: MDS plots for HPV status (left) and HNC anatomical site (right) show significant 
correlation between OPC and HPV status 
 
Chapter 5 of this thesis employs one of the largest OPC epigenetic data resources in 
epidemiological literature (N = 448), investigating DNA methylation data from the current BeadChip 
platform with the greatest coverage (Illumina MethylationEPIC). Novel methylation signatures relating 
to smoking, alcohol consumption and ~4-year OPC mortality were discovered in single-site EWAS. 




consumption, HPV and OPC mortality in a separate analysis. A novel application of MR, investigating 
DMR methylation against OPC mortality, identified that shared DNA methylation between smoking 
and OPC mortality at the SPEG gene locus and indicated a causal role for this gene locus in OPC 
mortality. This finding may have clinical relevance for OPC and prognostic studies more broadly if 
methylation and/or expression of SPEG is confirmed to be causally related to with survival. For 
example, there may be scope to target DNA methylation at this gene region therapeutically if a 
proportion of the effect of smoking on mortality is mediated through this pathway. However, 
appropriate validation and replication studies need to be conducted to establish the true effect of 
smoking-related DNAm at the SPEG gene region on mortality. Furthermore, quantification of the 
proportion of smoking-related mortality risk at this gene region will be crucial in determining whether 
targeting it is a cost-effective therapeutic target.  
 
Epigenetic prediction of complex traits and mortality 
 The utility of DNA methylation as an exposure indicator is an area of increasing 
research interest, exemplified in the burgeoning literature around the prediction of age through the 
use of epigenetic clocks [371]. As DNA methylation can reflect both a variety of risk factors and 
simultaneously capture information on the early stages of disease, it has high  potential for impact in 
clinical settings. Prediction of phenotypes, improvement of risk estimation/prognostication and 
insight into biological processes are all potential applications of DNA methylation [372, 373]. 
McCartney et al. found that DNA predictors of alcohol consumption, BMI, education and smoking 
correlate with lifestyle factors associated with health outcomes and mortality [348].  
In OPC, comparing the effect on mortality of both peripheral blood DNAm predictors and self-
reported phenotypes yielded similar results between the two. DNAm indices of established risk factors 
(alcohol, smoking, BMI and educational attainment) predicted 3-year mortality with the same 
accuracy as self-reported data, displaying similar effect sizes and variance explained of mortality 
across all traits assessed. Findings from this analysis suggest peripheral blood DNAm predictors can be 
used to supplement a prediction model of mortality in those with oropharyngeal cancer, potentially 
providing reliable insight into smoking, alcohol consumption and BMI measures in situations, 
particularly where self-reported phenotype information is not available for these individuals. This 
avenue of enquiry could be explored further with the advent of more extensive measurement of DNA 
methylation across the genome. The current analysis was restricted to probes present on the Illumina 
Methylation EPIC BeadChip, whereas a technology such as whole genome bisulphite sequencing may 





Strengths of work presented 
Perhaps one of the greatest strengths of this thesis is that the methodologies employed 
throughout use data which is specific to OPC, as opposed to a heterogenous mix of multiple head and 
neck cancers. There is a paucity of epidemiological literature which investigates the effect of risk 
factors in an OPC-specific context. As shown in the introduction, most observational epidemiological 
findings present the effects of risk factors with respect to “pharyngeal” cancers (nasopharyngeal, 
hypopharyngeal and oropharyngeal cancers [or a combination thereof]) or “oral cancer” (oral cavity 
and oropharyngeal combined). Whilst combining HNC anatomical sites boosts statistical power, 
translation or clinical utility of these findings presents an issue; the quantitative effect of a given risk 
factor on an OPC patient is ambiguous when effect estimates are derived for a combination of cancers. 
Despite their biological proximity, these cancers are not the same and therefore should not be treated 
so. A key example of this disparity is the comparison of hypopharyngeal cancer and OPC. HPV, in an 
observational context, confers a huge increased risk to OPC (OR: 147.3; 95% CI: 83.07 to 361.24) in 
large-scale multi-centre studies, whereas any link between HPV and hypopharyngeal risk is only 
currently proposed in a few small-scale studies, with few, if none, presenting ORs for hypopharyngeal 
cancer incidence [374]. Given the predominance of HPV as a risk factor for OPC and the lack of robust 
association with hypopharyngeal cancer, it would appear the causal landscape of these cancers differ. 
Pathologically-confirmed OPC cases in the HN5000 genetic and epigenetic data allow for OPC-specific 
risk estimates and appraisal of biological pathways with minimisation of bias from other primary sites. 
 
Secondly, the use of Mendelian randomization in particular is a key strength throughout this 
thesis. Observational epidemiological literature is prone to innate biases that prevent true causality 
from being established, the most notable being unmeasured confounding. Mendelian randomization 
circumvents the issue of unmeasured confounding by relying on genetic variants to proxy a phenotype 
of interest. Genetic variants which are uniquely associated with an exposure of interest, independent 
of OPC, cannot be confounded by unmeasured confounding (with the exception of genetic 
confounding by population stratification, which in a well-designed study in greatly minimised). In a 
MR analysis, genetic variants that influence levels of a trait of interest are randomly allocated at 
conception, as per the Laws of Segregation and Independent Assortment. Groups defined by a certain 
genotype (proxying a risk factor) should then be wholly comparable in the distribution of both genetic 
and environmental confounding factors, except for their exposure to a trait of interest. Any observed 
differences in OPC between groups defined by genotype can then be solely attributed to differences 




limitations, which have been reviewed at length elsewhere [254] but are briefly summarised below 
where they are pertinent to the findings in this thesis.  
 
In addition to instrumental variables having to fulfil a strict set of assumptions, MR is 
susceptible to a number of practical and theoretical limitations. Firstly, not every trait has a genetic 
polymorphism associated with it. Despite the 17,449 phenotypes examined in Chapter 4, some 
phenotypes considered important to OPC aetiology, such as HPV16 infection, could not be appraised 
in an MR framework. However, despite this limitation, GWAS have been (and continue to be) 
published at an exponential rate since their conception, with more traits per GWAS and a greater 
frequency of GWAS published year-on-year. Future MR-PheWAS can therefore be expected to 
investigate many more traits than those seen in Chapter 4 and provide increasingly comprehensive 
information regarding the causal landscape of a disease. A key development in GWAS design, and by 
extension the scope of MR methodology, is the appraisal of molecular intermediates. It is important 
to know which risk factors causally affect a disease; once this has been determined, it is then important 
to know how a risk factor affects a disease. By conducting MR from OPC intermediates to OPC 
mortality, biological pathways of disease aetiology can begin to be investigated. Moreover, if a 
molecular intermediate (i.e. methylation) can be established as a causal mediator of the two, these 
findings may be of clinical use as either risk stratification biomarkers or therapeutic targets. This thesis 
has shed light on one such pathway/target in methylation at the SPEG gene (Chapter 5), potentially 
mediating the causal association seen between smoking and OPC mortality. Whilst more analysis is 
needed to confirm a true causal effect of smoking → methylation at the SPEG locus, methylation in 
response to smoking appears to show a causal effect on OPC mortality.  
 
Additional developments are currently underway in the application of Mendelian 
randomization to understand the causal factors in disease progression including in the context of 
cancer [256]. This presents some additional methodological challenges and is limited at the current 
time by the paucity of GWAS that have looked specifically at disease survival or outcomes post 
diagnosis. However, this is an interesting and active area of research and may be a fruitful avenue to 
explore going forward. 
 
Thirdly, this thesis was able to address a key gap in observational literature by employing 
causal inference methods (namely two-sample and two-step MR) associated with genetic and 
epigenetic data. As mentioned previously, a pitfall of observational epidemiology is a lack of ability to 




for smoking, alcohol and HPV infection/oral sex were mediating a “risk-taking” phenotype. Co-
adjusting for smoking, alcohol and HPV infection/oral sex in observational analyses would likely be 
insufficient if this was the case, as the breadth of impact “risk-taking” would have on an individual’s 
life beyond these 3 phenotypes cannot be completely accounted for. Therefore, the observational 
effect of smoking, alcohol and HPV infection, respectively, could be biased by any of the other two 
risk factors, or by any other commonality between “risk-takers” (e.g. low SEP, high BMI, poor dental 
hygiene). Using genetic data to appraise smoking and alcohol consumption allowed for an 
independent effect of these respective factors, free of traditional confounding.  
 
Limitations of work presented 
 The use of an approach based on text mining of published literature to derive novel risk factors 
for OPC only clarified the existence of risk factors which are already established for this disease in 
epidemiological literature, therefore this approach inevitably suffers from publication bias. It appears 
that a concentration of articles investigating alcohol, smoking and HPV against OPC risk, and a paucity 
of literature investigating OPC as a specific HNC sub-type (rather than grouping it with other sub-types) 
severely limited MELODI’s ability to infer novel links between publications. This is evident in the 
apparent mediation of smoking, alcohol and HPV infection by each other, with no other suggestions 
of modifiable risk factors for OPC. To this end, MELODI worked in its application in this thesis much 
more as a “review” of current literature than a “hypothesis generator”, as intended. Nevertheless, 
using MELODI to retrieve potential intermediates retrieved hundreds of concepts. A “concept” in the 
context of MELODI refers to any of: an amino acid, peptide, protein, bacteria, biologically active 
substance, carbohydrate, fungus, gene, hormone, lipid, neuroreactive substance or biogenic amine, 
pharmacologic substance or virus, as per the criteria outlined in Table 3.1 of Chapter 3. 
 
A key limitation of this thesis relates to epidemiological study design in general; behavioural 
phenotypes (e.g. smoking and alcohol consumption) are typically derived via self-report 
questionnaire. Accordingly, interpretation of observational results and MR results necessitates 
caution. Various factors affect how accurately a study can determine behavioural phenotypes from 
self-report questionnaires, including intentional patient misreporting (e.g. a patient defining 
themselves as an ex-smoker when they are actually a current smoker), recall bias (e.g. an OPC patient 
over-reporting historic units of alcohol consumed per week due to a belief that this behaviour caused 
their cancer) and a general inaccuracy in questionnaire design for the measurement of behaviours 




different numbers of cigarettes per day, and reporting alcohol consumed in units per week doesn’t 
necessarily account for binge-drinking).  
 
These limitations can also extend to some extent to the application of MR because these 
biased measures are the basis of GWAS conducted to generate SNP-trait associations. Poor phenotype 
measurements can potentially compromise the quality of GWAS outputs. Furthermore, when proxying 
a phenotype for MR using GWAS results, knowledge of both how the phenotype was measured and 
the biological plausibility SNPs used is essential. For example, when selecting SNPs for a smoking IV 
(e.g. cigarettes per day), some or all of these may reside within the CHRNA3 gene region. However, 
SNPs in this region are reported to proxy for smoking heaviness amongst smokers rather than being 
representative of cigarettes per day in a general population [375, 376]. As such, the outcome OPC 
GWAS data would have to be restricted to current smokers to produce a meaningful effect-estimate, 
which is not possible using summary (rather than individual-level) genetic data. Some of these 
limitations are overcome by utilising well-established and validated genetic instruments for 
application in MR i.e. those that have been identified in a reliably phenotyped, representative 
population that is independent of the OPC case series in which the MR analysis is being applied. 
 
A limitation of the epigenetic results chapters presented in this thesis is the lack of availability 
of tumour tissue-based methylation data, thus analyses being conducted in whole blood. Whole blood 
methylation has been established as a “biosocial archive”, changing robustly in response to long-term 
behaviours and exposures. However, use of blood rather than tumour tissue prevents identification 
of aberrant expression at the cancer site itself and is prone to confounding by cell composition. It has 
been used here to more precisely define risk or prognostic factors in prediction models, including their 
effect on mortality, rather than diagnosis or prognosis of OPC specifically. Substantial changes in 
methylation can be seen across a variety of tumour tissues, including those of OPC. Having access to 
tumour tissue methylation and the specificity it affords may prove particularly lucrative in discovering 
predictive diagnostic or prognostic methylation patterns to better improve clinical outcomes. 
However, in the absence of the availability of these data, robust relationships of blood-based 
methylation patterns with prognostic factors and OPC survival have been established in Chapters 5 
and 6, creating novel avenues and gene regions to be investigated and appraised with respect to the 





7.1.3. Future directions 
‘Omic’ MR analyses 
 One of the key strengths of this thesis was the ability to interrogate the causality of a vast 
number of phenotypes, many of which have not previously been appraised or hypothesised to be 
associated with OPC. The advancement of GWAS studies to discover SNPs associated with gene 
expression levels, methylation levels, metabolite levels and protein levels, in addition to novel 
phenotypes, allows for an exponentially greater number of hypotheses to be tested and for vastly 
improved insight into disease aetiology. It also allows for many of the intermediates identified by 
MELODI in Chapter 3 to be investigated. Despite molecular intermediates not typically possessing a 
large number of SNPs from GWAS to proxy them, precise measurement of these phenotypes (e.g. 
measurement of metabolites using nuclear magnetic resonance and liquid chromatography-mass 
spectronomy) result in relatively large GWAS per-allele effect sizes and phenotypic variance explained, 
both of which improve power to detect a true causal association. These “omic” associations may prove 
invaluable in the progression of OPC research, aiding the discovery and appraisal of important 
biological pathways with the ability to translate to biomarkers and therapeutic targets with clinical 
importance. 
 
MR of HPV status on OPC risk  
 At the time the analyses were conducted no data were available that allowed MR to be applied 
to explore the causal role between HPV status and OPC. GWAS of HPV status do exist [377] but do not 
provide beta values that are suitable for use in MR analysis. The identification of genetic instruments 
to proxy HPV status will be useful to probe this question but these are likely to be challenging to 
identify and be free from pleiotropic action, given what is known about the biological complexity of 
infection and immunity. 
 
Epigenetic signatures in saliva 
 In Chapter 5, blood-based epigenetic data from individuals from HN5000 was used to 
determine differentially methylated sites and regions associated with different risk factors. Chapter 6 
investigated the utility of methylation as a predictor of OPC mortality in the context of commonly 
reported risk factors. Methylation appeared to be associated with both alcohol and smoking status, 
with methylation at some novel gene regions measured by the MethylationEPIC BeadChip highlighted 




same efficacy as directly-measured phenotypes, showing promise as an objective archive of health 
behaviours; methylation is able to predict the exposure history of an individual with OPC independent 
of direct phenotype measurement. Although the use of minimally invasive samples as a source of DNA 
are commonly used (e.g. blood or saliva), there is logic in aiming to combine this with sources of DNA 
from the affected tissue. Indeed, many investigators have sought to identify DNA methylation 
signatures in circulating tumour DNA [373]. This is a promising avenue of exploration given the very 
profound changes to the methylome seen in tumour tissue (even if only tiny trace amounts can be 
isolated) when compared to the more subtle shifts in methylation patterns seen in somatic tissues. 
 
Saliva is present as a resource in HN5000, which may plausibly contain small amounts of shed 
tumour DNA; a potentially lucrative resource for early detection of cancer. DNA extraction from saliva 
samples (usually a mix of buccal epithelial cells and lymphocytes) is relatively routine. It would be of 
interest to compare DNA methylation data sources (blood vs saliva) to evaluate their respective 
performance in OPC prognosis. Saliva-based methylation translates to a less-invasive clinical test if 
notable methylation pattern differences in this tissue type occur between people with OPC, exposed 
vs unexposed to a risk factor.  
 
MR of risk factors for OPC progression 
 As mentioned above, methodological developments in the application of Mendelian 
randomization will in the future allow the better discrimination of causal factors associated with 
disease progression as opposed to those that cause disease to occur in the first instance. This has 
important implications for both treatment (causal factors affecting prognosis should be the targets of 
any therapy) and for secondary and tertiary prevention. For example, understanding whether smoking 
cessation impacts OPC prognosis or survival could be an important issue for those diagnosed with this 
cancer; if smoking does not causally impact survival after OPC has been diagnosed then it would not 
be a priority to stop smoking. It is plausible that a very different suite of factors influence disease (OPC) 
progression compared to those that influence disease onset so it would be advantageous to 
recapitulate the MR-PheWAS approach that I adopted in this thesis to investigate causal factors for 
OPC progression or survival once the requisite data are available. 
 
Case-control EWAS of OPC 
 The EWAS analysis undertaken as part of this thesis focused on an analysis of the relationship 




undertaken as this would require a case-control study design and the H&N5000 study is a case only 
cohort. DNA methylation data generation is highly prone to batch effects, it would therefore not be 
appropriate (as has been the case for GWAS) to use a separately sourced control population in an 
EWAS study design as any comparison would likely result in differentially methylated loci being 
confounded by batch. Future work is warranted to undertake a well-powered EWAS of OPC and this 
would require the recruitment (or identification) of an appropriately matched control group and 




 Possibly one or the most exciting areas of epigenetic epidemiology currently is the use of DNA 
methylation in prediction and prognosis. Although the use of DNA methylation as a tumour biomarker 
and its detection in circulating tumour DNA has been explored in various cancers [373], the potential 
of DNA methylation to harness information on lifelong exposure to a wide range of risk factors has 
not really been exploited. Work in this field has begun to apply machine learning approaches to 
maximise the informative component of multi-dimensional DNA methylation data [378] but there is 
far more that could be done to explore this further. This will be aided by the generation of more 
granular DNA methylation data on well phenotyped samples from patients with a detailed case 
history.  
 
7.1.4.  Conclusion 
This body of work highlights the potential of genetic and epigenetic data to augment 
understanding of OPC aetiology. It has shown the potential of two-sample MR analyses using genetic 
data to establish causal associations between risk factors and OPC. Smoking, alcohol, educational 
attainment, sexual behaviour and weight were all seen to be causally associated with OPC, thereby 
corroborating the observational literature findings for these risk factors. Unfortunately, HPV could not 
be appraised in an MR framework, and so no causal association could be established. Epigenetic data 
highlighted methylation pattern differences at novel gene regions for smoking, alcohol and HPV 
status. Methylation associated with OPC mortality was also appraised, allowing deeper insight into 
biological pathways associated with OPC. Using 2-step MR, causality was established between 
smoking-associated methylation at the SPEG gene region and OPC mortality. No evidence was found 
for methylation between HPV or alcohol and OPC mortality, respectively. Finally, epigenetic data 




and methodologies employed in this thesis have served to improve knowledge of the causal and 
biological landscape of OPC beyond that of observational literature. Advanced statistical and 
bioinformatic analyses have allowed for further evaluation with genetic and DNA methylation data to 
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